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ABSTRACT
Complications of type 2 diabetes (T2DM) are severe but can be minimized
through excellent glycemic control, optimally achieved by using intensive, or basalbolus, insulin management. The quality of life (QOL) effects of basal-bolus insulin
management are not fully known. This cross-sectional, observational study was based
on the Revised Wilson and Cleary Model for Health Related Quality of Life, which
measures five QOL domains (biological function, symptoms, functional status, general
health perceptions, and overall QOL). The study aims were to describe, compare, and
predict QOL in persons with T2DM based on type of insulin management (oral meds
only, basal insulin only, or basal-bolus insulin). A convenience sample of adults with
T2DM (n=107; 76% women; 84% non-Hispanic whites) completed self-report surveys
(Chronic Illness Resources Survey, Diabetes Symptom Checklist-Revised, Well-Being
Questionnaire 12, SF-12 Health Survey-version 2, Self-Care Inventory-Revised, Appraisal
of Diabetes Scale, Quality of Life Index: Diabetes Version) and a bloodspot HBA1c test
via postal mail. The sample reported high QOL (21.8±4.7). Female participants reported
lower well-being (23.0 vs 27.5, p<.01), greater negative well-being (2.2 vs 1.0, p<.05),
and lower QOL than study males (21.1 vs 24.0, p<.01). Per multiple regression, general
well-being (β = .51, p<.001) and appraisal of diabetes (β = -.23, p<.05) predicted QOL [R2
= .49, F (5, 90) = 17.04, p< .001]. Multiple regression analysis revealed that self-care
xiv

moderates the relationship between general well-being and QOL [R2 = .45, F (3, 102) =
27.73, p<.001]. No significant differences were detected in QOL between insulin
management groups. This study may provide greater insight into the QOL in adults with
T2DM.
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CHAPTER ONE
PROBLEM STATEMENT
Diabetes is a significant cause of death and disability across the world. Diabetesrelated complications were documented as the seventh leading cause of death in the US
in 2010 (Centers for Disease Control and Prevention [CDC], 2014). The mortality risk for
other leading causes of death, such as heart attack and stroke, is nearly doubled by
diabetes mellitus (DM; CDC, 2014). Diabetes is the leading cause of new cases of
blindness, renal failure, and non-traumatic lower limb amputations in US adults (CDC,
2014). In the US, DM-related complications are costly, resulting in 176 billion dollars of
medical costs and over 69 billion dollars of indirect costs related to disability and
premature death (CDC, 2014).
Although complications of DM are severe, they can be minimized or avoided
through excellent glycemic control (The Diabetes Control and Complications Trial [DCCT]
Research Group, 1993; UK Prospective Diabetes Study [UKPDS] Group, 1998). Optimal
glycemic control can be achieved through intensive insulin therapy but requires
significant patient commitment. Increased hypoglycemia is common with insulin use,
especially when given three or more times daily (Frier, 2008; Levy, Christensen, &
Johnson, 2008). However, dietary freedom is increased with more frequent insulin
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dosing (DAFNE Study Group, 2002) and may lead to increased quality of life (QOL;
Manini, Foriani, Moscatiello, Zannoni, Marzocchi & Marchesini, 2007; Ashwell, Witthaus,
Bradley, Home & Stephens, 2008). QOL studies in DM managed with basal-bolus, or
intensive, insulin dosing have shown mixed findings (Ashwell et al., 2008; Bendik et al.,
2009; DAFNE Study Group, 2002; Kalergis, Pacaud, Strychar, Meltzer, Jones & Yale,
2000; Linkeschova, Raoul, Bott, Berger & Spraul, 2002; Schiel & Muller, 1999). As
diabetes is a self-managed disease, it is important to understand the impact of insulin
management on health-related QOL (HRQOL).
Current treatment recommendations for DM emphasize the use of technology
and self-care to optimize glycemic control. Dietary modification and exercise are
universally recommended for all patients with DM. Patients with insulin-dependent
diabetes (IDDM) include all requiring insulin, regardless of age at diagnosis. Of the 21
million persons with diagnosed DM in the US, approximately 6 million adults require
exogenous insulin to survive (CDC, 2014). For these persons, insulin is the foundation of
treatment, but cannot be used in isolation to achieve glycemic control. Diabetes selfmanagement (DSM), which combines self-monitoring of blood glucose (SMBG), dietary
modification, and exercise, with insulin dosing, is necessary to optimize control of blood
sugars (American Diabetes Association, 2014). The “gold standard” of diabetes care is
intensive diabetes management, defined as “a mode of treatment for the person with
diabetes that has the goal of achieving euglycemia or near-normal glycemia, using all
available resources to accomplish this goal” (Wolfsdorf, 2009). Intensive diabetes
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management is recommended by the American Diabetes Association (ADA, 2014).
Intensive insulin management uses DSM and insulin administered in a basal-bolus
format, typically three or more times per day. The doses may be given through multiple
daily injections of insulin (MDI) or continuous subcutaneous insulin infusion (CSII) to
achieve near-normal levels of blood sugar, as measured by SMBG and glycosylated
hemoglobin (A1C). Most patients using basal-bolus insulin management use
carbohydrate counting to determine the food-based amount of bolus insulin to be
given. Often, intensive diabetes management requires recognition of glycemic patterns
over hours or days.
Traditional management of DM also uses medical nutrition therapy, exercise,
SMBG, and insulin. However, in this treatment strategy, insulin is given in fixed doses.
Some patients with Type 2 DM (T2DM) may be prescribed daily long-acting insulin
analogue injections in addition to oral medications. Other patients with IDDM may give
insulin once or twice daily, adjusting doses according to a sliding-scale based on SMBG
readings. This method of insulin administration is called basal insulin dosing. Patients
using basal insulin dosing do not have a prescribed method of adjusting insulin doses
based on dietary intake or activity. Thus, for success, this strategy requires eating set
amounts of carbohydrates at scheduled times and maintaining a predetermined level of
activity.
In reality, despite ADA practice guidelines, intensive diabetes management is not
universally used for all patients with IDDM. Although the exact rates of patients using
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basal vs. basal-bolus insulin management are not known, basal-only insulin is still used
by many patients with T2DM. One strategy used for basal insulin administration of DM
is insulin premix, a combination product requiring fixed dietary intake and timing
(Henske, Griffith & Fowler, 2009; Hirsch, Bergenstal, Parkin, Wright & Buse, 2005;
Niswender, 2009). The use of premix insulin has increased over the last ten years:
instead of declining production, leading insulin manufacturers have produced more
premix products (e.g., Humalog Mix 75/25, Humalog Mix 50/50, NovoLog Mix 70/30) in
response to demand (Lilly USA, 2014; Novo Nordisk A/S, 2014). Why is intensive
diabetes management not used universally? Although basal-bolus insulin management
can produce optimal glycemic control, it requires substantial patient involvement.
Increased hypoglycemia is associated with basal-bolus insulin management (Frier, 2008;
Levy, Christensen, & Johnson, 2008). However, more frequent insulin dosing is
associated with dietary freedom (DAFNE Study Group, 2002) and may lead to increased
quality of life (QOL). From the patient’s perspective, QOL may be a more important goal
than glycemic control, due to its tangibility. Perhaps because intensive diabetes
management is so demanding, glycemic goals are not consistently met by many patients
with DM. Per national studies, only 52.5% of patients with DM have achieved glycemic
control, as measured by A1C less than seven percent (Casagrande, Fradkin, Saydah, Rust
& Cowie, 2013).
Successful intensive diabetes management requires significant patient
engagement. Patients’ beliefs have been shown to influence treatment adherence in
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chronic illness (DiMatteo, Haskard & Williams, 2007). It is likely that perceived QOL
benefits can impact adherence to intensive diabetes management. Limited evidence
has shown that intensive DM management can increase QOL (Bendik et al., 2009;
Hanberger, Ludvigsson, & Nordfeldt, 2009; Menard et al., 2007). However, other QOL
studies in IDDM related to basal-bolus insulin management have shown mixed findings,
partially due to inadequate measurement of QOL. As DM is a self-managed disease, it is
important to understand the impact of intensive insulin management on health-related
QOL (HRQOL).
Purpose
The study examined the quality of life in patients with type 2 diabetes according
to type of glycemic management. In this study, quality of life is assumed to be a
multidimensional construct, including biological, symptomatic, functional, and
comprehensive factors. Guided by the revised Wilson and Cleary Model for HealthRelated Quality of Life, the study utilized psychosocial instruments and hemoglobin A1C
testing to comprehensively assess quality of life in patients with type 2 diabetes
according to insulin management strategy.
Theoretical Framework
Wilson and Cleary (1995) proposed a conceptual model of health-related QOL
(HRQOL) to define and clarify the multifactorial nature of QOL as related to health. The
model was modified by Ferrans, Zerwic, Wilbur, and Larson (2005) to depict the
individual and environmental factors that influence HRQOL (Figure 1). In the model,
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both the environment and the individual can impact patient outcomes, all of which
contribute to HRQOL. Patient outcomes comprise the center of the model and are
divided into five types of measures: biological, symptoms, functional status, general
health perceptions, and overall QOL (Ferrans et al., 2005). The five types are causally
linked to each other, and all are influenced by individual and environmental
characteristics. Biological measures are basic physiologic variables such as labs, vital
signs, and body mass index. Symptoms are the physical, emotional, and psychological
symptoms reported by the patient. Functional status refers to the patient’s ability to
function physically, psychologically, socially, and in assumed roles. General health
perceptions include the patient’s subjective evaluation of health, including biological,
symptom-related, and functional influences. Finally, overall quality of life is the
patient’s general satisfaction with life as a whole. The model acknowledges that
relationships between model components may be reciprocal but typical directionality is
indicated in the arrows (Figure 1). The revised Wilson and Cleary model is useful in
directing the assessment of DM-related QOL because it is multidimensional and includes
individual and environmental influences.
The concept of quality of life has been depicted in many different ways. The use
of a model in quality of life research provides an organizing framework and description
of a complex concept. The Revised Wilson and Cleary model has been used to study
QOL in a few distinct populations: 1) persons on hemodialysis (Kring, 2008), 2) persons
with HIV and liver problems (Henderson, 2007), and 3) patients with T2DM (Chia, 2007).
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For patients with T2DM, Chia (2007) found the model to be valid in relating
demographic and physiological variables to QOL. The only weakness in using this model
in studying QOL in intensive insulin management of DM is that it does not emphasize
the complex nature of diabetes self-management. However, self-management can be
included in the functional status component of the model. The model is depicted in
Figure 1.

Characteristics of
the individual

Biological
function

Symptoms

Functional
Status

General
Health
Perceptions

Overall
quality of
life

Characteristics of
the environment

Figure 1. Revised Wilson and Cleary Model of Health-Related Quality of Life

Specific Aims
The aims for this study were (1) to describe the HRQOL of persons with T2DM
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according to type of glycemic management [Oral meds only, Basal insulin only (once or
twice daily), Basal-bolus insulin (three or more times daily)], (2) to determine if HRQOL
of persons with T2DM differs depending on type of glycemic management, and (3) to
determine if type of glycemic management is predictive of HRQOL after controlling for
covariates.
In summary, QOL in T2DM is a critical construct which has not been adequately
studied. The impact of glycemic management strategies in T2DM on QOL has not been
determined. The revised Wilson and Cleary Model of Health-Related Quality of Life was
used to guide this study of the impact of insulin management on QOL in T2DM. Aims of
the study included describing and determining QOL differences based on glycemic
management strategy which provided greater insight into QOL in T2DM.

CHAPTER TWO
LITERATURE REVIEW
A literature search was conducted to examine the relationship between
intensive diabetes management of DM and QOL which included the years 1996 to 2009
and 32 articles were identified. All articles examined quality of life in intensively
managed DM. Databases searched were CINAHL, Medline, PsycINFO, Cochrane, Pub
Med, and SSCI. Search limits included English language, human, and research articles.
Keywords included: insulin, diabetes, diabetes mellitus, quality of life, flexible, multiple
daily, intensive, insulin pump, continuous subcutaneous insulin, and CSI*. Since that
time, there have been 12 new studies which are included at the end of this review.
Results
For the 32 studies, the majority of studies in the literature review (n=18)
examined QOL in patients already using intensive diabetes management. The remaining
studies (n=14) compared various types of intensive diabetes management with
traditional treatment, typically fixed-dose insulin. Of the 32 studies in the literature
review, five studies examined QOL in CSII; ten studies compared QOL in CSII vs. MDI
(Table 1). Ten studies evaluated MDI subjects only (Table 1). Seven studies examined
intensive diabetes management by combining CSII and MDI subjects in the same group
(n=3) or intensifying the subjects’ prior regimens (n=4; Table 1). To summarize the
9
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studies, QOL outcomes will be reported in biologic, symptomatic, psychosocial, and
functional dimensions.
Table 1. Intensive Diabetes Management Studies: Sample, Design, and Outcomes
Study
Aberle, 2009

Bruttomesso,
2002

Gimenez,
2007

Linkeschova,
2002

Ritholz, 2007

Sample

Design
CSII only
n=51 German patients
Crossw/T1DM
sectional
Age 36.5±12yr
descriptive
59% female
Educational years 11±3
DM Duration 19±10
years
n=138 Italian patients
Crossw/ T1DM
sectional:
Age 33±1 years
Retrospective
64% female
descriptive
DM duration 13.1±0.7
years
n=153 Spain patients
Longitudinal:
w/ T1DM
Prospective,
Age 35±11 years
observational
71% female
DM duration 18.5±9.5
years
n=103 German patients Longitudinal:
w/ T1DM
Pre-Post
Age 33±11 years
Observational
56% female
27% with late
complications of DM
n=30 US patients w/
Qualitative:
IDDM, CSII users
Focus Groups
Age 47±9.5
59% female
97% white, 76%
married
A1C: low (6.8±0.4%)

Outcomes
Glycemic control, QOL,
treatment satisfaction,
depressive symptoms,
coping style, locus of control,
self-efficacy

Glycemic control, QOL
(partial data only), severe
hypoglycemia, DKA

Glycemic control, QOL,
severe hypoglycemia,
hypoglycemia

Glycemic Control, Severe
Hypoglycemia; QOL;
treatment satisfaction

Psychosocial factors, selfcare, emotional reactions
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Barnard &
Skinner, 2008

DeVries, 2002

Doyle, 2004

EQuality1
Study Group,
2008

mid (7.8±0.3%) high
(9.1±0.5%)
DM duration 27.3±13.1
years
educational years
15.4±1.5
CSII vs. MDI
n=642 U.K. patients w/ CrossT1DM
sectional
Age 45±14
matched
69% female
group survey
DM duration 24±12
years
All Dutch patients
RCT: Crossw/T1DM in poor
over
control (A1C≥8.5%)
Group A: n=39, age
36±10, 46% female, DM
duration 18±10 years,
49% retinopathy;
Group B: n=40, age
37±11, 47% female, DM
duration 18±9 years,
42.5% retinopathy
All U.S. youth w/T1DM, RCT
age range 8-21 years;
Group A: n=16, age
12.5±3.2, 63% female,
68% Caucasian, 19%
Hispanic, 13% Black,
DM duration 7±4 years
Group B: n=16, age
13±2.8, 50% female,
81% Caucasian, 13%
Hispanic, 6% Black, DM
duration 6±4 years
All Italian patients w/
CrossT1DM, 69% employed
sectional
Group A: n=481, age
case-control
35±11, 57% female;

QOL, treatment satisfaction,
hypoglycemia fear, “problem
areas” in DM, glycemic
control (proxy measure via
SMBG frequency)
Glycemic control; QOL

Glycemic control, QOL
(incomplete data)

Glycemic control; QOL;
treatment satisfaction

12

Herman, 2005

Hoogma,
2006

Hoogma,
2004

Kamoi, 2004

31% retinopathy;
Group B: n=860, age
35±12, 46% female,
22% retinopathy
All U.S. older adults
w/T2DM (IDDM), age
>60 years (mean age
66±5);
Group A: n=53, 28%
female, 81% Caucasian,
8% Hispanic, 8% Black,
DM duration 17±9 yr,
42% retinopathy;
Group B: n=54, 64%
female, 91% Caucasian,
4% Hispanic, 4% Black,
DM duration 15±9 yr;
36% retinopathy
All European patients
w/ T1DM
Group A: n=129, age
37±11, 53% female;
Group B: n=127, age
35±10, 52% female
All Dutch patients
w/T1DM
Group A: n=49, age
41±11,73% female, 65%
had DM duration >10
years;
Group B: n=79, age
43±15 yr, 46% female,
73% had DM duration
>10 yrs.
All Japan patients w/
T1DM
Group A: n=16, age
48±17, 62.5% female,
DM duration 7±6 yr,
13% retinopathy

RCT

Glycemic control; QOL;
hypoglycemia; treatment
satisfaction

RCT: 2-way
crossover

Glycemic control,
Hypoglycemia; QOL; severe
adverse events

Crosssectional

Glycemic control; QOL;
treatment satisfaction, wellbeing

Longitudinal:
Prospective
experimental

Glycemic control; QOL;
hypoglycemia
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Scheidegger,
2007

Tsui, 2001

Bendik, 2009

DAFNE, 2002

Group B: n=12, age
55±13, 66% female, DM
Duration 21±7.9yr, 25%
retinopathy
All Swiss patients
Crossw/T1DM
sectional
Group A: n=78, age
43±13, 47% female, DM
duration 19±11 yr, 29%
retinopathy, 73%
professional education,
86% working;
Group B: n=81, age
42±11, 48% female, DM
duration 17±11 yr, 27%
retinopathy, 72%
professional education,
89% working
Group L: n=19, age
Longitudinal
43±11, 74% female, DM study
duration 18±11 yr, 47%
retinopathy, 68%
professional education,
79% working
All Canadian patients
RCT
w/T1DM
Group A: n=13, age
36±12, 38% female, DM
duration 17±10 years;
Group B: n=14, age
36±10, 29% female, DM
duration 15±9yr
MDI only
n=45 Swiss patients w/ Longitudinal:
T1DM
Pre-Post
age 41 (range 18-74),
47% female, DM
duration 10 (range 149) years
N=169 U.K. patients w/ RCT: control

Glycemic control; QOL,
treatment satisfaction,
severe hypoglycemia

Glycemic control,
Hypoglycemia; QOL

Glycemic control; QOL;
severe hypoglycemia, locus
of control, DM knowledge,
SMBG frequency

Glycemic control; severe
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Gale, 2000

Jansa, 2006

Kalergis, 2000

Langewitz,
1997

Lowe, 2008

Manini, 2007

T1DM in moderate
glycemic control (HA1c
7.5-12%), age 40±9 yr,
56% female, 37%
retinopathy
n= 93 U.K. patients w/
T1DM, on MDI
Age 35 (range 18-63),
47% female
DM duration 13 (range
1-51) years
All patients in Spain w/
T1DM, 100% employed
or full-time students,
race unspecified;
Group A: n=19, age
27±11, 47% female, DM
duration 12±6 years;
Group B: n=16, age
23±5, 31% female, DM
duration 10±6 years
n=15 Canadians w/
T1DM; Age 38 (range
23-59 yr); 60% female;
race unspecified
n=43 Swiss patients
w/T1DM, Age 33±10,
61% female, DM
Duration 15±10 years

crossover

hypoglycemia; QOL;
Psychological well-being;
treatment satisfaction, CV
risk factors

RCT

Glycemic control; QOL;
hypoglycemia

RCT

Glycemic control; QOL;
hypoglycemia; selfmanagement (SMBG, insulin
dose adjustment frequency),
DM knowledge

RCT:
crossover

Glycemic control; QOL, selfefficacy, stress, perceived
complexity

Longitudinal:
Pre-Post

n=137 Australians
w/IDDM; age 47±15
years; 55% female; 40%
T2DM
All Italian patients w/
T1DM
Group A: n=47, age 46
(range 25-74), 46%
female, DM duration 19
(range 4-61) years, 32%

Longitudinal:
Prospective
Observational

Glycemic control; QOL;
severe hypoglycemia,
anxiety, depression; selfdetermination/responsibility;
hierarchy MD-patient
Glycemic control; selfefficacy; QOL

Longitudinal: Glycemic control; QOL,
Pre-post,
hypoglycemia
external
group used as
controls
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Pfutzner,
1996

Zoppini, 2003

Ashwell, 2008

Chantelau,
1997

DCCT
Research
Group, 1996

Forlani, 2006

retinopathy;
Group B: n=40, age 44
(range 23-70), 36%
female, DM duration 22
(range 7-60) years; 17%
retinopathy
n=107 German patients RCT: control
Glycemic control; QOL;
w/ T1DM; age 32±10
crossover
glucose variability,
years; 50% female
hypoglycemia, adverse
DM duration 10±8
events
years
All Italian patients w/
CrossGlycemic control; QOL
T1DM
sectional
Age 26±6 yr, 43%
female, Duration DM
14±7 years
Intensive Diabetes Management
n=48 U.K. patients w/
RCT: 2-way
QOL; treatment satisfaction
T1DM; 62.5% female;
crossover
Group1: Age 42±14
Group2: Age 42±9
All German patients w/ Longitudinal: Glycemic control; QOL
IDDM
Prospective
(satisfaction)
Group A: n=77, Age
Cohort (self32±9, 49% female, 30% selected)
retinopathy, 49% white
collar job; Group B:
n=55, Age 31±8; 49%
female; 35%
retinopathy; 62% white
collar job
n=1441 US patients w/ RCT:
Glycemic control; DM
IDDM, age 27±0.3 yrs., Longitudinal
complications; QOL,
96% Caucasian;
psychiatric symptoms,
Group A: 49% female,
psychosocial event data
51% retinopathy;
Group B: 46% female,
48% retinopathy
All Italian patients w/
Longitudinal: Glycemic control; QOL;
T1DM
Experimental mood/emotional status
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Insabella,
2007

Schiel &
Muller, 1999

Weinger,
2001

Group A: n=54, age 43
(range 18-65), 62%
female; 17%
retinopathy
Group B: n=36, age 41
(range 26-65), 34%
female, 37%
retinopathy
n= 117 U.S. youth
w/T1DM
Age 14.4±2, 61.5%
female, 93% Caucasian,
3.5% Hispanic, 3.5%
black, DM duration
5.7±3.7 years
All German patients w/
IDDM (T2)
Group A: n=40, Age
51±7, 22% female, 23%
disabled;
Group B: n=77, Age
54±5.9, 41% female,
26% disabled
n=55 US patients w/
T1DM using intensive
diabetes management,
age 34±8, 56% female,
DM Duration 9±3 years,
NO complications

Pre-Post
(refusers as
controls)

Longitudinal:
Prospective

Glycemic control; QOL,
depressive symptoms,
functional outcomes, DM
complications

Crosssectional
descriptive

Glycemic control; QOL;
treatment satisfaction;
acute/long-term
complications

Longitudinal:
Pre-post

Glycemic control; QOL,
emotional distress, hypoglycemia fears, DM hassles,
“problem areas” in DM, selfmanagement problems,
SMBG frequency

Note. CV = cardiovascular; CSII = continuous subcutaneous insulin infusion; DKA = diabetic ketoacidosis;
DM = diabetes mellitus; MDI = multiple daily injections; QOL = quality of life; RCT = randomized controlled
trial; SMBG = self-monitoring of blood glucose; T1DM = type one diabetes mellitus; T2DM = type two
diabetes mellitus

Intensive Diabetes Management: QOL Dimensions
Biologic
Biologic dimensions of QOL range from demographic factors to glycemic control
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and diabetic complications. All have the potential to impact QOL in IDDM. Glycemic
control, as measured by A1C, is reported as an outcome in the majority of diabetes
studies over the past 30 years (Jeffcoate, 2004). Glycemic control was measured by A1C
in 31 of 32 studies. The literature has documented weak relationships between QOL
and improved A1C (Barnard, Lloyd & Skinner, 2007). Glycemic variability was examined
in select studies of the literature review via glucose profiles, or graphs of seven-point
daily SMBG results (DeVries, Snoek, Kostense, Masurel & Heine, 2002), and postprandial glucose excursions (Pfutzner et al., 1996). The majority of the studies’ subjects
were in young to middle adulthood, with the exception of older adults in Herman et al.
(2005) and two studies of “youth”, inclusive of adolescents and young adults (Doyle et
al., 2004; Insabella, Grey, Knafl & Tamborlane, 2007). Subjects’ age had no significant
impact on QOL findings. Diabetes complications (micro- and/or macrovascular) were
assessed at baseline by ten studies (Bruttomesso et al., 2002; Chantelau, Schiffers,
Schutze & Hansen, 1997; EQuality1 Study Group, 2008, Herman et al., 2005; Insabella et
al., 2007; Kamoi, Miyakoshi & Maruyama, 2004; Linkeshova, Raoul, Bot, Berger & Spraul,
2002; Manini et al., 2007; Schiel & Muller, 1999; Zoppini, Carlini & Muggeo, 2003). QOL
effects according to DM complication rates were not reported in these 10 studies;
however, other studies have examined QOL in DM with complications. The presence of
co-morbid diagnoses and DM-related complications significantly decreases QOL in
patients with type 2 DM (Goddijn et al., 1999; Lloyd, Sawyer, & Hopkinson, 2001; Solli,
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Stavem & Kristiansen, 2010). In the absence of late-stage complications of DM, higher
QOL and better glycemic control has been reported in patients with Type 1 diabetes
(T1DM; Bott, Mulhauser, Overmann & Berger, 1998). Duration of DM was reported in
21 studies; however, none reported a relationship with QOL. In patients with T2DM
treated with oral medications only, increased duration of DM is associated with
decreased psychological QOL (β = -0.29, SD = -5.87, P = 0.007; Fal et al., 2010). The
majority of the studies do not mention subjects’ race or ethnicity. This may be due to
the European origin of many studies in the literature review.
Prescribed method of DM control is a biological factor related to QOL. The
Diabetes Control and Complications Trial (DCCT, 1993), provided strong evidentiary
support for the use of intensive diabetes management as a method for preventing or
delaying DM-related complications. QOL did not differ between groups of experimental
and control DCCT subjects and remained stable over time (DCCT, 1993). In other
studies, intensification of DSM to MDI regimens using analogue insulin was associated
with improved QOL over time (Manini et al., 2007; Ashwell, Witthaus, Bradley, Home &
Stephens, 2008). Intensive insulin management may provide QOL benefits in
comparison to fixed-dose insulin therapy; at the very least, it has not been associated
with QOL deterioration. Research has not conclusively proven which type of intensive
insulin management, CSII vs. MDI, is superior as related to QOL. Studies comparing CSII
and MDI have shown mixed findings. Of the reviewed articles, six studies have shown
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significantly improved QOL scores in CSII subjects (Barnard & Skinner, 2008; DeVries et
al., 2002; EQuality1 Study Group, 2008; Hoogma et al., 2006; Kamoi et al., 2004;
Scheidegger, Allemann, Scheidegger & Diem, 2007). Four studies showed no difference
in QOL results between groups of CSII vs. MDI (Doyle et al., 2004; Herman et al., 2005;
Hoogma et al., 2004; Tsui, Barnie, Ross, Parkes & Zinman, 2001). It should be noted that
all four studies had relatively small samples (n= 32, 107, 49, 27), decreasing the
likelihood of detecting significant findings. Method of intensive insulin management is
one biological factor that may impact QOL in DM.
QOL in intensively managed DM has been largely studied in T1DM. The majority
of reviewed studies examined subjects with T1DM only, with the exception of two
studies that enrolled all adults with T2DM (Herman et al., 2005; Schiel & Muller, 1999),
and Lowe, Linjawi, Mensch, James, and Attia (2008), who had a mixed sample of T1 and
T2DM patients. These studies had mixed findings on the relationship between QOL and
intensive diabetes management. In Herman et al. (2005), both groups of adults with
T2DM reported increased QOL while in the study; however, subjects using intensive
diabetes management did not show a significant difference from controls. In an
admittedly underpowered small study (n=117), Schiel and Muller (1999) were unable to
detect group differences between subjects using basal-bolus or fixed-dosing of insulin.
Lowe et al. (2008) reported a borderline improvement in QOL (p=.05) among subjects
using intensive diabetes management; however, approximately 75 percent of subjects

20

had missing data or did not complete the program. The study of QOL in intensively
managed T2DM is incomplete. There is a need to study this phenomenon in persons
with T2DM, especially as it is becoming more prevalent. Type 2 diabetes is closely
related to sedentary lifestyle and obesity—all are rising to epidemic levels in the United
States. In the last 30 years, the incidence of T2DM has doubled in adults (Fox et al.,
2006). In 2012, the prevalence of DM was 12.3 percent of U.S. adults, with 90 to 95%
T2DM (CDC, 2014). More than one-fourth of adults with DM are insulin-dependent
(with or without oral medication; CDC, 2014). Experts recommend the early initiation of
insulin therapy in T2DM to protect beta cell mass and function (DeFronzo, 2009;
Niswender, 2009). For patients with insulin-dependent T2DM, glycemic control is still
the primary goal, best achieved through intensive diabetes management (DeFronzo,
2009). Many patients with insulin-dependent T2DM are not using intensive diabetes
management; however, this is expected to change due to the epidemic of T2DM in this
country (Niswender, 2009). Although related, T1 and T2DM are not the same illness,
differing in age of onset, pathophysiology, progression, duration, and severity. QOL in
intensively managed T1 and T2DM cannot be assumed to be the same.
Symptoms
Many DM-related symptoms exist, including those related to hypo- or
hyperglycemia. Hypoglycemia is considered to be particularly dangerous and disruptive
to patients with DM; indeed, hypoglycemia has been noted to be the single most
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limiting factor to obtaining tight glucose control (Cryer, 2008; Heller, 2008). Intensive
insulin management increases the frequency of hypoglycemia (DCCT, 1993): one
estimate reported that on average, a patient with intensively managed T1DM
experiences up to 10 episodes of symptomatic hypoglycemia per week and at least one
episode of severe hypoglycemia per year (Briscoe & Davis, 2006). However,
hypoglycemia is somewhat abated by the use of rapid-acting analogues and CSII (Cryer
2008; Heller, 2008; Pfutzner et al., 1996; Gale, 2000). CSII may be associated with less
frequent or severe hypoglycemia than MDI (Fatourechi et al., 2009). QOL is decreased
by hypoglycemia that is frequent (Tierney et al., 2008) or severe (Davis et al., 2005). Of
the studies reviewed, over half assessed hypoglycemia by patient report, medical record
review, or glucose meter downloading (n=19; Table 2). Most useful is the assessment of
severe hypoglycemia, defined as hypoglycemia requiring assistance of another person.
Severe hypoglycemia is disruptive, alarming, and dangerous, producing significantly
negative QOL effects. Thirteen of the reviewed studies examined rates of severe
hypoglycemia (Table 2). Significant decreases in severe hypoglycemic episodes were
strongly associated with QOL improvement in five studies (Table 2). Changes in mild or
overall hypoglycemia were shown to be associated with QOL improvement in a few
studies (n=4; Table 2). For patients treated with insulin, regardless of DM type,
hypoglycemia is a frequent reality, with overall (mild to severe) prevalence of up to 93
percent (Zammitt & Frier, 2005). Hypoglycemia is less frequent in insulin-dependent
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T2DM, with a rate of 16 events of overall hypoglycemia per patient-year, compared to
43 events per patient-year in T1DM (Briscoe & Davis, 2006). Due to physiologic
differences, patients with T2DM experience hypoglycemia with less severity and more
warning symptoms (Zammitt & Frier, 2005). Only one study examined hypoglycemia
and QOL in T2DM; no significant relationships were detected (Herman et al., 2005).
Table 2. Hypoglycemia and Quality of Life: Longitudinal Studies and Randomized
Controlled Trials
Study
Bendik, 2009
Bruttomesso,
2002
DAFNE, 2002
Experimental
Controls
DCCT, 1996
Intensive
Controls
Doyle, 2004
CSII
MDI
Gimenez,
2007
Severe HYPO
Overall HYPO
(>5/week)
Herman,

Hypoglycemic Frequency
QOL effects
Baseline
Follow-up
Baseline
Follow-up
Severe Hypoglycemia
Events/6 months
DQOL: ↓score= ↑QOL
.33
.03 *
91.8±22.5 85.6±20.0***
Events/year
DQOL
.31±0.07
.09±0.02 **
-73.0±1.8
% patients with ≥1 event/6
ADDQOL: AWI
months
22
18
-2.0±1.6
-1.6±1.6
11
15
1.9±1.3
-1.9±1.4
≥1 event in Events/100
DQOL:
last year
patient-years
5% of
62***
78±8
78±9
subjects
4% of
19
78±9
78±9
subjects
Events/16 weeks
No change in QOL; data
-2
not reported
-5
Events/patient-year

DQOL: impact

Other

QOL between
groups at 6
months**
No change in
QOL

Baseline
HYPO not
reported

All subscales
of DQOL
improved, no
0.31±0.46
0.07±0.25***
44.8±9.5 39.5±7.4*** total scores
44% of
5% of
given
subjects
subjects***
Events/patient-year
DQOL-CTQ: Impact scores Severe HYPO
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2005
CSII --MDI
Hoogma,
2006

.08
.23

Events/patient-year
CSII --MDI

Insabella,
2007
Langewitz,
1997
Linkeschova,
2002
Scheidegger,
2007

0.2
0.5

No events
16.7 events/
in last 6
100 patientmonths
years
% of patients w/ event last
year
18.6
7*
Cases/patient-year
0.70
0.06***
50 events in 1 event in
228 subject- 104 subjectmonths
months

increased +2 points from
baseline in both
groups**, no between
group differences
DQOL total:
---

75
71

DQOL-Y: Impact
47±3
43±6 (n.s.)
DQOL: satisfaction
33.3±8
25.8±7.7***
All subscales of DSQOLS
improved (p=.025-.000);
no total scores given
DSQOLS:
248±45
277±34*

Tsui, 2001

No between-group or over
No between-group or
time differences
over time differences
Mild Hypoglycemia
DeVries,2002 Events/week
SF-36: General, Mental
CSII 2.13±2.05
.98±2.02*
-+5.9*, +5.2
MDI 1.97±1.53

-.02±1.18

--

Jansa, 2006

-1.2, -0.6

% of patients with ≥3
events/ week
Telecare 75
6***

44±6

41±7 (n.s.)

Controls 79

43±7

38±6*

Gale, 2000
Lispro --

15***

shown/no
differences in
mild HYPO;
T2DM’s
↓severe
HYPO and
↑QOL in CSII
at followup***
Severe HYPO
increased, no
sig reported

DQOL: Impact

Nocturnal Hypoglycemia
Events/month
No change in QOL; no
0.7 ±1.6***
scores reported

No sig.
reported for
HYPO data
Severe and
mild HYPO
No
differences in
severe HYPO
(not shown)
No betweengroups
differences at
any time;
Only DQOL
impact scale
sig. (others
n.s.)
Overall HYPO
rates not
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Controls -Kalergis,
2000

1.8±3.1
Overall Hypoglycemia

DQOL (total scaled
20 events/100 patient-years score): 2.0±0.1

Kamoi, 2004
Events/3 months
MDI 10.8±23.9
6.3±12.6
0.9±1.6
0.5±1.4

ITR-QOL:
80.2±20.9 86.3±21.8
99.4±13.3 101.8±11.6

CSII
Pfutzner,
1996
Lispro --Controls

Events/month
8.57±0.7 **
9.61±0.72

QOL: satisfaction
improved in lispro group;
no differences in other
domains

shown (n.s.)
No change
from baseline
or between
groups
Odd HYPO
stats (n.s.);
QOL
difference
between
groups**
No baseline
HYPO rates
reported; less
HYPO during
lispro (than
w/ regular
human
insulin)**

Note. -- No data provided by study authors.
ADDQOL-AWI = Audit of Diabetes-Dependent Quality of Life—Adjusted Weighted Index; CSII = continuous
subcutaneous insulin infusion; DQOL = Diabetes Quality of Life instrument; DQOL-CTQ = Diabetes Quality
of Life—Clinical Trial Questionnaire; DQOL-Y = Diabetes Quality of Life—Youth; DSQOLS = DiabetesSpecific Quality of Life Scale; HYPO = hypoglycemia; ITR-QOL = Insulin therapy-related—Quality-of-Life
instrument; MDI = multiple daily injections; QOL = quality of life; SF-36 = Medical Outcomes Study Short
Form-36; T2DM = type two diabetes mellitus
*p<.05, **p<.01, ***p<.001

Hyperglycemia can also impact QOL. In patients with T2DM, symptoms of high
blood sugar have been associated with decreased QOL (Goddijn et al., 1999). Symptoms
of hyperglycemia were assessed in the DCCT (1996) and by Jansa et al. (2006); no
relationship between these symptoms and QOL was detected. Diabetic ketoacidosis,
usually requiring hospitalization, has substantial potential to impact QOL and was
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assessed by six studies (Bruttomesso et al., 2002; Doyle et al., 2004; Gimenez et al.,
2007; Linkeschova, Raoul, Bott, Berger & Spraul, 2002; Schiel & Muller, 1999; Tsui et al.,
2001). Symptoms related to glycemic extremes have strong effects on QOL.
Patients with DM have other symptoms which can affect QOL. More recently,
symptoms of emotional distress (e.g., anxiety, depression, DM-related distress) have
also been shown to have a significant impact of QOL as well. Psychological distress is
reportedly experienced by one-third of young adults with T1DM (Hislop, Fegan,
Schlaeppi, Duck & Yeap, 2008). In a study of 51 adults on CSII, depressive symptoms
significantly correlated with lower QOL (r=-0.542, p<0.01; Aberle et al., 2009). As
compared to peers without DM, patients with T2DM have increased depression, which
results in decreased QOL, especially in those patients prescribed insulin (Aikens, Perkins,
Piette & Lipton, 2008). Less depressive symptoms and DM-related distress are related
to improved QOL and glycemic control (Langewitz, Wossmer, Iseli & Berger, 1997).
Other studies have examined psychological symptoms as related to QOL, including
anxiety and DM-related distress (Table 3). Presence of symptoms due to complications
of DM can decrease QOL (Garratt, Schmidt, Mackintosh & Fitzpatrick, 2000). Chronic
pain and visual impairment are associated with decreased QOL in patients with T2DM
(Boutoille, Feraille, Maulaz & Krempf, 2008; Smith et al., 2008). In the literature review,
no significant relationship between QOL and DM-complications was reported; however,
this relationship was not often examined. One unexpected finding was the decreased
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energy levels in patients with T2DM on basal-bolus insulin management, compared to
controls using fixed insulin dosing (Schiel & Muller, 1999). Patients with DM have
reported increased suicidal thoughts and lower QOL than similar peers without DM
(Pompili et al., 2009). Clearly, many symptoms can affect QOL in patients with IDDM.
Table 3. Psychosocial Outcomes and Quality of Life
Outcome
Depressive
Symptoms or
Depression
Anxiety
Coping
Self-efficacy
Locus of Control
Self-control
Selfdetermination/selfresponsibility
DM-related
emotional distress

Social worries

Cross-Sectional
Aberle, 2009

Study Design
Longitudinal
Insabella, 2007
Langewitz, 1997

RCT

Langewitz, 1997
Aberle 2009
Aberle, 2009

Linkeschova, 2002
Lowe, 2008

Aberle, 2009
Bendik, 2009
Langewitz, 1997

Barnard &
Skinner,2008
Bruttomesso, 2002
Hoogma, 2004
Zoppini, 2003

Bruttomesso, 2002
Hoogma, 2004
Scheidegger, 2007
Zoppini, 2003

Bendik, 2009
Chantelau, 1997
Forlani, 2006
Gimenez, 2007
Insabella, 2007
Langewitz, 1997
Weinger, 2001
Bendik, 2009
Chantelau, 1997
Gimenez, 2007
Insabella, 2007
Langewitz, 1997
Linkeschova, 2002
Scheidegger, 2007
Weinger, 2001

DCCT, 1996
Doyle, 2004
Herman, 2005
Hoogma, 2006
Jansa, 2006
Kalergis, 2000
Tsui, 2001
DCCT, 1996
Doyle, 2004
Herman, 2005
Hoogma, 2006
Jansa, 2006
Kalergis, 2000
Tsui, 2001
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Well-being

Forlani, 2006

DAFNE, 2002

Note. DCCT = Diabetes Control and Complications Trial; DM = diabetes mellitus; RCT = Randomized
Controlled Trial

Psychosocial
For patients with IDDM, psychosocial dimensions can have considerable impact
on QOL. Intensive diabetes management requires self-efficacy and self-motivation.
Table 3 reports psychosocial constructs examined by studies in the literature review.
Aberle et al. (2009) found that among CSII users, higher self-efficacy was correlated with
better QOL and less depressive symptoms (r=0.601 and -0.453 respectively, p<0.01). In
the same study, locus of control was found to be the most significant predictor of A1C
(R2=0.479, p<0.01), with a significant correlation between high external locus of control
and increased A1C (r=0.56, p<.01). In a focus group study, an external locus of control
was commonly found in CSII subjects in poor glycemic control (A1C>8.0%; Ritholz et al.,
2007). In the same study, focus groups with well-controlled T1DM (A1C<7.0%) reported
using an active approach to DSM and feeling more “normal” since beginning CSII (Ritholz
et al., 2007). Weinger and Jacobson (2001) conducted a prospective study of 55 adults
with T1DM. The subjects attended an intensive diabetes management clinic and
educational program over four to five months. The study revealed that patients with
improvements in DM-related emotional distress also improved their glycemic control
(r=0.38, p<0.02) and satisfaction-related QOL (p<0.001). Intensive diabetes
management can impact psychosocial outcomes: initial functional insulin therapy
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testing showed a reduction in depression and anxiety after training (t=4.37 and 5.52,
p<0.001; Langewitz et al., 1997). These preliminary studies clearly indicate a
relationship between psychosocial outcomes and QOL in intensively managed DM, but
further inquiry is required.
Functional Status
Patients’ ability to function physically, emotionally, and socially is a primary
determinant of QOL. Cognitive function is an important component of role
performance. Increased AIC over time has been linked to cognitive dysfunction or
decline in elderly and young adult patients with DM (Munshi et al., 2006; Musen et al.,
2008). In a large, multi-site, longitudinal randomized controlled trial of patients with
IDDM, neither intensive insulin management nor severe hypoglycemia had an impact on
cognitive performance in young adults (Musen et al., 2008). Physical abilities also affect
role performance. Decreased mobility and activity tolerance due to DM-related
complications has been linked to lower QOL scores (Boutoille et al., 2008). In a study of
53 young adult T1DM patients, self-reported regular exercise was significantly
associated with higher QOL (p<0.05, Forlani, Zannoni, Tarrini, Melchionda & Marchesini,
2006). Frequent hypoglycemia is linked to decreased work productivity in patients with
T1 and T2DM (Davis et al., 2005). Of the literature reviewed, only four examined
employment (Forlani et al., 2006; Scheidegger et al., 2007) or functional outcomes
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(Insabella et al., 2007; Jansa, et al., 2006) as related to QOL; no significant findings were
reported.
One critical functional dimension for patients with DM is self-care, or the
performance of DSM behaviors. Successful performance of DSM has been linked to
higher QOL (Ayalon, Gross, Tabenkin, Porath, Heymann & Porter, 2008). Of the studies
in the literature review, none reported deterioration in QOL, despite the
implementation or continuation of complex and time-consuming DSM behaviors. Some
studies (n=6), reported increased QOL after changing from fixed-dose to basal-bolus
insulin management (Bendik et al. 2009; Chantelau et al., 1997; DAFNE Study Group,
2002; Langewitz et al., 1997; Linkeshova et al., 2002; Lowe et al., 2008). Table 4 reports
self-care practices measured by the studies of the literature review. SMBG frequency
was documented in one-fourth of the studies in the literature review (Table 4). In
T1DM, increased frequency of SMBG has been linked to improved glycemic control and
QOL (Schiel & Muller, 1999). Self-adjustment of insulin doses according to activity, food,
and SMBG results is an important DSM behavior in intensive insulin management.
While only measured by a few studies in the literature review, higher frequency of
insulin dose self-adjustment was associated with improved glycemic control (Jansa et
al., 2006; Schiel & Muller, 1999) and QOL improvements (EQuality1 Study Group, 2008;
Jansa et al., 2006). For patients with T2DM using intensive insulin management, self-
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adjustment of insulin doses was not associated with improved QOL (Schiel & Muller,
1999).

Table 4. Self-Care Measures and Quality of Life
Self-care activity
Diet
Exercise

SMBG frequency

Insulin dose
adjustment

“Self-management”

Cross-sectional
EQuality1 Study
Group, 2008
Zoppini, 2003
Barnard &
Skinner,2008
Hoogma, 2004
Scheidegger, 2007
Schiel & Muller,
1999
EQuality1 Study
Group, 2008
Schiel & Muller,
1999

Study Design
Longitudinal
Lowe, 2008

RCT

Lowe, 2008
Bendik, 2009
Scheidegger, 2007
Weinger, 2001

Doyle, 2004
Jansa, 2006

Jansa, 2006

Weinger, 2001

Note. RCT = Randomized controlled trial; SMBG = self-monitoring of blood glucose

Kalergis et al. (2000) examined the relationship between self-management and
QOL in a very small study of adults with T1DM (n=15). Pre-study insulin regimens were
MDI with minimal to no self-adjustments of insulin doses. Three treatment strategies
were used: simplified, qualitative, and quantitative. In the simplified strategy, subjects
had a set meal plan and were permitted insulin self-adjustments based on SMBG results
only. In the qualitative strategy, subjects were permitted to self-adjust insulin
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qualitatively based on SMBG results, food intake (according to food exchange lists),
exercise, and stress. In the quantitative strategy, subjects used carbohydrate counting,
insulin-to-carbohydrate ratios, and correction factors to self-adjust insulin doses for
SMBG results, food intake, exercise, and stress. All subjects (n=5 per group) followed
each strategy for 3.5 months before rotating. The groups did not significantly differ in
terms of metabolic control (A1C), frequency of severe hypoglycemia, QOL, or selfefficacy. As expected, the most frequent dose adjustments were made in the
quantitative regimen (p<0.01). The same strategy, quantitative, was also perceived as
the most complex (p<0.001). Surprisingly, at the conclusion of the study, the majority of
patients (n=12) chose to continue with the qualitative regimen, whereas only three
subjects continued with the quantitative strategy. The authors concluded that patients
with T1DM would prefer an intensive insulin management regimen that maximizes
flexibility but does not require very complex calculations of insulin dosing. The study
provides a unique outlook on intensive diabetes management; however, larger studies
must be conducted before conclusions can be drawn.
Basal-bolus insulin management requires a high degree of DSM and can provide
better glycemic control. During periods of glycemic control, persons with DM are able
to optimize their social and role functioning. However, mood disturbances and DMrelated distress can affect self-management and glycemic control. Depressive
symptoms occur in many patients with T1 and T2DM. In a study of adults with T1DM,
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increased prevalence of anxiety in women and depression in men was reported
(Shaban, Fosbury, Kerr & Cavan, 2006). In patients with T2DM, a meta-analysis
estimated the rate of depression to be 17.6 percent, or 1 out of every 6 adults with
T2DM (Ali, Stone, Peters & Khunti, 2006). Patients with DM and mood disturbances
have decreased glycemic control (Hislop et al., 2008) and self-care (Ciechanowski, Katon,
Russo, & Hirsch, 2003). Stress, coping skills, and depressive symptoms have an impact
on self-care practices (Peyrot, McMurry & Kruger, 1999) and glycemic control
(Ciechanowski et al., 2003) in DM. Pediatric patients with T1DM and depression have
poorer glycemic control, adherence, and QOL than their non-depressed peers (Hassan,
Loar, Anderson & Heptulla, 2006; Korbel, Wiebe, Berg & Palmer, 2007). Negative
stressors and DM-related distress have been linked to decreased self-care in DM (Lloyd,
Smith & Weinger, 2005). None of the studies in the literature review examined
depressive symptoms, DSM, and QOL; however, Weinger and Jacobson (2001)
demonstrated that patients with high DM-related distress have worse glycemic control
and self-management, despite interventions (p<.05). Depressive symptoms can affect
self-management and glycemic control, leading to a decrease in overall functional
status. Although the relationships between depression, glycemic control, and functional
status are not fully established, it is clear that all contribute to QOL.
Conventional Measurement of QOL
Many studies have been conducted regarding diabetes and QOL, in both T1DM
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and T2DM. In the past, QOL was infrequently used as the primary outcome measure but
rather a supplemental measure to glycemic control. Over the last decade, QOL has been
used as a major study variable, especially in comparisons between CSII and MDI. The
relationship between CSII and QOL was examined in a systematic literature review by
Barnard, Lloyd, and Skinner, finding no clear QOL benefit from CSII use (2007). A metaanalysis of children with intensively managed T1DM revealed mixed QOL benefits from
CSII vs. MDI (Pankowska, Blazik, Dziechchiarz, Szypowska & Szajewska, 2009). In both
reviews, the authors noted a problematic lack of consistency in QOL measurement. In
many studies, QOL is measured using the Diabetes Quality of Life (DQOL) instrument;
however, the DQOL may not be sensitive or specific enough to measure HRQOL in
diabetes, especially when related to treatment differences (Speight, J. in Barnard, Lloyd
& Skinner, 2007, p.614). The 32 studies of the literature review utilized over 12
different instruments to measure QOL (Table 5). This study is different because it uses
multiple components to measure the unique factors that contribute to HRQOL. By
measuring QOL comprehensively, differences related to type of diabetes management
will be identified.
Table 5. Quality of Life Measures Used by Study Design
QOL Measure

Cross-Sectional

ADDQOL (n=3)
DQOL (n=13)

Bruttomesso, 2002
Hoogma, 2004

Study Design
Longitudinal
Lowe, 2008
Bendik, 2009
Chantelau, 1997

RCT
Ashwell, 2008
DAFNE, 2002
DCCT, 1996
Hoogma, 2006
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Zoppini, 2003

DQOL-CTQ (n=1)
DQOL-Y (n=2)
DSQOLS (n=3)

DTSQ (n=1 primary,
6 secondary)

ITR-QOL (n=1)
SF-36 (n=2 primary;
n=4 secondary)

SF-12 as secondary
measure (n=2)
VITA (n=1)
W-BQ12

EQ1 Study Group,
2008
Scheidegger, 2007
EQ1 Study Group,
2008τ
Hoogma, 2004 τ
(2nd) Schiel &
Mueller, 1999 τ
EQ1 Study Group,
2008 τ

Insabella, 2007
Linkeschova, 2002
Scheidegger, 2007

Jansa, 2006
Kalergis, 2000
Tsui, 2001
Herman, 2005
Doyle, 2004

Ashwell, 2008 τ
DAFNE, 2002 τ
DeVries, 2002 τ
Gale, 2000
Kamoi, 2004
Forlani, 2006
Kalergis, 2000
(MOS) τ

DCCT, 1996 τ
DeVries, 2002
Herman, 2005 τ

Gimenez, 2007 τ

Hoogma, 2006 τ

Aberle, 2009
DAFNE, 2002 τ
Gale, 2000

WED (n=2)
WHO Well-Being
Questionnaire (n=1)
WHOQOL-BREF
(n=1)
Unspecified (n=2)

Gimenez, 2007
Langewitz, 1997
Weinger, 2001

Manini, 2007
Forlani, 2006 τ
Hoogma, 2004 τ
Barnard &
Skinner,2008
Schiel & Muller,
1999

Pfutzner, 1996

Note. ADDQOL = Audit of Diabetes-Dependent Quality of Life; DCCT = Diabetes Control and Complications
Trial; DQOL = Diabetes Quality of Life instrument; DQOL-CTQ = Diabetes Quality of Life—Clinical Trial
Questionnaire; DQOL-Y = Diabetes Quality of Life—Youth; DSQOLS = Diabetes-Specific Quality of Life
Scale; DTSQ = Diabetes Treatment Satisfaction Questionnaire; ITR-QOL = Insulin therapy-related—Qualityof-Life instrument; QOL = quality of life; SF-12 = Short Form-12; SF-36 = Medical Outcomes Study Short
Form-36; RCT = Randomized controlled trial; W-BQ12 = Well-Being Questionnaire 12; WED = Well-Being
Enquiry for Diabetics; WHO = World Health Organization; WHOQOL-BREF = World Health Organization
Quality of Life-Brief instrument
τ
Used as secondary measure

35

Supplemental Literature Review
A supplemental review of the literature was conducted to describe the current
status of research related to intensively-managed T2DM and QOL. The detailed search
strategy is provided in Appendix A. The review identified 12 articles reporting the
findings from nine research projects (Appendix A). The updated search provides a much
greater representation of T2DM in intensively-managed DM research; that is, 11 out of
12 studies exclusively enrolled subjects with T2DM. The remaining study was primarily
composed of participants with T2DM (80%; Testa et al., 2012). Studies have also
improved in methodology: of the nine research studies, five are randomized controlled
trials and four are longitudinal. None were cross-sectional. Sample sizes ranged from
34 to 66,726. Of the reviewed articles, eight examined multiple daily injections (basalbolus; Banerjee, Maji & Baruah, 2013; Hajos et al., 2012; Levin et al., 2011; Opsteen et
al., 2012; Peyrot & Rubin, 2011; Shah et al., 2011; Testa et al., 2012; Vinagre et al.,
2013), 2 studied CSII (Peyrot et al., 2011 and Rubin et al., 2010), and one reported an
intensive management educational program (Hermanns et al., 2012). The remaining
study examined a decrease in intensity of insulin management and will be discussed in
detail below (Dieuzeide et al., 2014).
All studies examined glycemic control, primarily through A1C, but Testa and
colleagues also examined glucose variability (2012). Significant A1C reductions were
reported with improved QOL in six articles (Banerjee, Maji & Baruah, 2013; Hajos et al.,
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2012; Hermanns et al., 2012; Opsteen et al., 2012; Shah et al., 2011; Testa et al., 2012).
Several studies reported hypoglycemia data; none reported associations between
hypoglycemia and QOL. Diabetes symptoms were examined in four papers; three
studies linked reductions in symptoms with improved QOL (Hajos et al., 2012; Opsteen
et al., 2012; Rubin et al., 2010). Depression, anxiety, and DM-distress were measured by
Hermanns et al., who reported decreased depressive symptoms in insulin-naïve subjects
after three months of basal-bolus insulin therapy (2010).
Similar to the initial literature review, the authors used a large variety of
instruments to study QOL. QOL instruments included the DQOL (n=4), SF-12 or SF-36
(n=3), EQ-5DTM (n=6), the WHO-5 Wellbeing Index (n=1), and an author’s own
instrument (n=1; Testa et al., 2012). The diversity of measures used makes comparison
difficult; however, the majority of the articles (n=7) revealed significantly improved QOL
(Appendix A). Lack of QOL effects could be due to small sample sizes (n=37, Vinagre et
al., 2013; n=54, Peyrot et al., 2011) or using instruments with lower sensitivity to QOL in
DM (DQOL, Levin et al., 2011; SF-36, Peyrot & Rubin, 2011). It should be noted that no
studies showed decreased QOL after beginning intensive insulin management.
One article of the literature review had unique findings. Dieuzeide and
colleagues conducted a sub-study (n=1024) of the data from the A1chieve study, a large
multi-national trial of analog insulin initiation (n=66,726). In the sub-study, patients on
multiple daily injections (basal-bolus) changed to analog premixed insulin (basal only;
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Dieuzeide et al., 2014). Significantly improved QOL was found with this less intensive
insulin management strategy (p<.001). However, it should be noted that over 88% of
subjects in the study were using non-analog insulin (Regular and/or NPH) prior to study
enrollment. Use of analog insulin has been linked to improved QOL (Hartman, 2008).
The sub-study subjects also experienced significantly improved glycemic control (mean
A1C decrease by 2%, p<.001) and less hypoglycemia, especially in the baseline NPH
group (n=770; p<.001). Both of these factors may be confounding variables in the
analysis of insulin management strategy and QOL. Finally, the Dieuzeide study suffered
from large sample attrition as 491 subjects (48%) were lost to follow-up. Attrition
greater than 20% may affect generalizability and internal validity (Polit & Beck, 2004).
The findings of this study must be considered carefully and should be replicated before
making final conclusions regarding QOL in intensive insulin management .

CHAPTER THREE
METHODOLOGY

The study was an observational study to examine quality of life in patients with
type 2 diabetes, according to type of glycemic management. The aims are as follows: (1)
to describe the HRQOL of persons with T2DM according to type of glycemic
management [Oral meds only, Insulin once or twice daily (basal only), Insulin three or
more times daily (basal-bolus)], (2) to determine if HRQOL of persons with T2DM differs
depending on type of glycemic management, and (3) To determine if type of glycemic
management is predictive of HRQOL after controlling for covariates (i.e., age, gender,
complications of DM, duration of DM).
Design
The study was a cross-sectional, observational study exploring differences in
HRQOL outcomes in patients with type 2 diabetes, based on type of diabetes
management. The study attempted to determine whether the type of insulin
management has a significant impact on HRQOL in persons with T2DM.
Setting
The study was conducted through the mail, with recruitment of participants
through clinic, electronic, and community sources. Data collection occurred over a
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period of 15 months (January 2012 to March 2013). All participants lived within the
United States.
Sample
Inclusion Criteria
All adults 18 years and older who reported that they had “adult onset” or “type 2
diabetes” for at least six months and could read, write, and speak English were eligible
for the study. Participants had to have been taking antihyperglycemic medications at
least daily (insulin or oral) and be using the same medication regimen (insulin or oral)
for the past three months. The inclusion criteria of having diabetes for at least six
months was selected as it is the time where the maintenance phase of treatment occurs
with a new health behavior (Prochaska & Velicer, 1997).
Exclusion Criteria
Patients were excluded if they had the following co-morbid diagnoses with
potential to impact HRQOL: major psychiatric disorders (not including depression),
dementia, Alzheimer’s, HIV, cancer (requiring chemotherapy or radiation in the last 3
years), or other chronic conditions that may impact QOL (e.g., sickle cell disease,
multiple sclerosis, fibromyalgia). Patients reporting current pregnancy were excluded
from the study. The participant screening tool is shown in Appendix B.
Sample Size Estimation
Power analyses were completed using G*power version 3.1.2 (F. Faul,
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Universität Kiel, Germany; Faul, Erdfelder, Lang & Buchner, 2007). As the three research
aims have different statistical analyses, three preliminary power analyses were
conducted using G*power, to obtain minimum sample size for the study. Medium
effect sizes were chosen for the power analyses; values for medium effect size were
provided by G*power. Alpha was set at 0.05 for all power analyses. For a fixed-effects,
one-way ANOVA (3 groups), a total sample size of 159 is required to achieve 80% power
with an effect size of F=0.25. For the special effects MANOVA with interactions, a
sample size of 73 is necessary to achieve an F2 of 0.25 at 95% power with four groups,
three predictors, and one response variable. For a fixed-model multiple regression,
assuming a R2 deviation from zero, a sample size of 138 subjects is required to obtain an
F2 of 0.15 at 95% power with five predictors. Details of the power analyses are given in
Table 6. Given that 159 is the maximum number of persons needed to meet the aims,
and that a maximum of missing or incomplete data could be approximately 25 percent,
the enrollment goal of the study was 199 total subjects.

Table 6. Power Analysis: Sample Size Calculations Based on Statistical Test
Statistical
Test

Effect
size

Alpha

Power

Groups

Predictors

Response
Variables

N
required

ANOVA

F=0.25

0.05

0.80

3

n/a

n/a

159

MANOVA

F2=0.25

0.05

0.95

4

3

1

73

Multiple
regression

F2=0.15

0.05

0.95

n/a

5

n/a

138
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Data Collection
Recruitment
Participants were recruited through one of seven methods: (1) letter mailed to
persons with diabetes who have agreed to be informed of diabetes studies through a
National Institute of Health (NIH)-funded study of women with T2DM informing them of
the proposed study (Appendix C), (2) flyers posted at outpatient clinics in the Midwest
suburbs of Chicago (Appendix D), (3) electronic flyers posted to websites of interest to
people with diabetes (Table 7), (4) Chicago Diabetes EXPO (April 14, 2012, at McCormick
Place), (5) study notification (containing electronic flyer) sent to all staff members at a
Chicago-area University Medical Center via Novell Web Access e-mail broadcast, (6)
community posting of flyers in churches, park districts, coffeehouses, etc. and (7)
snowball recruitment (study contact information was given by an enrolled subject to a
friend/family member who then initiated contact with the primary investigator). The
query letter and flyer directed participants to contact the primary investigator (Sandra
McCormick) via phone call. Within 48 hours, calls were returned to explain the study,
determine agreement for participation, and screen for eligibility. Subjects meeting the
inclusion criteria were asked for their mailing address and the best way to contact them
(e-mail or phone). Subsequently, a study packet was sent to their mailing address,
including a pre-addressed, stamped envelope for return of study materials.
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Table 7. Diabetes-Related Websites for Study Recruitment
Website Name
American Diabetes
Association: Chicago
American Diabetes
Association
Dailystrength.org

Diabetes Blog Network
Diabeticconnect.com
Facebook

Type
Social media
site
Support Forum
“Adults Living
with Type 2”
Message Board
“People with
Type 2
Diabetes”
Diabetes blogs
Discussion
boards
Social media
site

Website Address
http://www.facebook.com/chicagoada
http://community.diabetes.org/t5/AdultsLiving-with-Type-2/bd-p/Adults-Livingwith-Type-2
http://www.dailystrength.org/c/DiabetesType-2/support-group

http://www.diabetesblognetwork.com/
http://www.diabeticconnect.com/
http://www.facebook.com/T2Diabetes

Procedure of Data Collection
The study packet included a cover letter describing the study, the process for
participation, and instructions to contact the study investigator, Ms. McCormick, with
any questions (Appendix E). The letter stated that participation would take about 90
minutes of their time. The letter delineated the three steps of participation: (1)
completion of an 18-page questionnaire booklet, which includes seven study tools, (2)
performance of a fingerstick A1C test kit with instructions, and (3) return of the
completed materials by U.S. Mail in the provided pre-paid envelope. The envelope was
pre-addressed to the study investigator’s Post Office Box. Each questionnaire booklet
and A1C test kit had a pre-assigned ID number. Upon receipt of the materials, the study
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investigator sent the A1C blood spots for testing. Data collection occurred concurrently
among subjects.
Measurements
All additional study variables were assessed using established, psychometrically
validated instruments as discussed below. The measurements for the respective
variables are described below using the framework used to guide this study (Table 8).
Table 8. Variables and Measurements of Study
Revised Wilson and Cleary
HRQOL Concepts
Individual Characteristics
Environmental
Characteristics
Biological function

Symptoms

Functional Performance

Study Variable

Measurement Tool

Demographics
Access to diabetes care
Social Support
Insulin dosing frequency
Comorbidities/complications
Glycemic control
Hypoglycemia
Hyperglycemia
Mood
Pain
Vision
Activity tolerance
Social Functioning (Mental
Health Summary)
Role functioning (Physical
Health Summary)
Diabetes Self-Management
Overall health

Questionnaire
Brief-CIRS item
Brief-CIRS
Questionnaire
Questionnaire

General health perception
Quality of life

Acceptance of diabetes
Perceived HRQOL

A1C (Reli On, Heritage Labs)
DSC-R & self-report items
DSC-R
Well-Being Questionnaire 12
DSC-R
DSC-R
DSC-R
SF-12 Health Survey (version
2): MCS
SF-12 Health Survey (version
2): PCS
Self Care Inventory-Revised
General health item of SF-12
(v2)
Appraisal of Diabetes Scale
Quality of Life Index

Note. HRQOL = Health-Related Quality of Life; CIRS = Chronic Illness Resources Survey; A1C = Glycosylated
Hemoglobin; DSC-R = Diabetes Symptom Checklist-Revised.
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Instrument costs and access are noted in Table 9.
Table 9. Study Instruments: Costs, Access, and Websites
Instrument
Name
Brief Chronic
Illness Resource
Survey
Diabetes
Symptom
ChecklistRevised
Well-Being
Questionnaire
12
SF-12 Health
Survey, version
2
Self-Care
InventoryRevised
Appraisal of
Diabetes Scale
Quality of Life
Index: Diabetes
Version

Need
Permission

Website

Free

No

https://www.gembeta.org/public/MeasureDetail.aspx?mid=116&
cat=2&mode=m

Free

No

www.vumc.com/afdelingen/diabetespsychology/Measures

Cost

$

a

Yes

a

http://www.healthpsychologyresearch.com/Ad
min/uploaded/Summary/wbq12%20summary%20rev_15jan07.pdf

$b

Yes b

http://www.sf-36.org/tools/sf12.shtml

Free

Yes c

http://www.psy.miami.edu/faculty/alagreca/SCI
_manual_2004.pdf

Free

No

www.musc.edu/dfm/RCMAR/DiabetesTools.ht
ml

Free

Not for
non-profit

www.uic.edu/orgs/qli

a

Student licensing agreement received. No cost for unfunded students.
Student license agreement received. No cost for unfunded students.
c
Permission received from copyright holder Dr. LaGreca.
b

Individual Characteristics
Individual characteristics were assessed via demographic questionnaire
(Appendix F). The questionnaire also assessed insulin dosing frequency and presence of
co-morbidities and diabetes complications (Appendix F). Additional single items were
scored using Likert-type scoring, ranging from “not at all” to “a great deal”.
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Biologic Function
Biologic function was assessed by glycemic control, diabetes complications, and
insulin dosing frequency. For glycemic control, hemoglobin A1C was measured using
the Reli-On Home A1C test (Heritage Labs International, Olathe, KS), an at-home
fingerstick test kit that uses filter paper and postal submission to their laboratory
(Heritage Labs, n.d.). The Reli On Home Diabetes A1C Test is manufactured and tested
by Heritage Labs International (Olathe, KS). Designed for home use by retail consumers,
the test uses fingerstick blood sampling on filter paper to provide A1C assessment. The
sample is submitted by mail to the laboratory. The CLIA-certified results are available
online within 3 business days or can be mailed directly to the patient and/or researcher
(CLIA Registration number 17D0943396). Use of capillary blood filter paper A1C testing
has been compared to venous laboratory testing (r=0.987) and is considered a valid
method of measuring A1C, with between-filter coefficient of variation of 1.8 percent
(Fokkema et al., 2009). Heritage Labs reports the air-dried filter paper blood specimens
are stable for at least 30 days at room temperature (Heritage Labs, n.d.). Precision of
the Reli On has been demonstrated using within-assay variability at four levels of A1C,
with a coefficient of variation less than two percent (Table 10). Linearity was
established in a full range of A1C values (3.10 to 16.23) with a maximum deviation of 1.3
percent. Accuracy of the Reli On was verified using comparison of samples with whole
blood A1C samples in a diverse range (linear regression R2 = 0.9979; Heritage Labs, n.d.).
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The Reli On Home Diabetes A1C kit provided a simple, valid, and accurate method of
measuring A1C in this study.
Table 10. Within-assay Variability: Reli On® / Appraise® Hemoglobin A1C Test
Mean Hemoglobin A1C (%)
5.6
7.3
8.7
10.4

Standard Deviation
0.1
0.0
0.0
0.0

Coefficient of Variation (%)
1.8
0.0
0.0
0.0

Specimens tested 20 times
From Appraise® Hemoglobin A1C Test, Heritage Labs, Olathe, KS

Environmental Characteristics
Access to diabetes care. Access to care was measured using a single item from
the Brief-CIRS instrument (discussed below), “Have you had health insurance that
covered most of the costs of your medical needs including medicine?” (Glasgow,
Toobert, Barrera & Strycker, 2004).
Social support. This was measured using the Chronic Illness Resources Survey.
The Chronic Illness Resources Survey (CIRS) was developed to provide a measurement of
socio-ecological support for chronic disease self-management (Glasgow, Strycker,
Toobert & Eakin, 2000). The original instrument was 64 items and had subscales of
personal, family/friends, physician/health care team, neighborhood/community,
organizations, work, media & policy. Items were scored on a Likert-type scale (1=not at
all to 5=a great deal); means were calculated for subscale scores. High scores denote
high support for disease self-management. The original 64-item instrument was
reduced to 29 items and then to 22 items to create the Brief-CIRS, without sacrificing
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internal consistency (α = 0.82) or test-retest reliability (r=0.70; Glasgow et al., 2004).
Some individual subscales from the Brief-CIRS are not as valid as the original CIRS
(α=0.40-0.55; Glasgow et al., 2004); therefore, the subscales of media & policy,
organizations, and neighborhood/community were not used individually in this study.
The Brief-CIRS was administered in original format; however, items from the subscales
in question were used only to calculate the overall score. Remaining subscales of the
Brief-CIRS have acceptable internal consistency (e.g., personal, family/friends and
physician/health care team). Convergent validity was tentatively established for the
Brief-CIRS total score and subscales using correlation with existing measures of social
support (Interpersonal Support Evaluation Checklist), and healthful eating and activity
patterns (Social Support for Eating Habits and Exercise Survey; r=0.17 to 0.56; Glasgow
et al., 2004). The Brief-CIRS provided a multidimensional assessment of environmental
support for the study (Appendix F). For the present study, the Cronbach’s alpha was
0.810, indicating acceptable reliability (Polit & Beck, 2004).
Symptoms
Hypoglycemia. Frequency of hypoglycemia was assessed using two self-report
questions developed by the author: (1) in the last week, how many times have you
experienced hypoglycemia? and (2) in the past year, how many times have you
experienced hypoglycemia requiring the help of another person? (Appendix F).
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Diabetes symptoms. Designed to measure the symptoms experienced by
patients with T2DM, the Diabetes Symptom Checklist-Revised (DSC-R) is an instrument
which quantifies the presence and perceived burden of physical and psychological
symptoms of diabetes and its complications (Grootenhuis, Snoek, Heine & Bouter,
1994). The 34-item questionnaire allows respondents to report the presence (or
absence) and rate the degree of discomfort the symptom has caused using Likert scaling
(from 1=”not at all troublesome” to 5=”extremely troublesome”). The DSC-R explores
symptoms from eight dimensions: hyperglycemia, hypoglycemia, ophthalmology,
cardiology, neuro-sensory, neuro-pain, psychology-cognitive, and psychology-fatigue.
Total scores and subscale scores range from zero to five, with higher scores indicating
greater diabetes-related symptoms.
Originally developed in 1994 from literature reviews and consultation with
physician experts, the DSC was revised in 2009 to clarify scaling and presence of
symptoms (Arbuckle et al., 2009). Internal consistency of the DSC-R was measured by
Cronbach’s alpha ranging from 0.76-0.95 for all dimensions (α=0.69-0.87 subscales, 0.95
overall; Arbuckle et al., 2009). Test-retest reliability was established (r=0.79-0.94) and
confirmatory factor analysis verified validity of subscale dimensions (GFI= .9022;
Arbuckle et al., 2009). Concurrent validity was documented by correlations between
DSC-R scores and SF-36 scores (r=-0.22 to -0.69; Arbuckle et al., 2009). The DSC-R
measured the importance and presence of diabetes-related symptoms for the subjects
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in the study (Appendix F). For the present study, the Cronbach’s alpha was 0.942,
indicating a very reliable instrument.
Mood symptoms. The Well-Being Questionnaire 12 (W-BQ12) was used to
measure psychological well-being (Bradley, 2007). The twelve-item scale is a revision of
the W-BQ22, which was developed from interviews of clinicians and patients with IDDM
(Garratt et al., 2000). The W-BQ12 is a brief assessment of positive and negative
psychological well-being. Each of the 12 items is scored from 0 (“not at all”) to 3 (“all
the time”; Bradley, 2007). The first three subscales (negative well-being, energy,
positive well-being) ranging from 0 to 12 points are totaled to obtain the general wellbeing, or summary score, of 0 to 36 points (Bradley, 2007). Higher scores represent
greater well-being. The negative well-being subscale is negatively worded and reversescored in the summary total. The W-BQ12 has been successfully used in subjects with
IDDM and DM treated with oral medications (Garratt et al., 2000).
Factor analysis of the W-BQ12 supported the three-factor solution (≥90% of
variance explained; Pouwer, Snoek, van der Ploeg, Ader & Heine, 2000). Item-total
correlations were acceptable (0.38 to 0.75; Pouwer et al., 2000). Internal consistency,
as measured by Cronbach’s alpha, ranged from 0.73 (negative well-being) to 0.91
(general well-being; Pouwer, van der Ploeg, Ader, Heine & Snoek, 1999). Test-retest
reliability was 0.66 to 0.83 over two months (Pouwer et al., 1999). Construct validity
was demonstrated by correlations between negative well-being and the following

50

instruments: the Hospital Anxiety and Depression Scale (r=0.54-0.60), the State/Trait
Anxiety Inventory (r=0.63-0.76), and the Center for Epidemiological Studies Depression
Scale (r=0.67). Furthermore, general well-being correlated positively with the SF-36
(r=0.22-0.49) and negatively with the Center for Epidemiological Studies Depression
Scale (r= -0.80; Pouwer et al., 1999). In conjunction with the psychological dimensions
of the DSC-R, the W-BQ12 measured psychological well-being in study subjects
(Appendix F). Diagnoses of depression or anxiety were not made. For the present
study, the Cronbach’s alpha was 0.883 for general well-being. For the subscales, the
Cronbach’s alpha was 0.746 for negative well-being, 0.796 for energy, and 0.829 for
positive well-being.
Functional Performance
Social and role function. Social and role functioning were assessed using the SF12 Health Survey (version 2). The SF-12 (v2) is an abbreviated version of the SF-36, a
measure of physical and mental functional health status (Ware, Kosinski, Turner-Bowker
& Gandek, 2002). The SF-12 is widely used in health care research and has been used
with adult patients with a variety of medical diagnoses, including DM. Each of the 12
questions is scored on a 5-point Likert-type scale with higher scores equaling better
functioning. The SF-12 has eight subscales: physical functioning, role-physical
functioning, body pain, general health, vitality, social functioning, role-emotional
functioning, and mental health. Scoring is provided for each subscale and for both a
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physical and mental composite score. The SF-12 has acceptable test-retest reliability
(0.76 – 0.89; Ware et al., 2002). The instrument has high internal consistency as
measured by Cronbach’s alpha of 0.80 to 0.90 for composite scores (Ware et al., 2002).
Subscale scores are less reliable, with Cronbach’s alpha ranging from 0.66 to 0.90 in the
general population (Ware et al., 2002). For this study, only the physical and mental
composite scores of the SF-12 were used to represent functional status. The SF-12 is
shown in Appendix F. Instrument reliability in this study was demonstrated with a
Cronbach’s alpha of 0.815 (physical composite score) and 0.792 (mental composite
score).
Diabetes self-management. Another dimension of functional performance,
diabetes self-management, was assessed using the Self Care Inventory-Revised (SCI-R).
The Self Care Inventory was originally developed in 1988 to measure patients’
perceptions and performance of self-care activities as related to DM (LaGreca et al. in
Weinger, Butler, Welch & LaGreca, 2005). It was later revised to reflect changes in DSM
practice. The 15-item questionnaire includes assessment of dietary practices, blood
glucose monitoring, medication administration practices (including insulin), exercise,
hypoglycemia treatment, and basic diabetes self-care. Items are rated on a Likert scale
of “never” to “always”, with the option of “not applicable” for insulin, pills, and ketone
testing. Items are averaged and converted to a scale of 0-100 points. Tested in patients
with T1 and T2DM, reliability was established with internal consistency of α = 0.87.
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Concurrent validity was established with an existing measure of diabetes self-care
(r=0.63); convergent validity was documented via negative correlation with diabetesrelated distress (r=-0.36; Weinger et al., 2005). Principal components analysis
confirmed the single-scaling of the measure (Eigenvalue=4.5 explained 38% variance in
n=199 subjects with T2DM, factor loadings 0.44 to 0.79); responsiveness was
established by documented improvement in SCI-R scores after receiving DSM education
(Weinger et al., 2005). In this study, the SCI-R measured subjects’ performance of DSM
activities (Appendix F). For the present study, Cronbach’s alpha was 0.651, indicating
sub-optimal reliability for the overall scale. The Cronbach’s alpha was recalculated
without two items (“check ketones when glucose level is high” and “carry quick acting
sugar to treat low blood glucose”). The SCI-R was originally developed for patients with
T1DM. Patients with T2DM are less likely to experience hypoglycemia and be instructed
to check ketones. In subjects taking oral medication only, the recalculated Cronbach’s
alpha was 0.714. The Cronbach’s alpha was 0.713 for subjects on insulin, indicating
acceptable reliability of the measure in both groups.
General Health Perceptions
To assess for subjects’ acceptance of diabetes, the Appraisal of Diabetes Scale
(ADS) was used. The ADS is a seven-item questionnaire that can be completed within
five minutes (Carey et al., 1991). Originally tested on 200 men with diabetes (n=132
with IDDM), the ADS was designed as a single factor scale to evaluate personal beliefs
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about DM and its impact. The questions assess control, uncertainty, coping, effect of
diabetes on life goals, predictive view of diabetes and degree of distress caused by
diabetes (Garratt, Schmidt & Fitzpatrick, 2002). A higher ADS score indicates a greater
negative impact of DM or less personal acceptance of the disease. Internal consistency
was measured 0.73 by Cronbach’s alpha; reliability was measured by a test-retest
correlation of 0.85-0.89 (Carey et al., 1991). Validity was established via correlation
with existing measures: Diabetic Daily Hassles Scale (r=0.59), Diabetes Health Belief
Questionnaire (r=0.31-0.42) and the Perceived Stress Scale (r=0.49; Garratt, Schmidt, &
Fitzpatrick, 2002). Principal components analysis confirmed single-scaling of the ADS
(Eigenvalue=2.73 explained 39% variance, factor loadings 0.424 to 0.752; Carey et al.,
1991). The ADS provided a quantitative measure of subjects’ personal models and
acceptance of diabetes for this study (Appendix F). For the present study, Cronbach’s
alpha was 0.820, indicating acceptable reliability.
Quality of Life
Perceived health-related quality of life was assessed by the Quality of Life Index:
Diabetes Version. The Ferrans and Powers Quality of Life Index (QLI) was developed
originally in 1984 as a measure of multidimensional QOL (Ferrans & Powers, 1985).
Respondents rate their satisfaction with (1=very dissatisfied to 6=very satisfied) and the
importance of (1=very unimportant to 6=very important) QOL-related items using a
Likert scale. Satisfaction ratings are weighted by importance to calculate an overall
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score and subscores for four domains: health and functioning, psychological and
spiritual, social and economic, and family. Possible total scores range from zero to 30.
The mean score of 23.00 represents the normal population and 20.56 represents
persons with diabetes. From the generic version, additional versions of the QLI have
been created for a variety of disease populations, including arthritis, cancer, cardiac,
chronic fatigue, DM, dialysis, epilepsy, renal and liver transplant, multiple sclerosis,
pulmonary, spinal cord injury, and stroke (Ferrans & Powers, n.d.a). The diabetes
version has 34 items and is available in five languages including English. It is written at
the fourth-grade reading level and can be self-administered in approximately ten
minutes. Construct validity of the QLI was established via strong correlations (r=0.610.93) with the Campbell, Converse, and Rodgers measure of life satisfaction (1976) and
factor analysis confirming the subscales and explaining 91 percent of the variance
(Ferrans & Powers, 1992; Ferrans & Powers, n.d.b) The QLI has demonstrated sensitivity
to change (DeSouza & Nairy, 2003; Hathaway et al., 1994a; Hathaway et al., 1994b) and
test-retest reliability (r=0.87 for 2 week interval; Ferrans & Powers, 1985). Both total
and sub-scales have demonstrated excellent internal consistency, with a Cronbach’s
alpha ranging from 0.85 to 0.97 (DeSouza & Nairy, 2003; Ozer & Efe, 2006). Although
the QLI has not been used in any published studies of DM managed with basal-bolus
insulin, the QLI-Diabetes version has been used in four studies of patients with T2DM
(Arun et al., 2008; DeSouza & Nairy, 2003; Hu, Wallace & Tesh, 2010; Quinn, 1996) and
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one study of patients with either T1 or T2DM (Lewko, et al., 2013; see Table 11). Also,
the QLI-generic version was used in a study of patients with T1DM undergoing
transplantation (Hathaway et al., 1994a; Hathaway et al., 1994b; see Table 11).
Although the QLI-Diabetes version has not been used with patients using intensive
insulin management for their DM 1, it has well-established reliability and validity and is a
promising multidimensional tool for QOL assessment in this population. The QLI:
Diabetes Version provided a multidimensional measurement of HRQOL in study subjects
(Appendix F). For the present study, Cronbach’s alpha was 0.949 for overall quality of
life and for the subscales was 0.914 for health and functioning, 0.908 for psychological
and spiritual, 0.773 for social and economic, and 0.714 for family.

1

As of 6/1/2014, per searches of OVID, PubMed, and CINAHL, no studies were found using the QLI in DM
managed with basal or basal-bolus insulin.
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Table 11. Studies Using the Quality of Life Index
Authors

Design

Arun et al.
2008
DeSouza &
Nairy,
2003

RCT: role of
pharmacist
Longitudinal:
Nurse-directed
intervention
CrossHu,
sectional: Diet,
Wallace & Exercise,
Tesh, 2010 Obesity as QOL
predictors
Crosssectional: hand
Lewko et
neuropathy,
al. 2013
function as
related to QOL
and depression
Quinn,
RCT: impact of
1996
exercise
Hathaway
et al.
1994a;
Hathaway
et al.,
1994b

Longitudinal:
Pre-Post
Transplant
(Kidney only or
kidneypancreas)

Mean
Age
QLI: Diabetes Version
Rural India:
154
58
outpatient
65%
India:
60
are
outpatient
41-60
Setting

N

%
Female

DM
type

Duration
(months)

55

2a

5

28

b

2

Southeastern
US:
outpatient

59

49

68

2c

0

Poland:
inpatient

71

55

52

1 or
2d

0

50

2e

2

60

1

6

Urban US:
10
60
outpatient
QLI: Generic Version
US: Large
medical &
transplant
center

30

40

Note. DM = diabetes mellitus; RCT = randomized controlled trial; QOL = quality of life
a
Controlled by oral medications only
b
Type of DM not specified; 78% of sample treated with oral medications and diet
c
Majority of subjects took oral medications; 25.6% on insulin
d
Majority of subjects (70%) had T2DM. No medication regimen(s) reported
e
Controlled by diet or oral medications
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Data Analysis
Data Entry and Cleaning
De-identified data was entered directly from questionnaire booklets into an SPSS
file (SPSS Windows Version 20.0, SPSS, Chicago, IL). Data cleaning was performed using
frequency distributions (categorical and interval variables) and descriptive statistics
(continuous variables) to verify freedom from data entry errors. Missing data was
reported using descriptive statistics and is reported in Chapter 4. Demographic
information was analyzed using descriptive statistics.
Analysis per Aims
Data analysis for each aim included:
Aim 1: To describe the HRQOL of persons with T2DM according to type of
glycemic management. Analysis: Patients were divided into groups based on
medication dosing frequency [Oral meds only, Insulin once or twice daily (basal only),
Insulin three or more times daily (basal-bolus)]. Descriptive statistics were used to
report total and subscale QOL and to describe the sample.
Aim 2: To determine if HRQOL of persons with T2DM differs depending on type
of glycemic management. Analysis: ANOVA/MANOVA. Subjects were divided into
three groups based on the type of glycemic management: oral meds only, insulin once
or twice daily (basal), insulin three or more times daily (basal-bolus). The dependent
variable, quality of life, was represented by QLI scores. Group differences in QLI scores
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were examined using Analysis of Variance (ANOVA), with post-hoc testing planned to
establish pair-wise group differences (Munro, 2005).
To examine complex interactions that may confound QOL measurement in this
population, Multifactorial Analysis of Variance (MANOVA) was used. In the MANOVA,
the variables tested included: type of glycemic management (oral, basal insulin, or
basal-bolus insulin), glycemic control (Hemoglobin A1C), diabetes symptoms, mood
(psychological well-being), diabetes self-care, acceptance of diabetes, and quality of life.
These variables were chosen according to the study model, which represents subjects’
overall adjustment to life with diabetes. Sources of variation in the MANOVA included
main effects as well as interactions between variables. Analysis of two- and three-way
interactions can provide a greater understanding of interrelation between complex
variables that can affect a dependent variable (Munro, 2005).
Aim 3: To determine if type of glycemic management is predictive of HRQOL
after controlling for covariates (age, gender, complications of DM, duration of DM).
Analysis: Multiple Regression. Multiple regression is a statistical technique which uses
several independent variables to predict a dependent variable in an equation format
(Munro, 2005). Three multiple regressions were performed. In the first regression,
predictor variables such as hemoglobin A1C, diabetes symptoms, diabetes self-care,
general well-being, and acceptance of diabetes were entered with QLI scores in a
simultaneous manner to obtain the prediction equation. In the second regression, the
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same predictor variables were entered in a forward method to predict QLI scores. All
variables’ beta weights were examined for significance (p≤.05) before inclusion into the
prediction equation (Munro, 2005). Variables that do not contribute a significant R 2
change to the equation were not included. Finally, the predictor variables of general
well-being and diabetes self-care were used in a multiple regression (forward method)
followed by forced entry of the moderation effect between the two predictors of QOL.
Details of the analyses are discussed in Chapter Four.
Human Subjects Protection
Human subjects procedures included the telephone screening process,
answering of the questionnaire booklet, and the performance of fingerstick capillary
blood sampling on filter paper for A1C testing. The study included both male and
female adult patients with T2DM. Patients with major psychiatric disorders (not
including depression), dementia, Alzheimer’s, HIV, cancer (requiring chemotherapy or
radiation in the last 5 years), sickle cell disease, fibromyalgia, or active pregnancy were
excluded from the study, due to the impact of these conditions on QOL and possible
confounding effects. Persons who were unable to read, write, and speak English were
excluded from the study. As the study was conducted by a graduate student with
limited funding, it was beyond the scope of this study to provide interpretive services
for potential subjects.
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To ensure protection against risks, all data was collected from de-identified
questionnaire booklets and from fingerstick A1C card, resulted from the company using
a unique identification number assigned by the study investigator.
Potential risks included breach of confidentiality and infection at fingerstick site.
The above potential risks were judged as unlikely to occur as precautions to ensure
confidentiality were taken. The list of eligible subjects and recorded data is kept in a
locked file drawer. Completed instruments fingerstick card (sent through the mail), and
results do not have any identifying information. Only research team members have
access to this data. Pregnant women and children were not included in this research
study. To prevent infection, explicit directions on how to perform an aseptic fingerstick
bloodspot sample were provided; however, since most subjects routinely perform selfmonitoring of blood glucose, this fingerstick sample was a familiar experience. The
potential risks were minimal and precautions to prevent breach of confidentiality
continue with the de-identification and aggregation of all data. For this study, there was
no breach of confidentiality or infection known to this investigator.
There were no direct benefits from participation in the study; however, the
results of the study may help caregivers to better understand the experience of persons
living with T2DM which may help them to provide better care. All participants were
sent a copy of their A1C results by mail. Subjects who completed the study received a
$10 gift card as an honorarium for their time.

CHAPTER FOUR
RESULTS
The purpose of the study was to examine quality of life in patients with type 2
diabetes according to type of glycemic management. Description of the sample is
provided via descriptive statistics. The aims of the study were as follows: (1) to
describe the HRQOL of persons with T2DM according to type of glycemic management
[Oral meds only, Basal insulin only (once or twice daily), Basal-bolus insulin (three or
more times daily)], (2) to determine if HRQOL of persons with T2DM differs depending
on type of glycemic management, and (3) to determine if type of glycemic management
is predictive of HRQOL after controlling for covariates.
Recruitment Information
One hundred thirty eight people called the study voice mail (See Figure 2 for
enrollment diagram). Of these, 120 met criteria and agreed to be enrolled in the study.
Of the 120 enrolled, 107 subjects completed and returned their study packets. The final
sample was 107 adults (73 on oral medications only, 15 on basal insulin, 19 on basalbolus insulin). Sources of recruitment for the sample are shown in Table 12. The most
common sources of recruitment were a database of local patients who had agreed to be
notified of diabetes studies (43%) and internet flier posting (Facebook; 39%).
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Figure 2. Enrollment Diagram

Table 12. Recruitment Sources
Recruitment Source
Database
Expo
Facebook
LUMC Diabetes
Snowball
Diabetic Connect
Staff email LUMC
Total

Final Sample
Frequency
Percent
46
43.0
3
2.8
39
36.4
4
3.7
9
8.4
2
1.9
4
3.7
107
100.0

Excluded/Non-respondents
Frequency
Percent
12
38.7
3
9.7
7
22.6
2
6.5
4
12.9
3
9.6
0
0
31
100.0
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Missing Data
Missing data was limited because all booklets were checked for completion upon
return. All subjects with missing data had agreed to be contacted by the primary
investigator in case of questions regarding survey completion. Subjects were contacted
by telephone and provided information regarding missing items (i.e., skipped
accidentally or on purpose). Purposeful blank items were accepted. There was less
than one percent of unexpected missing data (total 21 items in entire sample). Some
data was expected to be missing; for example, the majority of the sample was retired,
work-related items were not completed by these subjects. In most cases, expected
missing data did not affect scoring because authors of the study instruments had
provided for missing data while designing the scoring metric (CIRS, QLI). Replacement
of data was done as reported in Appendix G. When data could not be deductively
imputed without excessive risk of distorting relationships between variables, it was not
replaced. Data was not replaced in the following items: income (7.5%), history of eye
problems (<1%), work-related questions (34-67%), children/sex life/spouse (9-20%).
Details are provided in Appendix G.
In nine cases, the hemoglobin A1C was unable to be processed by the laboratory
due to insufficient specimen quantity. These subjects were all re-contacted to request
an additional fingerstick specimen; of the three subjects reached, all returned a second
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specimen for successful testing. Six subjects were lost to follow-up for obtaining a
second sample of testing (5.6%).
Expected missing data included employment- and family-related items. Both the
CIRS and QLI had expected missing data related to employment. The majority of
subjects (67.3%) reported not currently working outside the home. The QLI also had
expected missing data related to family. Forty-two percent of subjects reported their
marital status as single, divorced, separated, or widowed. Also, 9.3% of subjects stated
no children. These items were accepted as blank and not replaced. Total and most
subscale scores were successfully calculated without the expected missing items. The
exception was the CIRS work subscale, which could only be calculated for 35 subjects.
Characteristics of Overall Sample
The majority of the sample was female (75.7%), non-Hispanic (96.2%), Caucasian
(84.1%), married (57.9%), retired (52.3%), and had an average age of 64 years.
Demographics of the sample are provided in Table 13. Subjects were divided into
groups based on type of insulin management (oral medication only, basal insulin, basalbolus insulin). Chi-square tests did not detect differences between groups in gender,
ethnicity, income, education, and employment. Using chi-square, significant differences
were found between groups in race and marital status. White subjects were most likely
to be on oral medication only; black subjects were equally likely to be on oral
medication or basal insulin (χ=27.050, p<.01). Subjects using basal-bolus insulin were
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89.5% Caucasian. Subjects who were never married were most likely to be using basal
insulin; subjects of every other marital status were most likely to be taking oral
medications only (χ=30.828, p<.001). Subjects on basal insulin were slightly younger
than subjects on oral medications only or basal-bolus insulin; however, per one-way
ANOVA, this was not statistically significant.
Table 13. Description of the Sample

Variable
Age
Gender
Ethnicity
Race**

Marital
Status***

Income
(n=99)

Mean ± SD
Range
Female
Male
Hispanic
Non-Hispanic
White
Black
Asian
American Indian
Other
Married
Divorced
Never Married
Widowed
Separated
Less than $9,999
$10,000-14,999
$15,000-19,999
$20,000-29,999
$30,000-39,999
$40,000-49,999
$50,000-59,999
$60,000-69,999
Over $70,000

Total
Sample
N=107 (%)
63.8 ± 11.8
27-87
81 (76%)
26 (24%)
4 (4%)
103 (96%)
90 (84%)
12 (11%)
3 (3%)
1 (1%)
1 (1%)
62 (58%)
16 (15%)
14 (13%)
13 (12%)
2 (2%)
6 (6%)
4 (4%)
5 (5%)
13 (13%)
11 (11%)
9 (9%)
9 (9%)
5 (5%)
37 (37%)

Oral
Medication
N= 73
65.3 ± 11.6
27-87
55
18
3
70
65
5
3
0
0
48
8
5
10
2
2
2
4
8
5
3
7
3
32

Insulin
Basal
Basal-Bolus
N=15
N=19
57.4 ± 12.2 63.1 ± 11.2
36-82
42-83
14
12
1
7
0
1
15
18
8
17
6
1
0
0
1
0
0
1
4
10
2
6
8
1
1
2
0
0
2
2
1
1
1
0
2
3
3
3
2
4
1
1
1
1
2
3
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Education

Graduate Degree
Bachelors
Associate
Some college
High School Grad
9th-12th grade
Less than 9th
Employment Working FullTime
Working PartTime
Unemployed
Homemaker
Retired
Disabled
Other

13 (12%)
26 (24%)
11 (10%)
35 (33%)
16 (15%)
4 (4%)
2 (2%)
26 (24%)

13
18
7
24
8
1
2
17

0
5
0
5
4
1
0
5

0
3
4
6
4
2
0
4

7 (7%)

5

2

0

3 (3%)
3 (3%)
56 (52%)
10 (9%)
2 (2%)

3
3
39
5
1

0
0
5
2
1

0
0
12
3
0

**Significant differences between insulin management (p<.01)
***Significant differences between insulin management groups (p<.001)

Health history and diabetes-related complications are reported in Table 14. The
majority of subjects were overweight (mean BMI 32.9), on oral medications (72.8% on
metformin), with long-standing T2DM (mean 12.6 years) and at least one diabetesrelated complication (38% with neuropathy) and co-morbid illness (79% hypertension).
Both simple (0.48/week) and severe (0.60/year) hypoglycemia were rare in the overall
sample. Some DM complications [foot ulcers (4%), renal failure (3%), and gastroparesis
(4%)] were rare in the sample. Type of insulin management strategy was used to
compare health and diabetes-related items. Using ANOVA, no significant group
differences were found in duration of insulin therapy and amount of severe
hypoglycemia. The groups did not differ in the frequency of most DM-related
complications and co-morbidities, with the exception of heart disease and chronic pain.

67

Heart disease was three times greater in subjects taking insulin (26.6% of basal and
26.3% of basal-bolus groups) than oral medications (8.2%; χ=6.411, p<.05). Chronic
pain was most likely in subjects using basal-bolus insulin (36.8%), than basal only insulin
(6.7%) or oral medications (13.7%; χ=7.057, p<.05). The insulin management groups
also differed on type of oral medication used: most subjects on basal-bolus insulin took
no oral medications (57.9%; χ=40.481, p<.001), most subjects on basal only insulin took
metformin (66.7%; χ=11.443, p<.01), and subjects on oral medications only had a
greater frequency of taking two or more oral diabetes medications (45.2%; χ=41.639,
p<.001). Subjects using basal-bolus insulin had a longer DM duration [F (2, 100) =6.670,
p<.01], more frequent simple hypoglycemia [F (2,104) =4.151, p<.05], and total number
of diabetes-related complications [F (2,104) =6.252, p<.01] than subjects on oral
medications alone. Per one-way ANOVA, BMI was highest in the basal insulin group [F
(2, 102) = 3.876, p<.05]. Erectile dysfunction occurred in the majority of men in the
sample (57.7%); this parameter could not be compared across insulin management
groups due to insufficient data.
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Table 14. Health History of the Sample
Oral
Medication
N= 73

Mean ± SD
Range
Yes
No
Mean ± SD
Range

Total
Sample
N=107 (%)
N=105
32.9 ± 6.7
19.1-53.7
N=103
12.6 ± 9.2
1-39
14 (13%)
78 (73%)
40 (37%)
16 (15%)
N=30
8.3 ± 8.9
1-31
9 (8%)
98 (92%)
0.5 ± 1.1
0-6

7
66
0.3 ± 0.9
0-6

Insulin
Basal
Basal-Bolus
N=15
N=19
N=13
37.4 ± 4.4 31.2 ± 6.5
31.5-44.6 19.1-45.8
N=12
N=18
16.5 ± 11
18.0 ± 10.5
3-39
1-38
3
11
10
8
6
3
1
0
N=14
N=16
5.0 ± 5.8
11.1 ± 10.2
1-18
1-31
2
0
13
19
0.6 ± 1.1
1.1 ± 1.2
0-3
0-4

Mean ± SD
Range

0.6 ± 1.9
0-12

0.4 ± 1.7
0-12

0.5 ± 1.6
0-6

1.3 ± 2.5
0-10

1.4 ± 1.7
0-7
38 (36%)
22 (21%)
16 (15%)
15 (14%)

1.0 ± 1.3
0-4
21
14
9
6

1.5 ± 1.9
0-6
6
1
2
4

2.5 ± 2.2
0-7
11
7
5
5

15 (14%)

8

3

4

15 (57.7%)

9

1

5

36 (34%)
71 (66%)
79 (74%)

25
48
54

6
9
11

5
14
14

Variable
BMI*
Mean ± SD
Range
Duration of
DM**
Oral
Medication***

Insulin Duration
(years)
Taking byetta?
Simple
Hypoglycemia1*
(episodes/wk.)
Severe
Hypoglycemia1
(episodes/year)
Total # DM
Complications *
DM
Complications

Mean ± SD
Range
None
Metformin
Sulfonylurea
Sitagliptin

Mean ± SD
Range
Neuropathy
Claudication
PVD
Heart
Disease*
Eye Disease/
Laser Surgery
Erectile Dysfunction
(men only, N=26)
History of
Yes
Depression?
No
Co-morbidities Hypertension

32.5 ± 6.8
20.3-53.7
10.6 ± 7.7
1-32
0
60
31
15
n/a
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Cataracts
Arthritis
DJD
Sleep Apnea
Chronic Pain*
Asthma

41 (38%)
39 (36%)
26 (24%)
20 (19%)
18 (17%)
13 (12%)

29
27
18
14
10
11

4
7
1
2
1
0

8
5
7
4
7
2

1

Hypoglycemia was experienced by a minority of subjects: 79% of subjects reported no
hypoglycemic episodes in last week; 83% of subjects reported no severe hypoglycemia in the
past year.
*Significant differences between insulin management groups (p<.05)
**Significant differences between insulin management groups (p<.01)
***Significant differences between insulin management groups (p<.001)
Data Analysis per Study Aims
The aims of the study were as follows: (1) to describe the HRQOL of persons with T2DM
according to type of glycemic management (Oral meds only, Basal insulin only, Basal-bolus
insulin), (2) to determine if HRQOL of persons with T2DM differs depending on type of glycemic
management, and (3) to determine if type of glycemic management is predictive of HRQOL after
controlling for covariates. Statistical tests performed and assumptions are discussed per aim.
Data Analysis: Aim 1
The first aim of the study was to describe the HRQOL of persons with T2DM according to
type of glycemic management. This was done in several steps. First, using the conceptual
model for the study, descriptive statistics were generated for measurements on all QOL specific
domains (environmental, biologic, symptoms, functional performance, general health
perception and quality of life) and are presented in Table 15.

Table 15. Multidimensional Quality of Life Variables per Study Model
Revised Wilson
and Cleary
HRQOL Concepts

Study Variable

Mean (± SD)

Range

Norms
Healthy
Diabetes
Mean (SD)
Mean (SD)

Access to
diabetes care

CIRS item (#15)

Social Support

CIRS Overall
CIRS Health Care Team
CIRS Family/Friends
CIRS Personal
CIRS Work (n=35)
CIRS Neighborhood
CIRS Media/Policy
CIRS Organizations

91% of subjects reported having
insurance that covered most of
diabetes costs including medicine
2.85 (± 0.55)
1.6 – 4.5
3.97 (± 0.91)
1.3 – 5.0
2.30 (± 0.95)
1.0 – 4.7
3.23 (± 0.94)
1.0 – 5.0
2.78 (± 1.13)
1.0 – 5.0
2.32 (± 0.76)
1.0 – 4.8
3.46 (± 0.76)
1.7 – 5.0
2.03 (± 0.93)
1.0 – 4.7

Glycemic control

A1C

7.990 (±1.579)

5.4 – 13.1

WBQ-12: General WellBeing
Energy
Positive Well Being
Negative Well-Being
DSC-R overall

24.12 (± 6.67)

5 – 36

24.4 (7.2)

6.60 (± 2.70)
7.46 (± 2.97)
1.90 (± 2.23)
1.11 (± 0.77)

0-12
0-12
1-12
0 - 3.91

7.5 (3.0)
7.6 (2.8)
2.7 (2.9)
0.82 (0.71)

DSC-R: hypoglycemia

1.21 (± 1.18)

0 – 4.33

0.80 (1.00)

Environmental
Characteristics

Biological
function

Measurement Tool

Mood
Symptoms
DM-related
(Total)
Hypoglycemia

2.7 (0.5)
3.4 (1.1)
2.4 (1.0)
3.3 (0.8)
2.5 (0.9)
2.2 (0.9)
3.4 (0.8)
1.9 (0.9)
4.0 - 5.6
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Hyperglycemia
Pain

Functional
Performance

General health
perception

Quality of life

DSC-R: hyperglycemia
DSC-R: neurosensory
subscale
Vision
DSC-R: ophthalmologic
Activity tolerance DSC-R: cardiac
Social functioning SF-12 (v2) Mental
Composite Score
Role functioning
SF-12 (v2) Physical
Composite Score
Diabetes SelfSelf-Care InventoryManagement
Revised
Overall health
General health item of SF12 (v2)
Acceptance of
Appraisal of Diabetes Scale
diabetes
Perceived HRQOL Quality of Life Index
Overall
QLI: Health & Functioning
QLI: Social & Economic
QLI: Psych & Spiritual
QLI: Family

1.44 (± 1.07)
0.91 (± 1.03)

0 – 4.25
0 – 4.33

1.24 (1.15)
0.60 (0.82)

0.67 (± 0.93)
0.89 (± 0.84)
50.93 (± 9.91)

0.61 (0.87)
0.67 (0.79)
47.28
(10.72)
41.52
(11.07)
64.4 (17.9)

3.06 (± 0.95)

0 – 4.6
0 – 3.5
23.56 –
70.71
12.18 –
60.42
28.85 –
89.29
1–5

17.10 (± 4.46)

9 - 28

21.81 (± 4.70)

8.15 29.45
5 – 30
10.29 – 30
2.57 – 30
6.25 – 30

41.47 (± 11.97)
61.61 (± 13.68)

20.71 (± 5.14)
22.45 (± 5.11)
22.81 (± 5.71)
22.60 (± 5.56)

50 (10)
50 (10)

18.65 (4.04)
23.00

20.56

Note. HRQOL = Health-Related Quality of Life; CIRS = Chronic Illness Resources Survey; A1C = Glycosylated Hemoglobin; WBQ-12= Well-Being Questionnaire 12;
DSC-R = Diabetes Symptom Checklist-Revised.
Sources for Norms: CIRS: Glasgow, Strycker, Toobert & Eakin, 2000; A1C: National Diabetes Information Clearinghouse, 2011; WBQ-12: Pouwer et al., 1999;
DSC-R: Arbuckle et al., 2009; SF-12(v2): Ware, Kosinski, Turner-Bowker & Gandek, 2002; SCI-R: Weinger, Butler, Welch & LaGreca, 2005; ADS: Carey et al.,
1991; QLI: Ferrans & Powers (n.d.b)
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Second, relationships between key study variables were examined using
Pearson’s correlations and are presented in Table 16. Quality of life was found to be
positively correlated with age (r=.25, p<.05), social support (r=.31, p<.01), general wellbeing (r=.65, p<.01), role functioning (SF-12 PCS, r=.43, p<.01), and social functioning
(SF-12 MCS, r=.50, p<.01). In contrast, QOL was found to be negatively correlated with
BMI (r=-.29, p<.01), A1C (r=-.21, p<.05), DM complications (r=-.24, p<.05), DM
symptoms (r=-.54, p<.01), and ADS scores (r=-.50, p<.01). This means that QOL
decreased as obesity, poor glycemic control, and diabetes-related complications and
symptoms increased. Quality of life was also decreased in subjects who had poor
acceptance of their disease as measured by the ADS. Insulin management and diabetes
self-care were not significantly correlated with QOL. As many of the variables are
significantly correlated, it should be noted that no correlation is greater than .65, which
is important as correlations greater than .90 indicate collinearity (Field, 2009).
Third, because gender is a major variable impacting QOL perceptions, the sample
was examined for gender differences in QOL and related study variables (Table 17).
Women and men did not significantly differ on several factors: ethnicity, duration of
DM, social support, glycemic control (A1C), BMI, diabetes self-care, and acceptance of
diabetes (ADS). In addition, there were insufficient numbers per group to analyze
insulin management by gender. Details of gender differences are provided in Table 17.
Men in the sample were older (t= 2.078, p<.05) and more likely to be married (χ=16.918,
p<.01). Women in the study reported higher incidences of non-partnered marital status
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(divorced, never married, or widowed; Table 17). Although not statistically significant,
there were more minority women than men in the sample (19.8% vs. 3.8%, χ=5.219,
n.s.). Diagnosed depression was more common in women than men (39.5% vs. 15.4%,
χ=5.130, p<.05). Diabetes-related complications were more prevalent in men (t=2.634,
p<.05); however, both genders reported equivalent amounts of diabetes related
symptoms, with exception of cardiac/activity symptoms, which occurred more
frequently in women (t= -2.765, p<.01).

Table 16. Correlations between Key Variables
CIRS

Age
CIRS
Insulin
Management
BMI
A1C
DM
Complications
General WellBeing
Diabetes
Symptoms
SF-12 PCS
SF-12 MCS
Self-Care
ADS

-.119

Insulin
Mgmt.
-.123
-.171

BMI

-.146
-.132
-.009

A1C

DM
General DSC
SF
SF
Complications Well- Total Physical Mental
Being
-.169
.019
.208* -.181
-.060 .281**
-.003
-.137
.202* -.110
.195*
.063

SelfCare

Appraisal QLI
of
overall
Diabetes
.122
-.293** .246*
.302**
-.121 .311**

.368**

.323**

-.134

.055

-.257**

-.002

.336**

.157

.078
-.007

-.223*
-.173

.072
.130

-.340**
-.211*

-.131
-.096

-.286**
.046

.080 -.286**
.292** -.207*

-.123 .335**

-.421**

.113

.095

.331** -.242*

-

.442**

.738**

.122

-.480** .646**

-.537**

-.395**

-.124

.611** -.543**

-.014

.036
.145

-.394** .430**
-.259** .502**
-.087
.148
-.504**

.634

**

.212*

-.185

**Correlation is significant at the p<.01 level (2-tailed), *Correlation is significant at the p<.05 level (2-tailed)
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Table 17. Study Variables Differing by Gender
Study Variable

Measurement Tool

Age*

Total Sample
Mean (± SD)

Men (n=26)
Mean (SD)

63.8 (11.8)

67.9 (9.32)

Women
(n=81)
Mean (SD)
62.4 (12.24)

Marital Status**

92.3%
married

Diagnosed with Depression*
Insulin Management
--Oral
--Basal Insulin
--Basal-Bolus
DM Complications*

15.4%

46.9%
married
18.5%
divorced
17.3% single
14.8%
widowed
39.5%

1.35 (1.67)

18
1
7
2.08 (1.81)

55
14
12
1.11 (1.57)

24.12 (6.67)

27.50 (6.54)

23.03 (6.38)

6.60 (2.70)
7.46 (2.97)
1.90 (2.23)
1.11 (0.77)
0.89 (0.84)
50.93 (9.91)

7.62 (2.74)
8.88 (2.72)
1.00 (2.10)
0.94 (0.79)
0.58 (0.56)
54.91 (9.03)

6.28 (2.62)
7.00 (2.91)
2.19 (2.21)
1.16 (0.76)
0.99 (0.89)
49.64 (9.89)

21.81 (4.70)
20.71 (5.14)

23.98 (4.13)
22.77 (4.90)

21.12 (4.69)
20.05 (5.06)

22.45 (5.11)

24.72 (3.11)

21.72 (5.42)

22.81 (5.71)

25.06 (4.27)

22.09 (5.94)

22.60 (5.56)

24.92 (5.24)

21.86 (5.49)

Mood: WBQ-12

Diabetes
Symptoms
Social
functioning
Perceived
HRQOL

* p<.05, **p<.01

General WellBeing**
Energy*
Positive Well Being**
Negative Well-Being*
DSC-R overall (n.s.)
DSC-R: cardiac**
SF-12 (v2) Mental
Composite Score*
QLI Overall**
QLI: Health &
Functioning*
QLI: Social &
Economic**
QLI: Psych &
Spiritual**
QLI: Family*
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The WBQ-12 measured both positive and negative mood in the study. Men
reported higher general well-being (t=3.089, p<.01), positive well-being (t=2.917, p<.01),
and energy (t=2.241, p<.05) than women in the study. Women reported greater
negative well-being (t=-2.425, p<.05). Men also reported higher levels of mental
performance (mental composite summary) on the SF-12 than women (t=2.389, p<.05).
The SF-12 did not detect significant physical composite score differences between
genders.
Quality of life was also reported as lower by women. Women reported lower
overall quality of life (21.12 vs. 23.98, t=2.784, p<.01) than men. Quality of life per all
QLI subscales was also reported as significantly lower in women (Table 18). The effect
of gender on QOL was tested as a moderating variable with general well-being;
however, this regression was not significant. Nevertheless, gender remains an
important factor in understanding QOL in T2DM.
Table 18. Quality of Life by Gender
Levene's Test for
Equality of
Equal
Variances
variances
assumed
F
Sig.
QLI overall
Health & Functioning
Social & Economic
Psychological &
Spiritual
Family

t-test for Equality of Means
Sig. (2t
df
tailed)
2.784
105
.006
2.397
105
.018
3.491
75.087
.001

.434
.030
13.558

.511
.864
.000

Yes
Yes
No

3.192

.077

Yes

2.359

105

.020

.151

.698

Yes

2.499

104

.014
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Finally, type of management among the groups based on medication dosing
frequency [Oral meds only, Basal Insulin (once or twice daily), Basal-Bolus Insulin (three
or more times daily)] was examined. Descriptive statistics for QOL and the subscales of
QOL are presented below (Table 19).
Table 19. Quality of Life by Type of Glycemic Management
Quality of Life
Index
Overall
Health &
Functioning
Social & Economic
Psych & Spiritual
Family

N=107
21.81 (± 4.70)

Oral
Medication
N=73
22.40 (±4.42)

Insulin
Basal
Basal-Bolus
N=15
N=19
20.91 (±4.34) 20.27 (±5.74)

20.71 (± 5.14)

21.31 (±4.93 )

19.89 (±4.56)

19.07 (±6.09)

22.45 (± 5.11)
22.81 (± 5.71)
22.60 (± 5.56)

23.38 (±4.82)
23.43 (±5.10)
22.71 (±5.49)

20.61 (±5.16)
22.44 (±5.72)
21.77 (±6.04)

20.35 (±5.43)
20.73 (±7.49)
22.87 (±5.71)

Total Sample

Data Analysis: Aim 2
To determine if HRQOL of persons with T2DM differs depending on type of
glycemic management, subjects were divided into three groups based on the type of
glycemic management: oral meds only, insulin once or twice daily (basal), insulin three
or more times daily (basal-bolus). The dependent variable, quality of life, was
represented by QLI scores. Group differences in QLI scores were examined using
Analysis of Variance (ANOVA), with post-hoc testing to establish pair-wise group
differences (Munro, 2005).
Group means of the total and subscale QOL were compared using one-way
ANOVA. ANOVA assumptions include homogeneity of variance, independent
observations, and normality; these are discussed in Appendix H. There was no violation
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of homogeneity of variance in QLI among the three groups per Levene’s test. Remaining
assumptions of ANOVA were met. The analysis revealed that participants’ overall
quality of life was not significantly different across the three groups [Table 20; F (2, 104)
= 1.89, p>.05].
A post-hoc power analysis was conducted to verify the power achieved by the
one-way ANOVA of QOL by insulin management in this sample (n=107). Per post-hoc
analysis, the power obtained was 38 percent. To achieve 80% power in the one-way
ANOVA, a sample size of 285 participants was required. Due to lack of significant
findings, which may be due to low study power, the second study aim was not
supported. That is, no significant group differences in QOL were detected based on
insulin management.
Table 20. Examining Quality of Life by Insulin Management (ANOVA)

QLI overall

Between Groups
Within Groups
Total

Sum of
Squares
82.354
2263.090
2345.445

df
2
104
106

Mean
Square
41.177
21.760

F

Sig.

1.892

.156

To examine complex interactions that may confound QOL measurement in this
population, Multifactorial Analysis of Variance (MANOVA) was used (Table 21). In the
MANOVA, the variables tested included: type of glycemic management (oral, basal
insulin, or basal-bolus insulin), glycemic control (Hemoglobin A1C), diabetes symptoms,
mood (psychological well-being), diabetes self-care, acceptance of diabetes, and quality
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of life. These variables were chosen according to the study model, which represents
subjects’ overall adjustment to life with diabetes. Sources of variation in the MANOVA
included main effects as well as interactions between variables.
Table 21. Study Model and MANOVA Variables
Revised Wilson and Cleary
HRQOL Concepts
Biological function

Study Variable

Insulin dosing frequency
Glycemic Control
Mood

Symptoms

Functional Performance
General health perception
Quality of life

Diabetes-related
Symptoms
Diabetes SelfManagement
Acceptance of diabetes
Perceived HRQOL

Measurement Tool
Oral Medication
Basal Insulin
Basal-bolus Insulin
A1C
WBQ-12: General Well-Being
(overall)
DSC-R overall
Self-Care Inventory-Revised
Appraisal of Diabetes Scale
Quality of Life Index Overall

Assumptions of MANOVA include independence, random sampling, multivariate
normality, and homogeneity of covariance matrices (Appendix H). Wilks’ Lambda (p =
.001, p<.01) indicated that the set of six dependent variables significantly differed for
the independent variable (insulin management). To determine what variables the
groups differed on, the between-group effects were examined (Table 22). Glycemic
control [A1C; F (2, 95) = 7.044; p=.001] and diabetes self-care [F (2, 95) = 4.620, p<.05)
significantly differed for the insulin management groups. Post-hoc testing revealed that
A1C was significantly higher in subjects on basal insulin (p<.05) and basal-bolus insulin
(p<.05) than subjects on oral medication (Table 23). Also, subjects using basal-bolus
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insulin management performed considerably more diabetes self-care than patients on
oral medications (p<0.05). Per MANOVA, the remaining dependent variables (general
well-being, diabetes symptoms, and acceptance of diabetes) and QOL were not found to
differ significantly between insulin management groups.
Table 22. Tests of Between-Subjects Effects (MANOVA)
Source

Dependent Variable

Hemoglobin A1C
QLI
Corrected DSC Total
Model Self-Care Score
General Well-Being
ADS total score
Hemoglobin A1C
QLI
DSC Total
Intercept
Self-Care Score
General Well-Being
ADS total score
Hemoglobin A1C
QLI
DSC Total
Insulin
Self-Care Score
General Well-Being
ADS total score
Hemoglobin A1C
QLI
DSC Total
Error
Self-Care Score
General Well-Being
ADS total score
Hemoglobin A1C
Total
QLI
DSC Total

Type III Sum
of Squares
28.674a
77.891b
.257c
1559.868d
46.107e
69.921f
4189.057
27068.731
75.319
243848.681
34395.081
17875.180
28.674
77.891
.257
1559.868
46.107
69.921
189.295
1968.301
50.390
15699.226
4018.851
1788.818
6225.140
47644.991
164.592

df
2
2
2
2
2
2
1
1
1
1
1
1
2
2
2
2
2
2
93
93
93
93
93
93
96
96
96

Mean
Square
14.337
38.946
.129
779.934
23.054
34.961
4189.057
27068.731
75.319
243848.681
34395.081
17875.180
14.337
38.946
.129
779.934
23.054
34.961
2.035
21.165
.542
168.809
43.213
19.235

F

Sig.

7.044
1.840
.237
4.620
.533
1.818
2058.065
1278.967
139.011
1444.525
795.935
929.324
7.044
1.840
.237
4.620
.533
1.818

.001
.165
.789
.012
.588
.168
.000
.000
.000
.000
.000
.000
.001
.165
.789
.012
.588
.168
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Self-Care Score
General Well-Being
ADS total score
Hemoglobin A1C
QLI
Corrected DSC Total
Total
Self-Care Score
General Well-Being
ADS total score

374737.464
61200.000
29433.000
217.970
2046.193
50.647
17259.093
4064.958
1858.740

96
96
96
95
95
95
95
95
95

a. R Squared = .132 (Adjusted R Squared = .113)
b. R Squared = .038 (Adjusted R Squared = .017)
c. R Squared = .005 (Adjusted R Squared = -.016)
d. R Squared = .090 (Adjusted R Squared = .071)
e. R Squared = .011 (Adjusted R Squared = -.010)
f. R Squared = .038 (Adjusted R Squared = .017)

Table 23. Post Hoc Tests (MANOVA)

Dependent
(I) Taking insulin
Variable

No

(J) Taking
insulin
Yes, Basal

Mean
Diff.
(I-J)
-1.312*

Yes, Basal-Bolus -1.042*
No
1.312*
Hgb A1C
Yes, Basal
Yes, Basal-Bolus
.270
No
1.042*
Yes, Basal-Bolus
Yes, Basal
-.270
Yes, Basal
1.215
No
Yes, Basal-Bolus
2.349
No
-1.215
QLI overall Yes, Basal
Yes, Basal-Bolus
1.134
No
-2.349
Yes, Basal-Bolus
Yes, Basal
-1.134
Yes, Basal
-.021
No
Yes, Basal-Bolus
-.141
DSC Total
No
.021
Yes, Basal
Yes, Basal-Bolus
-.120

Std.
Error

Sig.

.398
.420
.522
.398
.522
1.354
1.282
1.354
1.684
1.282
1.684
.217
.205
.217
.269

.036
.010
.875
.036
.875
.670
.192
.670
.797
.192
.797
.995
.789
.995
.906

95% Confidence
Interval

Lower Upper
Bound Bound
.420 .010 -2.356 -.267
-2.031
.267
-1.029
.053
-1.569
-2.153
-.840
-4.582
-3.054
-5.538
-5.322
-.560
-.652
-.518
-.790

-.053
2.356
1.569
2.031
1.029
4.582
5.538
2.153
5.322
.840
3.054
.518
.369
.560
.550
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No
.141
Yes, Basal
.120
Yes, Basal
-3.834
No
Yes, Basal-Bolus -10.88*
No
3.834
Self-Care
Yes, Basal
Score
Yes, Basal-Bolus -7.048
No
10.882*
Yes, Basal-Bolus
Yes, Basal
7.048
Yes, Basal
1.78
No
Yes, Basal-Bolus
1.16
No
-1.78
General
Yes, Basal
Well-Being
Yes, Basal-Bolus
-.62
No
-1.16
Yes, Basal-Bolus
Yes, Basal
.62
Yes, Basal
.52
No
Yes, Basal-Bolus
-2.15
No
-.52
ADS total
Yes, Basal
Yes, Basal-Bolus
-2.67
score
No
2.15
Yes, Basal-Bolus
Yes, Basal
2.67
Yes, Basal-Bolus

.205
.269
3.823
3.621
3.823
4.755
3.621
4.755
1.934
1.832
1.934
2.406
1.832
2.406
1.290
1.222
1.290
1.605
1.222

.789
-.369
.652
.906
-.550
.790
.606 -13.345 5.6766
.013 -19.888 -1.875
.606 -5.677 13.345
.338 -18.876 4.781
.013
1.875 19.888
.338 -4.781 18.876
.657
-3.03
6.59
.818
-3.40
5.72
.657
-6.59
3.03
.968
-6.60
5.37
.818
-5.72
3.40
.968
-5.37
6.60
.921
-2.69
3.73
.219
-5.19
.89
.921
-3.73
2.69
.256
-6.66
1.32
.219
-.89
5.19

1.605 .256

-1.32

6.66

Scheffe test of multiple comparisons based on observed means.
The error term is Mean Square (Error) = 19.235.
*The mean difference is significant at the .05 level.

Data Analysis: Aim 3
The third aim of the study was to determine if type of glycemic management is
predictive of HRQOL after controlling for covariates. This aim was met through multiple
regression analysis. Assumptions of multiple regression include variable types, non-zero
variance, multicollinearity, non-externally correlated predictors, homoscedasticity, independent
error terms, normally distributed errors, independence, and linearity. The assumptions of
multiple regression were met (Appendix H).
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First, multiple regression was used to examine the effect of five predictors on QOL. The
simultaneous method, or forced entry, was used to enter glycemic control (A1C), general wellbeing, diabetes symptoms, diabetes self-management (SCI-R), and appraisal of diabetes as
predictors of QOL. The results indicated that the five predictors accounted for 49% of the
variance [R2 = .49, F (5, 90) = 17.04, p< .001] (Table 24). Of these predictors, examination of
beta weights showed that only general well-being (β = .51, p<.001) and appraisal of diabetes (β
= -.23, p<.05) significantly contributed to prediction of QOL (Table 25).

Table 24. Regression Analysis
Model Summaryb
Model

1

R

.697a

R
Adjusted
Std.
Change Statistics
Square R Square Error of
R
F
df1 df2
the
Square Change
Estimate Change

.486

.458 3.41745

.486

17.041

5

90

Sig. F
Change
.000

DurbinWatson

2.160

a. Predictors: (Constant), ADS, Self-Care Score, A1C, General Well-Being, Diabetes Symptoms
b. Dependent Variable: QLI overall

Model
1

Regression
Residual
Total

ANOVAa
Sum of Squares
df
995.087
5
1051.106
90
2046.193

Mean Square
199.017
11.679

F
17.041

95

a. Dependent Variable: QLI overall
b. Predictors: (Constant), ADS, Self-Care Score, A1C, General Well-Being, Diabetes Symptoms

Sig.
.000b

Table 25. Regression Coefficients

Model

(Constant)
Hemoglobin A1C
DSC Total
Self-Care Score
General WellBeing
Appraisal of DM

Unstandardized Standardized
Coefficients
Coefficients
B
Std.
Beta
Error
17.020
3.474
-.115
.241
-.037
-.247
.682
-.039
.020
.027
.059

Coefficientsa
t
Sig. 95.0% Confidence
Correlations
Collinearity
Interval for B
Statistics
Lower
Upper
Zero- Partial Part Tolerance VIF
Bound
Bound
order
4.899 .000
10.118
23.921
-.476 .636
-.594
.365 -.198 -.050 -.036
.920 1.087
-.362 .718
-1.601
1.108 -.502 -.038 -.027
.496 2.016
.771 .443
-.032
.073
.182 .081 .058
.963 1.039

.362

.068

.510

5.282 .000

.226

.498

.653

-.243

.102

-.232

-2.386 .019

-.446

-.041

-.499

.486

.399

.613 1.632

-.244 -.180

.605 1.632

a. Dependent Variable: QLI overall
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An additional multiple regression analysis was performed to examine a
moderated model of diabetes self-care, general well-being, and QOL (Figure 3).
General well-being had a main effect on QOL, but diabetes self-care did not have a
significant main effect on QOL. However, an interaction term between general wellbeing and diabetes self-care showed a significant predictive effect on QOL (β = -.155,
p<.05). The model of general well-being moderated by diabetes self-care to predict QOL
was significant [R2 = .45, F (3, 102) = 27.73, p<.001]. Model summary is provided in
Table 26.
Figure 3. Moderation Model

General Well-Being

Quality of Life

Diabetes Self-Care
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Table 26. Moderated Model Summary

Model
1
2
3

R
.646a
.653b
.670c

R
Adjusted
Square R Square
.418
.426
.449

.412
.415
.433

Std.
Change Statistics
Error of
R Square
F
the
df1
df2
Change Change
Estimate
3.61046
.418 74.569 1
104
3.60215
.008 1.480 1
103
3.54545
.023 4.321 1
102

Sig. F
Change
.000
.227
.040

1. Predictors: (Constant), General Well-Being
2. Predictors: (Constant), General Well-Being, Diabetes Self-Care
3. Predictors: (Constant), General Well-Being, Diabetes Self-Care, Interaction (GWB x SCI)

To further understand the moderation effects of diabetes self-care on QOL, the
model was analyzed with high and low levels of self-care. Multiple regressions using
high and low self-care were performed with the moderated model (Table 27). Using the
coefficients from these regressions, equations representing QOL moderated by self-care
were developed using one standard deviation of general well-being. General well-being
significantly increased participants’ quality of life when self-care scores were lower.
Diabetes self-care moderates the relationship between general well-being and QOL.
General well-being was more likely to increase participants’ quality of life when they
reported lower self-care scores, compared to the participants whose self-care scores
were higher. The moderation effect of self-care is shown graphically in Figure 4.
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Table 27. Moderated Model of Quality of Life by High and Low Self-Care

Coefficients

Model

.466
.114

95.0%
Confidence
T
Sig. Interval for B
Lower Upper
Bound Bound
45.068 .000 21.485 23.463
4.238 .000
.175
.483
1.524 .131 -.012
.092

-.227

-2.079 .040

.490
.069
.026

.769
.114

43.663 .000 20.428 22.372
7.835 .000
.405
.680
1.524 .131 -.012
.092

.004

-.206

-2.079 .040

Unstandardized Standardized
Coefficients
Coefficients
Std.
Error
22.474 .499
.329 .078
.040 .026
B

(Constant)
General Well-Being
High Self-Care
Interaction: High SC x
-.008
GWB
(Constant)
21.400
General Well-Being
.543
Low Self-Care
.040
Interaction: Low SC x
-.008
GWB
Dependent variable: QLI overall

.004

Beta

-.015

-.015

.000

.000
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Figure 4. Quality of Life Moderated by Self-Care

25.02 (b = .543)***
24.67 (b = .329)***

25.00

Quality of Life

23.00

High Self-Care

21.00

Low Self-Care

20.28

19.00

17.78
17.00
-1 SD

+1 SD

General Well-being

Given the gender differences noted in mood and QOL, an exploratory analysis
was conducted to further analyze the moderated model of general well-being, self-care
and QOL. The statistical analyses were repeated separately by gender (Tables 28 & 29).
The results differed significantly by gender. In men, the moderated model was not
supported. Only general well-being had a significant main effect on QOL. Self-care and
the interaction had no significant effects. In women, the moderated model approached
statistical significance [R2 = .39, F (3, 76) = 15.88, p=0.066]. General well-being had a
significant main effect. Self-care did not. The interaction between self-care and general
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well-being was a near-significant predictor of QOL in women (p=0.066). As the study
had low power, these findings indicate that self-care has a potential to moderate
general well-being on QOL in women. The moderated model, split by gender, is shown
in Figure 5.
Table 28. Moderated Model Summary (by Gender)
Males

Model
1
2
3

R
.749b
.752c
.752d

Std.
R
Adjusted Error of
Square R Square
the
Estimate
.562
.543
2.79206
.565
.527
2.84170
.566
.506
2.90285

Change Statistics
R Square
F
Change Change
.562
.003
.001

df1

30.746 1
.169
1
.041
1

df2
24
23
22

Sig. F
Change
.000
.685
.841

a. Gender = Male
b. Predictors: (Constant), General Well-Being
c. Predictors: (Constant), General Well-Being, Diabetes Self-Care
d. Predictors: (Constant), General Well-Being, Diabetes Self-Care, Interaction (GWB x SCI)

Females

Model
1
2
3

R
.582b
.598c
.621d

Std.
R
Adjusted Error of
Square R Square
the
Estimate
.339
.330
3.84644
.357
.340
3.81730
.385
.361
3.75704

Change Statistics
R Square
F
Change Change
.339
.018
.028

39.950 1
2.196 1
3.490 1

df1

df2
78
77
76

Sig. F
Change
.000
.142
.066

a. Gender = Female
b. Predictors: (Constant), General Well-Being
c. Predictors: (Constant), General Well-Being, Diabetes Self-Care
d. Predictors: (Constant), General Well-Being, Diabetes Self-Care, Interaction (GWB x SCI)
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Table 29. Moderated Model of Quality of Life by High and Low Self-Care (by Gender)
Coefficients: Males

Model

Unstandardized Standardized
Coefficients
Coefficients

T

Sig.

95.0%
Confidence
Interval for B
Lower Upper
Bound Bound
22.005 25.606
.145
.758
-.114
.087

(Constant)
General Well-Being
High Self-Care
Interaction: High SC x
GWB

23.805
.451
-.014

Std.
Error
.868
.148
.048

-.002

.009

(Constant)

24.165

.846

General Well-Being

.499

.146

.789

3.417 .002

.196

.802

Low Self-Care

-.014

.048

-.043

-.281

.782

-.114

.087

Interaction: Low SC x
GWB

-.002

.009

-.049

-.203

.841

-.020

.017

B

Beta
.714
-.043
-.049

27.417 .000
3.051 .006
-.281 .782
-.203

.841

-.020

.017

28.574 .000 22.411 25.918

Coefficients: Females

Model

Unstandardized Standardized
Coefficients
Coefficients

95.0%
Confidence
Interval for B
T
Sig.
Lower Upper
Bound Bound
36.223 .000 20.784 23.202

21.993

Std.
Error
.607

General Well-Being

.278

.100

.377

2.790 .007

.079

.476

High Self-Care

.054

.031

.155

1.700 .093

-.009

.116

Interaction: High SC x
GWB

-.009

.005

-.250

-1.868 .066

-.018

.001

20.534

.599

B
(Constant)

(Constant)

Beta

34.296 .000 19.342 21.727
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General Well-Being

.520

.087

.706

5.958 .000

.346

.694

Low Self-Care

.054

.031

.155

1.700 .093

-.009

.116

Interaction: Low SC x
GWB

-.009

.005

-.223

-1.868 .066

-.018

.001

Figure 5. Quality of Life and General Well-Being Moderated by Self-Care (by Gender)
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CHAPTER FIVE
DISCUSSION
This dissertation study was conducted to examine quality of life in patients with
type 2 diabetes according to type of glycemic management. The aims of the
dissertation study were: (1) to describe the HRQOL of persons with T2DM according to
type of glycemic management [Oral meds only, Basal insulin only (once or twice daily),
Basal-bolus insulin (three or more times daily)], (2) to determine if HRQOL of persons
with T2DM differs depending on type of glycemic management, and (3) to determine if
type of glycemic management is predictive of HRQOL after controlling for covariates.
Based on a review of the literature, it was hypothesized that persons with T2DM on
basal-bolus insulin would report higher quality of life when covariates were controlled.
Intensive diabetes management is recommended to minimize diabetes-related
complications and maximize longevity. However, the QOL effects of intensive diabetes
management have not been extensively explored, especially in T2DM.
The vast majority of prior research has examined quality of life in persons with
T1DM (Table 1; Appendix A). Subjects with T2DM have been included in a minority of
trials, although this has been recently changing (Table 1; Appendix A). Also, existing
studies have not conceptualized quality of life as a multidimensional construct.
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This dissertation study attempted to understand quality of life in T2DM by using
the Revised Wilson and Cleary Model of Quality of Life (Ferrans, Zerwic, Wilbur &
Larson, 2005). This model quantifies QOL by recognizing both individual and
environmental influences. Five dimensions (biological function, symptoms, functional
status, general health perceptions, and overall quality of life) are identified in the model
as constructs depicting QOL.
Characteristics of Overall Sample
The majority of the sample was female (75.7%), non-Hispanic (96.2%), Caucasian
(84.1%), married (57.9%), retired (52.3%), and an average age of 64 years. Although
T2DM occurs in all ages and racial groups, it is more prevalent in older adults (≥65 years
of age), men, and racial/ethnic minorities (CDC, 2014). Diabetes more frequently
occurs in Native Americans/Alaskan Natives (15.9%), Non-Hispanic blacks (13.2%), and
Hispanics (12.8%) than in non-Hispanic whites (7.6%; CDC, 2014). The dissertation
study’s homogenous sample represents only one subset of the population of persons
with diabetes. Despite the small sample size and composition, differences were noted
between groups based on type of insulin management. The insulin management
groups did not differ in key areas (gender, ethnicity, income, education, and
employment). However, differences were found between groups in race and marital
status. Subjects using basal-bolus insulin, or intensive insulin management, were more
likely to be Caucasian. Black subjects were most likely to be on basal insulin only.
Subjects taking basal insulin only were most likely to be single (never married).
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In health history and diabetes-related complications, the majority of subjects
were similar to the overall population of persons with T2DM (CDC, 2014; Davies,
Brophy, Williams & Taylor, 2006; The Action to Control Cardiovascular Risk in Diabetes
Study Group, 2008; Shah et al., 2011). The dissertation study subjects were overweight
(mean BMI 32.9), on oral medications (72.8% on metformin), with long-standing T2DM
(mean 12.6 years) and had at least one diabetes-related complication (38% with
neuropathy) and co-morbid illness (79% hypertension). As expected, hypoglycemia was
rare in the overall sample. Comparing subjects based on insulin management strategy
revealed no differences in the frequency of most DM-related complications and comorbidities, with the exception of heart disease and chronic pain. Subjects taking
insulin had more heart disease than those taking oral medications only; however, this
may be due to the significantly longer duration of DM among subjects taking insulin.
Subjects using basal-bolus insulin were most likely to report chronic pain, despite
equivalent (or lower) rates of obesity, neuropathy, and joint disease. The etiology of
this finding is unclear, but the impact of chronic pain on QOL cannot be discounted.
Basal-bolus subjects also had more frequent simple hypoglycemia and total number of
diabetes-related complications than subjects on oral medications alone. The majority of
male subjects reported erectile dysfunction, which can decrease QOL (McCabe & Althof,
2013). Due to insufficient data, this parameter could not be compared across insulin
management groups.
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Discussion of Aim 1: Describing QOL
The first aim was to describe the HRQOL of persons with T2DM according to type
of glycemic management. This was done in three ways: reporting QOL domains from
the dissertation study’s conceptual model, examining correlations between key study
constructs, and comparing QOL based on gender differences. The conceptual model for
the dissertation study was used to describe participants’ QOL by specific domains
(environmental, biologic, symptoms, functional performance, general health perception
and quality of life).
Environmental
Subjects reported high levels of access to diabetes care and social support. The
vast majority of subjects (91%) reported coverage of most of their diabetes costs,
including medicine. This is significantly higher than the percentage of adults with health
insurance in the last US census (81% having private and/or government health
insurance; DeNavas-Walt, Proctor & Smith, 2010). The dissertation study subjects
reported high levels of social support. Overall social support was reported at higher
levels (M=2.85) than in other studies using the CIRS (M=2.7; Glasgow, Strycker, Toobert
& Eakin, 2000; Glasgow, Toobert, Barrera & Strycker, 2004). Prior studies using the CIRS
are limited by size and lack of racial/ethnic diversity (>90% Caucasian). In a study of
adults with chronic illness including DM (n=123), support provided by the health care
team was reported as lower (M=3.4) than the dissertation study’s findings (M=3.97;
Glasgow et al., 2000). Another study of older adult females with T2DM (n=293)
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reported lower social support than the dissertation study participants, specifically in
health care team (M=3.64), personal (M=3.06), neighborhood (M=2.14), and
organizational (M=1.71; Glasgow et al., 2004) dimensions. In a systematic review of the
literature, Strom and Egede found that the vast majority of studies provided strong
evidence for the relationship between social support and improved DM outcomes
(2012). Greater social support was linked to improved clinical outcomes (glycemic
control, less DM-symptoms) in 34 of 37 research studies and to improved self-care
and/or DSM in 12 of 13 studies (Strom & Egede, 2012). Social support is an important
dimension of QOL. In access to care and social support, the dissertation study subjects
had average or above average environmental function.
Biological Function
Participants had a mean A1C of 7.9, with a wide range (5.4-13). Similar to
national averages, the majority of the dissertation study subjects had inadequate
glycemic control. In 2010, per National Health and Nutrition Examination Survey data,
only 52.5% of U.S. adults with diabetes achieved the treatment goal of A1C less than 7%
(Casagrande et al., 2013). In this study, 27% of subjects met the treatment goal of A1C
less than 7%. Suboptimal control (A1C between 7-8%) was achieved by an additional
33% of the dissertation study sample. This study’s suboptimal glycemic control may be
due to the revised glycemic control recommendations developed from the ACCORD
trial, which revealed a significantly increased rate of death in intensively-treated
patients with DM and cardiovascular disease (The Action to Control Cardiovascular Risk
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in Diabetes Study Group, 2008). An additional study of adults with T2DM found an
increased risk of cardiovascular events (stroke, myocardial infarction, or death due to
cardiovascular causes) in patients with an A1C of less than 6 or greater than 8 (Colayco,
Niu, McCombs & Cheetham, 2011). Currently, the ADA recommends the
individualization of A1C goals based on several factors, including age, comorbid
conditions, and known cardiovascular disease (American Diabetes Association, 2014).
As 14% of the dissertation study sample reported having cardiovascular disease, the
rates of suboptimal glycemic control are not surprising.
Diabetes Symptoms
The sample reported a substantial number of diabetes symptoms. Ninety-six
percent of subjects reported the presence of at least one symptom (ranging from
“present but not troublesome” to “extremely troublesome”). Hyperglycemic symptoms
were experienced by 80% of the sample, followed by cardiac symptoms (74% of
subjects) and neuro-sensory symptoms (66% of subjects). Compared to several other
studies of persons with T2DM, the dissertation study participants reported greater
diabetes symptom burden (Table 30). However, one small study by Opsteen and
colleagues (n=34 adults with T2DM, 38% female; Opsteen, Qi, Zinman & Retnakaran,
2012) reported greater overall symptom burden (M=2.3) than the dissertation study
(M=1.11 ±0.77, 95% CI= 0.96 to 1.26). This is remarkable as the Opsteen study sample
was slightly younger (59 vs. 63 years), with shorter duration of DM (5.9 vs. 12.6 years),
less DM complications (e.g. 28% vs. 36% self-reported neuropathy), and better glycemic
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control (A1C 7% vs. 7.9%). Due to the very small sample size in the Opsteen study, the
findings should be considered preliminary and possibly spurious.
Diabetes symptom distress varied per subscale. In the neuro-sensory, cardiac,
and hypoglycemic subscales, subjects reported higher more burdensome symptoms
than other studies using the DSC-R (Table 30). Several studies using the DSC or DSC-R
used a variety of scoring methods. The variable calculations made between-study
comparisons challenging; therefore, Table 30 includes only the studies with same
scoring as the dissertation study. In the ophthalmologic and hyperglycemic subscales,
subjects’ scores were consistent with other studies (Table 30). The literature
demonstrates that diabetes symptoms are burdensome for patients with T2DM and can
affect QOL. Physical symptoms, such as pain, sensory, and cardiovascular, are more
common in patients over age 60; however, psychological symptoms such as negative
mood or depression are greater in those younger than age 60 (p<0.001, Sudore et al.,
2012). Patients with T2DM and depression experience approximately three times more
symptom burden than patients with DM and no depression (p<0.01, Adriaanse et al.,
2008). In the dissertation study, patients with a history of depression reported greater
symptom burden (DSC total score 1.48 vs. 0.92, t=-3.732, p<0.001). Clearly, diabetes
symptoms have an impact on QOL.

Table 30. Diabetes Symptoms in Other Studies Using the Diabetes Symptom Checklist-Revised (DSC-R)

Study
McCormick
, 2014
Arbuckle,
2009

Kleefstra
2010+

Opsteen
2012++

Vadstrup
2011

N

Sample Characteristics
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Mean age 51 years, 42%
female; 88% Caucasian;
2023
newly diagnosed w/ T2DM
(US, Canada, Europe)
Mean age 59 yrs., 28%
female; DM duration 8
18
yrs.; 11% with ≥1 DM
complication (Netherlands)
Mean age 59 yrs., 38%
female; DM duration 6
34
years; 28% with ≥1 DM
complications (Canada)
Mean age 58 years, 40%
female, DM duration 6.4
143
years; 33% with ≥1 DM
complications (Denmark)

Diabetes Symptom Checklist-Revised
Subscales: Mean (SD)

TOTAL
score
M (SD)

NeuroSensory
0.91
(1.03)

0.89
(0.84)

0.67 (0.93)

1.21
(1.18)

1.44 (1.07)

1.11(0.77)

0.60
(0.82)

0.67
(0.79)

0.61 (0.87)

0.80
(1.00)

1.24 (1.15)

0.82
(0.71)

CV

Ophthalmologic

Hypo

Hyperglycemia

0.7 (0.4,
1.0)

0 (0-2.0)

0 (0-2.0)

0 (0-2.0)

0 (0-2.0)

2.0 (1-2.3)

2.3

0.5 (0.7)

0.7 (0.7)

0.5 (0.8)

1.0 (1.0)

1.5 (1.1)

0.9 (0.6)

+

Values presented are Median (25th percentile, 75th percentile) due to right-skewed distribution
++
Values are Median with interquartile range; no range provided for total score; Additional subscales: Fatigue 2.0 (0-2.3), Cognitive 2.0 (1.5-2.3)
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Mood Symptoms
In the overall sample, mood was not dissimilar from other studies of persons
with diabetes. Three studies have used the WBQ-12 to analyze mood in subjects with
T2DM (Table 31). None of the studies are from the US. Subjects in two studies had
shorter disease duration (mean DM duration less than 6 years). The dissertation
study’s WBQ-12 results are most similar to those of Pouwer et al. (1999), whose
subjects had a longer DM duration and at least one complication of DM. The presence
of DM-related complications and/or longer disease duration is associated with lower
psychological well-being and mood (Nicolucci et al., 2009; Savli & Sevinc, 2005). In the
dissertation sample, mean reports of mood-related symptoms were as expected.
Gender differences existed and are discussed below.
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Table 31. Psychological Well-being in Other Studies Using the Well Being Questionnaire12
WBQ Scores: Mean (SD)
Sample Characteristics
Positive
Author
N
General
(all T2DM outpatients)
Energy
Wellwell-being
Being
McCormick, 2014
24.1(6.7) 6.6 (2.7)
7.5(3.0)
Pouwer 349 Mean age 51 years,
et al.,
49% female; DM
1999
duration 16 years;
24.4(7.2) 7.5 (3.0)
7.6(2.8)
Dutch with at least 1
complication of DM
Reid et
218 Mean age 54 years,
al., 2010
35% female, DM
duration 5.4 years;
Canadians treated
26.1(5.4)
--with diet and/or oral
medications (no
insulin)
Van den 2217 Mean age 65 years,
Donk et
43% female; DM
25.0(6.3) 7.0(2.7)
8.0(2.9)
al., 2013
duration 5.7 years;
to
to
to
from 318 European
28.5(5.9) 8.5(2.6)
9.4(2.5)
clinics (4 centers)

Negative
WellBeing
1.9 (2.2)

2.7(2.9)

--

1.1(1.8)
to
2.1(2.5)

Functional Performance
Subjects’ functional performance was equal or greater than average. Subjects in
the dissertation study reported physical and mental functioning at similar levels to other
persons with DM. SF-12 normative data was developed from the National Survey of
Functional Health Status (1998; n=14906), representing the non-institutionalized US
adult population (Ware, Kosinski, Turner-Bowker & Gandek, 2002). In the dissertation
study, physical functioning (SF-12 physical composite scores, M=41.47± 11.97) was very
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similar to the diabetes normative data (M=41.52±11.07). Social functioning (SF-12
mental composite score) from the dissertation study (M= 50.93 ± 9.91) were slightly
above normative data for persons with DM (M=47.28±10.72).
Diabetes self-management was similar to published instrument data. The mean
SCI-R score in the dissertation study was 61.61(± 13.68). A study of 159 US adults with
T2DM (88% Caucasian, 57% female, age 47±15 years, diabetes duration 13±12 years)
revealed the mean score on the SCI-R to be 64.4 (SD=17.9; Weinger, Butler, Welch &
LaGreca, 2005). Similar results were found in a study of 353 UK adults with T2DM (39%
female, age 66±9 years, diabetes duration 17±7 years; mean SCI-R score 69.0±12.8;
Khagram, Martin, Davies & Speight, 2013). As with other studies, subjects in the
dissertation study reported a wide range of diabetes self-management performance
(Range: 28.85-89.29).
Health Perceptions
The Appraisal of Diabetes Scale assesses patients’ acceptance of DM and its
related burdens. A higher score indicates a greater disease burden. In the dissertation
study, subjects reported their DM as moderately challenging (M= 17.10 ± 4.46). In a
study of adults with similar demographics to the dissertation study (n=94 Midwestern
US outpatients with T2DM; mean age 61 years; 62% female), Poradzisz (2001) reported
similar scores on the ADS (M=17.84 ±5.05). The original study using the ADS reported
greater disease burden (M=18.65 ±4.04); however, all participants were male veterans
from the VA outpatient clinic (Carey et al., 1991). The ADS assesses control, uncertainty,
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effects of disease on life goals, and DM related distress. In the dissertation study,
subjects reported these dimensions at expected levels.
Quality of Life
Participants in the dissertation study rated their QOL highly. This is consistent
with other studies of persons with diabetes. The dissertation sample reported very high
quality of life in three subscales: Social & Economic, Psychological & Spiritual, and
Family. QOL was reported slightly lower in the Health and Functioning subscale, which
may be expected due to the presence of DM complications in the dissertation sample.
Other studies using the same instrument have reported overall means ranging from 20.5
to 23.40 (Table 32). This variability may be due to the diverse settings of the studies.
The highest mean QLI scores (23.40±3.55) were reported in a study of Hispanic adults
with T2DM, primarily immigrants from Mexico (74%) with an average of nine years living
in the US (Hu, Wallace & Tesh, 2010). Duration of DM was 4.5 years (SD ± 0.25). These
QOL findings are consistent with the findings of Naranjo and colleagues, who reported
decreased QOL in in Black adults with DM but not in their Latino peers, despite greater
perception of disease burden among Latinos (Naranjo, Hessler, Deol & Chesla, 2012).
Acculturation was found to have a significant moderating effect on QOL. Shorter
duration of DM has been linked to higher QOL (Narajo et al., 2012). These factors
should be considered in comparing these QLI scores to the dissertation study findings.
The dissertation study’s sample mean is within the range of the other studies’ findings.
The QOL reported by participants was good and in accordance with existing data.
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Table 32. Quality of Life in Other Studies Using the Quality of Life Index: Diabetes
Version
Author
McCormick, 2014
Hu, Wallace &
Tesh, 2010
Lewko et al. 2013
Poradzisz, 2001

Sample
Size
107
59
71
94

Sample Characteristics
Mean age 49 years; 68% female;
Hispanic outpatients in Southeast US
Mean age 55 years; 52% female;
Inpatients in Poland
Mean age 61 years; 62% female;
T2DM outpatients in Midwest US

QLI overall
mean (SD)
21.81 (4.70)
23.40 (3.55)
Gp. 1: 20.5 (3.8)
Gp. 2: 21.9 (4.5)
21.10 (4.38)

By examining QOL in a multidimensional manner, the construct is depicted more
fully. The dissertation study subjects reported adequate HRQOL. Certain dimensions of
QOL were rated highly. Study subjects reported better than average access to care,
social support, mood, social functioning, and diabetes self-management. Other
dimensions were equivalent to normative data, such as glycemic control, disease
appraisal, and role functioning. In contrast, diabetes symptoms were rated poorly by
subjects and were greater than several comparable studies.
The first study aim also examined using Pearson’s correlations to describe the
relationships between key study variables. Higher QOL was found with greater age,
social support, general well-being, role functioning, and social functioning. The positive
correlation between older age and quality of life is consistent with the higher mental
QOL reported by older adults in several studies. In a study of 353 adults with T2DM,
older adults (age > 65 years) reported better QOL and positive well-being despite lower
energy and more DM complications than their younger peers (age ≤65 years; Speight,
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Khagram & Davies, 2012). Similar findings were documented by a study of 191 adults
with insulin-dependent DM (68% T2DM; Trief, Wade, Pine & Weinstock, 2003). When
compared to middle-aged and young adults, older adults in the dissertation study
reported significantly better DM coping and less DM-related distress, despite having
worse physical functioning and role limitations. These findings are not specific to
diabetes. According to the US Behavioral Risk Factor Surveillance System, older adults
report better mental QOL, despite worse physical QOL and more self-ratings of “fair or
poor” health (Zack, 2013). This may be a generational or experiential effect.
The dissertation study subjects reported worse QOL with higher levels of obesity,
poor glycemic control, and diabetes-related complications and symptoms. Also, QOL
was decreased in subjects who had poor acceptance of their disease as measured by the
ADS. Individuals with a negative perception of their diabetes have reported lower QOL
(Scollan-Koliopoulos et al., 2013). Insulin management and diabetes self-care were not
significantly correlated with QOL. However, both correlations had low statistical power
(0.49 and 0.34, respectively) per post-hoc power analysis (G*Power 3.1.6). Power
should be 0.8 or greater to minimize the likelihood of a type II error (Field, 2009).
Finally, the first study aim described the gender differences in QOL and related
study variables. There were no significant gender differences in ethnicity, duration of
DM, social support, glycemic control (A1C), BMI, diabetes self-care, or acceptance of
diabetes (ADS). Insulin management could not be analyzed according to gender due to
insufficient numbers. Male and female subjects had some demographic differences.
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Males were older and most were married. Women were most likely to be nonpartnered (divorced, never married, or widowed). This is significant because being
married may provide a uniquely effective source of social support to some persons with
diabetes. Positive spousal support has been linked to decreased diabetes distress,
increased DSM behaviors, greater dietary adherence, and more physical activity
(Dempster, McCarthy & Davies, 2011; Franks et al., 2012; Khan, Stephens, Franks, Rook
& Salem, 2013; Stephens et al., 2013; Stephens, Rook, Franks, Khan & Lida, 2010). It
should be noted however, wives have been shown to provide greater psychological
support for their husbands with T2DM (Lida, Parris Stephens, Rook, Franks & Salem,
2010).
Health-related differences included both physical and psychological. Men
reported a greater number of diabetes-related complications. Despite men having more
complications, both genders reported equivalent amounts of diabetes-related
symptoms. This means that women experienced more diabetes-related symptoms even
with fewer diabetes complications. Numerous studies have documented greater
diabetes symptoms in women. One large study (n=14206) found a 50% greater risk of
painful neuropathic symptoms in women vs. men with T2DM (OR = 1.5, p<0.0001),
despite less clinical neuropathy (19 vs. 23%, p<0.0001; Abbott, Malik, van Ross, Kulkarni
& Boulton, 2011). Women with T2DM are also more likely than men to report symptoms
of gastroparesis (OR = 1.838, p<0.05; Dickman, Wainstein, Glezerman, Niv & Boaz,
2014). Significant fatigue has been reported in women with T2DM (Fritschi et al., 2012).
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Women also reported higher levels of cardiac symptoms, despite equal cardiac disease
prevalence as male participants. This is consistent with the findings of Tamis-Holland
and colleagues, who found that women with T2DM had more anginal symptoms than
men but had less obstructive cardiac disease (Tamis-Holland et al., 2011; Tamis-Holland
et al., 2013). Physical symptoms related to T2DM are different in women than in men.
Women in the dissertation study reported a greater prevalence of diagnosed
depression than men (OR = 3.61, p<.05). Per meta-analysis, depression is twice as likely
in people with DM as in their peers without DM (OR = 2.0, 95% CI 1.8-2.2; Anderson,
Freedland, Clouse & Lustman, 2001). Depressive symptoms are even more common,
reported by 44% of persons with DM in a large, multi-national study (Nicolucci et al.,
2013). Depression is especially prevalent in women with diabetes. There is a two-fold
increased likelihood of depressive symptoms in women with T2DM (Egede, 2007). In
the dissertation study, male participants reported higher general well-being, energy,
and positive well-being. When compared to data from other studies (Pouwer et al.,
1999; Reid et al., 2010; Van den Donk et al., 2013; see table 31 above), both general and
positive well-being were higher in dissertation study males. Female participants
reported more negative well-being than men in the dissertation study; however,
comparison with other studies (Pouwer et al., 1999; Van den Donk et al., 2013) reveals
that this sample (men and women) had less or equivalent negative well-being. Details
are provided in Figure 6. In addition to higher well-being, male subjects also reported
higher levels of mental performance per the SF-12.
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Figure 6. Well-Being by Gender
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In addition to well-being, quality of life was also reported as lower by women in
the dissertation study. In overall QOL and all subscales, women reported significantly
lower quality of life than men. Gender differences in QOL have been reported in
several studies. Compared to men, women with T2DM have lower QOL (Papadopoulos,
Kontodimopoulos, Frydas, Ikonomakis & Niakas, 2007; Glasgow, Ruggiero, Eakin,
Dryfoos & Chobanian, 1997) and more self-rated “unhealthy days” (OR = 0.66, p<0.01;
Clifford, Collins, Buckley, Fitzgerald & Perry, 2013). QOL is especially lower in obese
women with T2DM (Svenningsson, Marklund, Attvall, & Gedda, 2011). Women with
depression and T2DM are particularly vulnerable to QOL effects. Gender is clearly an
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important factor in understanding QOL in T2DM. Further research on this topic is
essential.
Discussion of Aim 2: QOL Differences
Aim 2 hypothesized that QOL would differ according to type of insulin
management. This study aim was not supported by the data--there were no significant
differences in QOL based on type of insulin management. The one-way ANOVA
achieved only 38 percent power, per post-hoc power analysis. Unfortunately, a sample
size of 285 would be required to achieve acceptable power of 80 percent. Therefore,
the second study aim was not statistically supported.
MANOVA testing was utilized to clarify the multiple interactions that may have
affected QOL measurement in the study. The study model was used to select variables
for MANOVA examination, and included type of glycemic management (oral, basal
insulin, or basal-bolus insulin), glycemic control (Hemoglobin A1C), diabetes symptoms,
mood (psychological well-being), diabetes self-care, acceptance of diabetes, and quality
of life. Despite accounting for related dependent variables, QOL was still not shown to
differ based on insulin management type.
Although QOL did not differ, MANOVA showed significant differences in diabetes
self-care performed by subjects using basal-bolus insulin and those using oral
medications alone. Subjects using basal-bolus insulin management scored higher on the
SCI-R than subjects on oral medications only. It should be noted that the SCI-R accounts
for different diabetes regimens. Persons completing the SCI-R may choose “not
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applicable” for certain items, such as checking ketones, taking insulin and/or pills, or
treating low blood glucose (Weinger, Welch, Butler & LaGreca, 2005). SCI-R scores
represent patients’ adherence to their prescribed DSM regimen. Therefore, subjects on
basal-bolus insulin were actually performing a greater proportion of prescribed diabetes
self-care. Even though these subjects had more required diabetes self-care activities,
they still performed a greater proportion of the prescribed self-care.
MANOVA also revealed differences in glycemic control. Subjects taking insulin
(basal only and basal-bolus) had worse glycemic control than those taking oral
medication alone. Historically, insulin has been prescribed later in the disease course of
T2DM, due to both physician and patient reluctance (Ratanawongsa et al., 2012; Nam,
Chesla, Stotts, Kroon & Janson, 2010). Newer diabetes guidelines seek earlier treatment
with insulin as needed to meet glycemic control goals (ADA, 2014; Shubrook, 2014). As
a cross-sectional study, it is impossible to know the temporal correlation of insulin
management and poor glycemic control in this sample.
After accounting for the effects of glycemic control and diabetes self-care with
MANOVA, QOL did not vary based on insulin management. Greater power would be
required to make conclusions regarding the original study aim.
Discussion of Aim 3: Predicting QOL
Multiple regression analysis was used to determine if type of glycemic
management was predictive of HRQOL after controlling for covariates. First,
simultaneous multiple regression tested the effects of five predictors on QOL. In this

111

regression, glycemic control, diabetes symptoms, and diabetes self-management were
not significant predictors per beta weight analysis. Significant QOL predictors were
general well-being and appraisal of diabetes. Examination of beta weights showed that
general well-being positively predicted QOL (β = .47, p<.001). Appraisal of diabetes
(ADS) negatively predicted QOL (β = -.22, p<.05). As a proxy measure for mood, it is
clear that general well-being would predict QOL in a positive manner. Correlations
between the WBQ and the mental health component of the SF-36 have been robust
(r=0.80, p<0.001; McMillan, Bradley, Gibney, Russell-Jones & Sonksen, 2006 and r=0.75,
p<0.001; Pouwer et al., 1999). The negative predictive relationship between the ADS
and QOL was expected: poor disease acceptance has been linked to lower QOL (r=-0.55,
p<0.01; Poradzisz, 2001).
A moderated model of diabetes self-care, general well-being, and QOL was
tested by multiple regression analysis (Figure 3). The model showed significant effects
on QOL by general well-being (main effect) and the interaction between general wellbeing and diabetes self-care. The relationship between general well-being and QOL is
moderated by diabetes self-care. This effect is most clearly evident with low general
well-being, where high self-care is related to a significantly higher QOL. The
moderation effect of self-care is shown graphically in Figure 4.
These findings are consistent with descriptions of moderated models. A
moderating variable is defined as a third variable that affects the relationship between
two other variables (Baron & Kenny, 1986). A moderator is an independent variable
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which affects the dependent variable (outcome) through interaction with the predictor
variable. The predictor variable may or may not have a significant main effect on the
outcome variable (Holmbeck, 1997). Traditionally, moderators are not antecedent or
causal (Baron & Kenny, 1986). The cross-sectional nature of the dissertation study
precludes temporal conclusions. The moderated model of this study should be
considered preliminary. Further testing is required to understand the directionality of
the relationship between general well-being, self-care, and QOL. However, these
concepts are indisputably linked.
Summary of Major Findings
The major study findings are summarized as follows. First, examination of major
study variables showed that the sample experienced satisfactory QOL and related
domains. Compared to other studies of persons with diabetes, subjects reported above
average access to care, social support, social functioning, diabetes self-management,
overall QOL, and subscale QOL (Social & Economic, Psychological & Spiritual, and
Family). Glycemic control, well-being (general and positive), role functioning, disease
acceptance, and health and functioning subscale QOL were consistent with existing
studies. However, study participants reported more diabetes symptoms, and less
energy than their peers. Second, correlations revealed that QOL was positively
influenced by age, social support, general well-being, role functioning, and social
functioning. QOL was negatively influenced by obesity, poor glycemic control, disease
acceptance, and diabetes-related complications and symptoms. Third, when analyzed
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by gender, women reported lower well-being and greater negative well-being, as well as
lower QOL. Female participants were also more likely to have diagnosed depression and
report more diabetes symptoms, despite less prevalence of diabetes-related
complications
Fourth, the study was designed to evaluate the relationship between insulin
management strategy and QOL. Both ANOVA and MANOVA failed to provide statistical
evidence to support this relationship. The study was insufficiently powered to declare
negative findings and will require further testing before conclusions can be made.
However, statistical modeling revealed that disease acceptance and general well-being
are significant predictors of QOL. Per multiple regression analysis, greater disease
acceptance and general well-being are positive predictors of QOL.
Finally, a moderated model of diabetes self-care, general well-being, and QOL
was examined by multiple regression analysis. The regression model revealed that selfcare is a moderator in the relationship between general well-being and QOL. Analysis
by gender revealed the moderating effect of self-care is most significant in women in
the presence of negative mood. Clearly, this area is grounds for future research.
Study Limitations
This study has limitations to both internal and external validity. Internal validity
is limited by several factors. First, the non-experimental design affects the internal
validity of the findings. As a cross-sectional, observational study, no conclusions of
causality can be made. Second, the study is limited by selection bias. The participants
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were a non-random convenience sample. A substantial minority of the sample (43%)
was recruited from a database of persons interested in diabetes and depression studies.
This may have resulted in a disproportionate share of women with depressive
symptoms in the sample. Third, instrumentation may have affected internal validity.
The questionnaires rely upon accurate self-assessment and honest reporting. It is
impossible to know if subjects over- or under-estimated parameters such as diabetes
self-management activities or negative mood symptoms. Fourth, although many
confounding variables were minimized through exclusion criteria, not all could be
eliminated. For example, duration of DM and presence of co-morbidities (heart disease,
chronic pain) were greater in the basal-bolus insulin group. Disease duration and comorbid illness have potential QOL effects. Due to uneven distribution of these factors
among insulin management groups, it is impossible to rule out confounding effects on
QOL. Additionally, the study had low power due to a small sample size and lower than
expected effect size. Finally, although minimized, any missing data may affect internal
validity.
External validity of the study was also affected by several factors. Most of the
threats to external validity are related to sampling; the sample was fairly homogenous.
Racial minorities were not sufficiently represented in the sample, nor younger adults.
Non-English speakers were excluded from the study. Recruitment was done through a
database of prior study volunteers, outpatient clinics in the Midwest US, and via the
internet. This means that the sample represented only people with media, clinic, and/or
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internet access. All participants were volunteers; this fact limits generalizability to those
who voluntarily participate in research. This study’s limitations should be noted when
interpreting the findings.
Nursing Implications
Nurses encounter persons with DM in nearly every healthcare setting. As
worldwide rates of T2DM are only expected to increase, it is essential for nurses to
understand QOL in DM. The study revealed gender differences in QOL. Women in the
study reported lower QOL and negative well-being, as well as more cardiac symptoms
than men. This is an important finding for nursing clinical practice. Nurses should be
aware of the higher risk of depressive symptoms in women with diabetes and the
resulting impact on QOL. Study subjects reporting lower general well-being and less
diabetes self-management activities experienced lower QOL. Although the study
findings do not demonstrate causality, nursing assessment of persons with DM should
include mood and performance of DSM behaviors. Nurses are very capable at
recognizing depressive symptoms and diabetes-related distress (Pouwer, Beekman,
Lubach & Snoek, 2006). Because women are at greater risk for depressive symptoms
(Egede, 2007), they are at particular risk for lower QOL and self-care. Nurses should be
aware of the relationship between mood, DSM practices and glycemic control. Nursing
interventions may include reinforcement of diabetic teaching, mood assessment, and
facilitating treatment of depression. Nurse-led psychoeducational group therapy for
depressed women with T2DM has been successful (Penckofer et al., 2012). A minimal

116

psychological intervention by nurses has been shown to modestly improve glycemic
control, diabetes symptoms, and diabetes-related distress (Lamers, Jonkers, Bosma,
Knottnerus & van Eijk, 2011). Patients who report decreased DSM practices and lower
mood are at risk for loss of glycemic control. Nurses have the potential to minimize this
risk.
Future Research
This study provides inspiration for future research. A larger study should be
conducted to confirm the potentially negative findings. Ideally, the larger study would
utilize a greater sample size and control for confounding factors such as DM duration
and co-morbidities with case-controls per insulin management strategy. Other future
studies could change the design or population. A longitudinal study of patients before
and after initiation of basal-bolus insulin therapy would provide a more rigorous
evaluation, as patients would serve as their own control subjects. Subjects could be
tested at 6 and 12 months after basal-bolus insulin initiation. Additional studies could
also focus on different age groups. A study of insulin management strategies and QOL
should be conducted in young adults with T2DM. The correlation between older age
and higher QOL could be further explored with qualitative research such as interviews
or focus groups of older adults with T2DM. This would provide greater insight into the
details of the age-QOL relationship. Future studies should include non-English speakers
as well as teenagers with T2DM.
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The moderating effect of DSM on well-being and QOL is grounds for future
research. Future studies to explore causality and temporal precedence of these
variables are crucial. One study could examine well-being and QOL in subjects before
and after intense DSM education programs, with a longitudinal follow-up. Most
importantly, studies should be conducted to explore the gender differences in the effect
of self-care on negative well-being and QOL. Studies sufficiently powered to detect the
effects of self-care in women are seminal. Qualitative studies, such as focus groups,
could facilitate greater understanding of self-care in women with diabetes and negative
mood. As the rates of type 2 diabetes continue to rise, future research is the key to
understanding the multiple dimensions of quality of life for all persons with diabetes.
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Database Search Strategy
#

S3

S4

S9

Search terms
(diabetes mellitus, type 2) or (MeSH Major Topic “diabetes mellitus,
type 2”)
(quality of life) or (QOL) or (“quality of life”, MeSH Major Topic, MeSH
Term)
(“insulin infusion systems”, MeSH Major Topic, MeSH Term) or (CSI) or
(Continuous subcutaneous insulin) or (MDI) or (multiple daily)

Operator

Prior Search

Results (PubMed)

AND

Insulin

66256

AND

S3

1458

AND

S4

150

Limits: 2009-2014, English language, human

71

After review of titles & abstracts

29

After review of full-text articles

12
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Study
Banerjee, Maji &
Baruah, 2013
A1chieve sub-study

Sample
Design
(all T2DM unless specified)
N=343
Longitudinal (24 wks.)
Age: 53 yrs.
Observational
41% female
DM duration: 9 yrs.
Analog basal-bolus
initiation

India
Dieuzeide et al., 2014 N=1024ŧ
Age 56±13 yrs.
A1chieve sub-study
52% female
DM duration: 10±8 yrs.
ŧ

Note: only 52% (533)
remained in study (others
28 countries lost to follow-up)
Hajos et al., 2012
N=447 w/T2DM
Age: 59±11 yrs.
49% female
DM duration: 11 yrs.
Netherlands

75% of sample insulinnaïve at baseline
Longitudinal (24 wks.)
Observational
MDI to premix analogs
(N=770 Reg-NPH,
N=136 Reg-Lantus,
N=104 analog basalbolus)
Longitudinal (6 mo.)
Started basal-bolus
insulin (baseline: basal
only or premix)

Outcomes
Glycemic Control
Hypoglycemia
QOL (EQ-5D)

Glycemic Control
Hypoglycemia
QOL (EQ-5D)

Findings
Huge A1C improvements
(9.3 to 7.7%, p<.001):
Less hypoglycemia in pts on
insulin prior to study
(p<.001)
↑QOL in both insulin-naïve
and experienced groups
(p<.001)
Huge A1C improvements
(2%, p<.001)
Less hypoglycemia, esp. in
NPH group (p<.001).

Glycemic control
Fear of hypoglycemia
Diabetes symptoms
(DSC-r)
QOL (WHO-5 wellbeing)

QOL greater after starting
premix(p<.001)
DM Symptoms improved
(p<0.001)
QOL/emotional well-being
improved (p<0.001)
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Study
Hermanns et al.,
2012

Sample
(all T2DM unless specified)
N=167
Age: 64±8 yrs.
45% female
DM duration: 14±7 yrs.

Germany
Levin et al., 2011
N=197
Age: 56 yrs.
54% female
DM duration: 13 yrs.
U.S.
Opsteen et al., 2012 N=34
Age: 59 yrs.
38% female
DM duration: 6±7 yrs.
Canada
Peyrot & Rubin,
N=618
2011
Age: 56±10 yrs.
53% female
DM duration: 13±7 yrs.
U.S.

Design
RCT (6 months)
Intensive basal-bolus
education vs. standard
RCT (9 months)
Basal-bolus vs. premix

Longitudinal (8 weeks)
Short-term intensive
(basal-bolus) insulin
therapy
RCT (45 weeks)
Basal-bolus (inhaled
bolus insulin) vs.
premix

Outcomes
Glycemic Control
QOL (SF-12)
DM distress (PAID)
Diabetes Knowledge
Self-care activities
Glycemic control
QOL (DQOL, EQ-5D)
Hypoglycemia
Cost-effectiveness
Work Productivity &
Activity
Glycemic control
QOL (SF-36, DQOL)
Diabetes Symptoms
(DSC-r)
Glycemic control
QOL (SF-36)
Treatment
Satisfaction (IITQ)

Findings
Exp. Gp. had less DM
distress (p<.001), improved
PCS of SF-12 (p<.05),
improved diabetes
knowledge
Exp. gp.: less work days
missed (p<.05), more costeffective
No signif. changes in QOL
SF-36 improved: PCS
(p<.01), MCS (p<.05)
DQOL “DM worries”
subscale improved (p<.01)
Less DM symptoms (p<.05)
No signif. changes in QOL
Less DM worries in B-B
group

121

Sample
(all T2DM unless specified)

Study

Design

Peyrot et al., 2011

Longitudinal (16 weeks)

U.S. N=54
Age: 57±10 yrs.
Rubin et al., 2010
50% female
DM duration: 13±6 yrs.

CSI initiation
Longitudinal (16 weeks)
All started CSI (differed by
baseline RX:
N=17 orals, N=17 basal,
N=20 basal-bolus
Longitudinal (24 weeks)
Observational

U.S.
Shah et al., 2011
N=66,726
Age: 54±12 yrs.
A1chieve study
44% female
DM duration: 8±6 yrs.
28 countries
(33% South Asia; 67% of sample insulin22% Middle East) naïve at baseline
Testa et al., 2012
N=388 (80% T2DM)
Age: 54±11 yrs.
53% female
DM duration: 16±9 yrs.

Routine analog initiation or
intensification (to premix,
basal, or basal-bolus)
RCT: Crossover (24 weeks)
Analog basal-bolus vs.
premix

U.S.
Vinagre et al.,
2013

N=37
Age 65±8 yrs.
38% female
Spain DM duration 18±8 yrs.

Longitudinal (6 months)
Basal only or premix (89%)
started basal-bolus insulin

Outcomes

Glycemic ctrl (A1C,
CGMS)
QOL (EQ-5D)
DM Symptoms (DSC-r)
Treatment Satisf.
(IDSRQ)
Glycemic Control
Hypoglycemia
QOL (EQ-5D)

Findings

No change in QOL overall
Less DM symptoms (p<.05)
Oral gp.: No QOL or Sx
changes
Basal and B-B groups: QOL
improved (p<.05), less DM
symptoms (p<.05)
Huge A1C improvements
(9.5 to 7.4%, p<.001):

QOL improved in all
subgroups (p<.001) &
countries (p<.001) in similar
amounts
Glycemic control &
With basal-bolus:
variability (A1C,
Better QOL (p<.001)
CGMS)
↓ symptom distress
Treatment satisfaction (p<.0001)
QOL (Author’s own
Better glycemic control and
instrument)
variability (p<.0001)
Glycemic control
No change in QOL (all
Severe hypoglycemia
subscales)
QOL (DQOL)
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Date of initial call:
Name:
Phone:
Screening Questions: Inclusion
1. Are you at least 18 years old?
2. Do you have diabetes?
3. Do you have “adult-onset” / “type 2” diabetes?
4. Do you take medication for your diabetes at least one time a day?
5. Have you been taking diabetes medicine for at least six months?
6. Have you had the same diabetes medication schedule for at least 3 months?
(for example, insulin doses per day)
7. Are you able to read, write, and speak English?

Yes

No*

*A “No” answer disqualifies a subject from study enrollment

Screening Questions: Exclusion
1. Are you pregnant right now?
2. Do you have sickle cell disease?
3. Have you been treated for cancer (chemo or radiation) in the last 3 years?
4. Do you have HIV (Human-Immunodeficiency Virus) or AIDS?
5. Do you have Alzheimer’s or dementia?
6. Do you have bipolar disorder or manic depressive disorder?
7. Do you have schizophrenia or schizoaffective disorder?
8. Do you any other major psychiatric disorder? (depression is acceptable)
9. Do you have fibromyalgia?

Yes**

No

Yes

No

**A “Yes” answer disqualifies a subject from study enrollment.

To assure appropriate distribution of subjects among diabetes management groups:
Screening Questions: Verification
1. Do you take insulin?
2. How many times per day do you take insulin:
a. Once a day?
b. Two times a day?
c. Three or more times a day?
3. Do you have an insulin pump?
4. Do you take short-acting insulin (i.e., Regular, Humalog, Novolog, Apidra)?
5. Do you take long-acting insulin (i.e. NPH, Lantus, Levemir, Lente)?
Can we mail you the study packet? No / Yes
Can I call you (with message if you are not home) or
email you to see if you got the booklet? No / Yes
Gender: M / F
Accepted into study: No / Yes
Contact attempts:

If yes, address:

How recruited:
If yes, Subject #:
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Marcella Niehoff School of Nursing
2160 South First Avenue
Maywood, Illinois 60532

June 14, 2012
Dear Sir or Madam,
I am a graduate student in nursing at Loyola University Chicago. I am conducting a
research project on quality of life in persons living with type 2 diabetes. Dr. Susan
Penckofer is my supervisor during this study and has given me permission to inform you
about this project. The study will consist of a questionnaire booklet and finger-stick
blood test for hemoglobin A1C which you will complete at home and return to me in a
pre-paid envelope. It will take about one hour to complete. You will be informed of
your hemoglobin A1C test results. Upon completion of the survey, you will also receive
a $10 gift card.
The results of this project will be used to help me complete my graduate studies.
Through your participation, I hope to understand more about the quality of life in
people with type 2 diabetes. The results will hopefully be useful for doctors and nurses
who care for people with diabetes. I also hope to share my results by publishing them in
a scientific journal.
There are no risks to you in participating in this survey, beyond what you already
experience in everyday life with diabetes. Your responses will be kept confidential.
Your name will not appear in any study results.
If you are interested in learning more about the study or participating in the study,
please call me at (630)-219-1331. I appreciate your time and help! Thank you.
Sincerely,
Sandra McCormick, RN, BSN
Graduate Student in Nursing
Loyola University Chicago
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IRB LU# 204151

Volunteers Needed for Research Study:
Quality of Life in Type 2 Diabetes

 The purpose of the study is to understand the quality of life for people
with type 2 diabetes
 The study is open to all English-speaking adults age 18 and older who
take medications (pills and/or insulin) for type 2 diabetes
 The study is not a treatment. Participants will fill out a questionnaire
booklet and complete a finger-stick blood test and return the study
packet by mail. You will receive a $10 gift card and your hemoglobin
A1C result.
Principal Investigator:

Sandra McCormick, RN, BSN
Graduate Nursing Student
Loyola University Chicago

Faculty Advisor: Susan Penckofer, RN, PhD

If interested, please contact:
Sandra McCormick at (630)-219-1331
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Marcella Niehoff School of Nursing
2160 South First Avenue
Maywood, Illinois 60532
Dear Sir or Madam,
Thank you for taking the time to participate in my research study. The information you provide
for the study is very valuable. It is important to complete the survey and blood test as soon as
possible. Once the survey packet and blood test are complete, you will mail both by U.S. Mail in
the pre-paid envelope within 10 days. Please feel free to contact me by phone (information
below). Instructions for completing the study materials are provided below.

1. Blood test (Hemoglobin A1C):
o
o
o
o

Detailed instructions on how to complete the blood test are on the next page
Sign and date the “Test Authorization Form”.
Blood test should take less than 5 minutes to collect
Allow the blood test to dry for at least 30 minutes before placing in envelope.

2. Survey (Questionnaire booklet):
o
o
o

Fill out the questionnaire booklet. It will take about 1 hour to complete.
If you have questions, please contact me at the number below.
If you do not want to answer a question, you can leave the question blank.

3. Place your completed booklet and blood test card in the large stamped envelope. Send by
U.S. Mail.
You may contact me at (630)-219-1331 or my faculty advisor (Susan Penckofer, 708-216-9303)
with any questions or concerns. If you have any questions concerning your rights as a research
participant, you may contact Dr. Kenneth Micetich, Chairman, Institutional Review Board for the
Protection of Human Subjects-Medical Center (708-216-4608).
Thank you again for your time and effort in participating in my study!
Sincerely,
Sandra McCormick, RN, BSN
Graduate Nursing Student
Loyola University Chicago
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HEMOGLOBIN A1c COLLECTION INSTRUCTIONS
PLEASE READ THOROUGHLY
Remember to complete all your personal information on the Hemoglobin A1C Test Authorization Form. Please read
and provide your signature and date under the Patient Consent in order to approve your sample for testing. Heritage
labs will not complete any testing without your signature and date.
Toll-free ReliOn customer support:

1-888-764-2384

1. Review the Contents of Your Kit

5. Use the Lancet Provided

Your test kit contains:
 Collection instruction sheet
 Hemoglobin A1C Test Authorization & Collection Form
 Lancet
 Alcohol Pad
 Gauze Pad
 Adhesive Bandage
 Postage Paid Return Envelope

Using the lancet provided,
remove the cap, place palm
up and position lancet on
finger. Press down on lancet
to puncture site. Wipe off
the first blood drop with the
alcohol pad.

2. Fill Out the Hemoglobin A1C Test
Authorization Form

The Hemoglobin A1C

The Hemoglobin A1C Test
Test Authorization
Authorization
Form has
Form been
has already
been
already
completed
by
the
researcher.
completed
byPlease
the
initial and date the testing
researcher.
form, or testing cannot be
done.

6. Blood Should Begin to Flow
Blood should begin to
flow freely. Place a
LARGE free-flowing drop
of blood on each circle of
the Collection Form as
shown. Do NOT place
one drop of blood on top
of the other. If blood
flow stops, wipe with
alcohol pad again to
assist blood flow.

Please sign and date the
test form, or testing
cannot be done.

3. Prepare Hands
Rinse hands in warm tap
water. Clean the selected
puncture site with the
alcohol pad and dry it with
the gauze pad.

7. Let the Blood Spot Air-Dry
Let the blood spot air-dry for at least 30 minutes. Make
sure spot is dry before folding the Test Form.

4. Stimulate Blood Flow

8. Mailing Instructions

Stimulate blood flow to the
selected finger by letting your
hand hang down at your side for
15-20 seconds. Shake your hand
back and forth several times.




Place the Hemoglobin A1C Test Authorization form
into the postage-paid return envelope.
Mail the sample within three days of collecting the
blood sample.
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Response Card (attached to front of questionnaire booklet)

Please circle the answer to the questions and return
this card with your packet.
1. You can call me if you have questions Yes
No
about my booklet.
2. I would like to receive my
Yes
No
Hemoglobin A1C results.
3. I would like to receive my “thank
Yes
No
you” $10 gift card.
My initials: ___________
ID # ___________
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1. What is your birth date?
______/_____/_____
Month / Date / Year
2. What is your gender?
1.
2.

□ Male
□ Female

3. What is your ethnicity?
1.
2.

□ Hispanic
□ Non-Hispanic

4. What is your race?

2.

□ American Indian or Alaskan Native
□ Asian or Pacific Islander

3.

□ Black or African-American

4.

□ White

5.

□ Other

1.

5. What is your marital status?
1.
2.
3.
4.
5.

□ Never Married
□ Married
□ Separated
□ Divorced
□ Widowed

6. Please check your highest level of
education:
□ Less than 9th grade
1.
□ 9th to 12th grade, no diploma
2.
□ High school graduate (includes
3.
GED)
□ Some college, no degree
4.
□ Associate degree
5.
□ Bachelor’s degree
6.
□ Graduate degree
7.
7. Please indicate your total household
income:
□ Less than $9,999
1.
□ $10,000 to $14,999
2.
□ $15,000 to $19,999
3.
□ $20,000 to $29,999
4.
□ $30,000 to $39,999
5.
□ $40,000 to $49,999
6.
□ $50,000 to $59,999
7.
□ $60,000 to $69,999
8.
□ $70,000 and over
9.
8. What is your employment status?
□ Working full time, 35 hours or
1.
more per week
□ Working part-time, less than 35
2.
hours per week
□ Unemployed or laid off and looking
3.
for work
□ Unemployed and not looking for
4.
work
□ Homemaker
5.
□ In School
6.
□ Retired
7.
□ Disabled, not able to work
8.
□ Other, please specify:
9.
____________
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Health Questionnaire
1. What is your height? ______ feet _____ inches
2. What is your weight? ______ pounds
3. What year were you told that you have diabetes? __________
4. Do you take pills for your diabetes?
1. □ No

2. □ Yes, name of medicine(s): ___________________________

5. Do you take insulin for your diabetes?
1.

□ No

2.

□ Yes

5a. How many times a day do you usually take your
insulin? (check ONE box)
1.
2.
3.
4.
5.

□ Once a day
□ Twice a day
□ Three times a day
□ Four (or more) times a day
□ I use an infusion pump

5b. How long have you taken insulin? ________ years
5c. Do you take short-acting insulin (Humulin Regular,
Humalog, Novolog, Apidra)?

1. □ No
2. □ Yes
5d. Do you take long-acting insulin (NPH, Lantus, Levemir,
Lente)?

1. □ No
2. □ Yes

6. Do you take Byetta (exenatide) injection for your diabetes?
1. □ No
2. □ Yes
7. In the last week, how many times have you experienced hypoglycemia? ______________
8. In the past year, how many times have you experienced hypoglycemia requiring the help of
another person? _______________
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9. Have you ever been told you have depression?
1.

□ No

□ Yes
10. Have you ever been treated for depression?
1.
□ No
2.
□ Yes
11. Are you taking medication for depression?
1.
□ No
2.
□ Yes, name of medicine(s):
2.

________________________________________________
12. Which of the following medical problems do you have?
Check off those that apply to you—even if treated
a. Asthma
m. Depression
b. Chronic Obstructive Pulmonary
n. Anxiety
Disease or Emphysema
c. Angina
o. Panic Disorder
d. Congestive Heart Failure
p. Vision problems (cataracts, glaucoma,
macular degeneration)
e. High Blood Pressure
q. Hearing impairment (very hard of
(Hypertension)
hearing, even with hearing aids)
f. Heart Disease
r. Arthritis (rheumatoid or
osteoarthritis)
g. Heart Attack (Myocardial
s. Degenerative disc disease (back
Infarction)
problems, spinal stenosis, severe back
pain)
h. Neurological Disease (Multiple
t. Sleep apnea
sclerosis, Parkinson’s)
i. Stroke, Mini-Stroke, or Transient
u. HIV or AIDS
Ischemic Attack (TIA)
j. Peripheral Vascular Disease
v. Fibromyalgia
k. Cancer
w. Chronic Pain
l. Sickle Cell Disease
x. Other:
13. Have you ever had any of the following procedures related to your heart? (circle one
number on each line)
No
Yes
a. Coronary Artery Bypass Surgery (Open Heart Surgery)
1
2

b. Coronary angioplasty (“Balloon” Heart Procedure)
c. Cardiac stent placed

1
1

2
2
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14. Do you have any of the following? (circle one number on each line)
a. Peripheral vascular disease (poor circulation to the legs)
b. Intermittent claudication (cramping in the legs after exercise)
c. Peripheral neuropathy (nerve problems causing numbness,
tingling, or burning in the feet or hands)
d. Foot ulcers (wounds that do not heal)

No
1
1
1

Yes
2
2
2

1

2

15. Have you ever had an amputation of a part of your leg or foot for a poorly healing
sore or poor circulation? (NOT due to an injury or accident: car crash, power tool
injury, war injury, etc.)—Circle one number on each line.
No
One (right side)
One (left side) Both
a. Toes
1
2
3
4
b. Part of a foot or feet
1
2
3
4
c. Leg below knee
1
2
3
4
d. Leg above knee
1
2
3
4
16. Have you ever have any of the following eye problems? (circle one number on each
line)
No
Yes/
Yes/Both
One eye Eyes
a. Cataracts
1
2
3
b. Glaucoma
1
2
3
c. Detached Retina
1
2
3
d. Blurred vision (not corrected by eyeglasses)
1
2
3
e. Retinopathy (diabetic eye disease)
1
2
3
f. Laser eye surgery
1
2
3
17. Do you have the following medical problems? (circle one number on each line)
No Yes
a. Kidney failure?
1
2
b. Renal insufficiency or nephropathy?
1
2
c. Have you ever been on kidney dialysis?
1
2
d. Have you ever been told you have diabetic gastroparesis?
1
2
e. Do you vomit (throw up) after eating large meals?
1
2
f. Men Only: Do you have difficulty getting or maintaining an
1
2
erection?
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Brief-Chronic Illness Resources Survey (CIRS)
The following questions ask about a variety of different resources that people may use
to manage their illness. For each item, select the number that best indicates your
experience over the past 6 months.

Over the past 6 months, to what extent:
1. Has your doctor involved you as an equal
partner in making decisions about illness
management strategies and goals?
2. Has your doctor or other health care
advisor listened carefully to what you had
to say about your illness?
3. Has your doctor or other health care
provider thoroughly explained the results
of test you had done (e.g., cholesterol,
blood pressure, or other laboratory tests?
4. Have family or friends exercised with you?
5. Have you shared healthy low-fat recipes
with friends or family members?
6. Family or friends bought food or prepared
food for you that were especially healthy
or recommended?
7. Have you focused on the things you did
well to manage your illness instead of
those you did not?
8. Have you thought about or reviewed how
you were doing in accomplishing your
disease management goals?
9. Have you arranged your schedule so that
you could more easily do the things you
needed to do for your illness?
10. Have you walked or exercised outdoors in
your neighborhood?
11. Have you walked or done other exercise
activities with neighbors?

Not
at all

A
Quite
A
A
moderate
a
great
little amount
bit
deal

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5
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Over the past 6 months, to what extent:
12. Have you eaten at a restaurant that
offered a variety of tasty, low-fat good
choices?
13. Have you gone to parks for picnics,
walks, or other outings?
14. Have you read articles in newspapers or
magazines about people who were
successfully managing a chronic illness?
15. Have you had health insurance that
covered most of the costs of your
medical needs including medicine?
16. Have you seen billboards or other
advertisements that encouraged not
smoking, low-fat eating, or regular
exercise?
17. Have you attended free or low-cost
meetings (for example, Weight
Watchers, church groups, hospital
programs) that supported you in
managing your illness?
18. Have you volunteered your time for
local organizations or causes?
19. Have you attended wellness programs
or fitness facilities?
20. Have you had a flexible work schedule
that you could adjust to meet your
needs? (Leave blank if you don’t work.)
21. Has your workplace had rules or policies
that made it easier for you to manage
your illness (such as no smoking rules or
time off work to exercise)? (Leave blank
if you don’t work.)
22. Have you had control over your job in
terms of making decisions and setting
priorities? (Leave blank if you don’t
work.)

Not
at all

A
little

A
moderate
amount

Quite
a
bit

A
great
deal

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5
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Self Care Inventory-Revised Version (SCI-R)
This survey measures what you actually do, not what you are advised to do. How have you
followed your diabetes treatment plan in the last 1-2 months?
Never

Rarely

Sometimes

Usually

Always

↓

↓

↓

↓

↓

1. Check blood glucose with
monitor

1

2

3

4

5

2. Record blood glucose results

1

2

3

4

5

3. If type 1: check ketones
when glucose level is high

1

2

3

4

5

4. Take the correct dose of
diabetes pills or insulin

1

2

3

4

5

5. Take diabetes pills or insulin
at the right time

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

8. Keep food records

1

2

3

4

5

9. Read food labels

1

2

3

4

5

1

2

3

4

5

11. Carry quick acting sugar to
treat low blood glucose

1

2

3

4

5

12. Come in for clinic
appointments

1

2

3

4

5

13. Wear a Medic Alert ID

1

2

3

4

5

14. Exercise

1

2

3

4

5

4

5

6. Eat the correct food
portions
7. Eat meals/snacks on time

10. Treat low blood glucose
with just the recommended
amount of carbohydrate

15. If on insulin: Adjust insulin
dosage based on glucose
1
2
3
values, food, and exercise
©
Copyright 2005: Annette M. LaGreca, University of Miami

Have type
2 diabetes
Not taking
diabetes
pills or
insulin
Not taking
diabetes
pills or
insulin

Never had
low blood
glucose

Not on
insulin
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Diabetes Symptom Checklist
Instructions
Please circle whether you have experienced the symptom or not in the last 4 weeks,
today included. If you circled “yes” then indicate to what extent the symptom listed has
caused you discomfort by circling the number that most closely reflects your experience.
If a symptom did not occur, please circle “No” in the column “DID SYMPTOM OCCUR”
EXAMPLE
DID
SYMPTOM
OCCUR?
Sore
throat?

THE SYMPTOM DID OCCUR AND WAS
…………………TROUBLESOME TO ME
Not at all

A little

Moderately

Very

Extremely

1

2

3

4

5

No
Yes

→→→→

This answer means: In the last 4 weeks I did have a sore throat and it was a little
troublesome to me.

How much trouble have these symptoms given you
over the last 4 weeks?
DID
SYMPTOM
OCCUR?

1. Lack of energy?
2. Aching calves when
walking?
3. Numbness (loss of
sensation) in the feet?
4. An overall sense of
fatigue?
5. Shortness of breath at
night?

No
Yes→→→→
No
Yes→→→→
No
Yes→→→→
No
Yes→→→→
No
Yes→→→→

THE SYMPTOM DID OCCUR AND WAS
…………………TROUBLESOME TO ME
Not at
all

A
little

Moderately Very

Extremely

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

142

DID
SYMPTOM
OCCUR?

6. Sleepiness or
drowsiness?
7. Difficulty concentrating?
8. Moodiness?
9. Numbness (loss of
sensation) in the hands?
10. Persistently blurry vision
(even with glasses on)?
11. Tingling sensations in
arms or legs at night?
12. Being very thirsty?
13. Palpitations or pounding
in the heart region?
14. Deteriorating vision?
15. Burning pain in the
calves at night?
16. Dry mouth?
17. Increasing fatigue during
the course of the day?
18. Flashes or black spots in
the field of vision?
19. Irritability just before a
meal?
20. Fatigue in the morning
when getting up?
21. Shooting pains in the
legs?
22. Alternating clear and
blurred vision?

No
Yes→→→→
No
Yes→→→→
No
Yes→→→→
No
Yes→→→→
No
Yes→→→→
No
Yes→→→→
No
Yes→→→→
No
Yes→→→→
No
Yes→→→→
No
Yes→→→→
No
Yes→→→→
No
Yes→→→→
No
Yes→→→→
No
Yes→→→→
No
Yes→→→→
No
Yes→→→→
No
Yes→→→→

THE SYMPTOM DID OCCUR AND WAS
…………………TROUBLESOME TO ME
Not at
all

A
little

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

Moderately Very Extremely
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DID
SYMPTOM
OCCUR?

THE SYMPTOM DID OCCUR AND WAS
…………………TROUBLESOME TO ME
Not at
all

23. Frequent need to
urinate?
24. Pains in the chest or
heart region?
25. Burning pain in the legs
during the day?
26. Tingling or prickling
sensations in hands or
fingers?
27. Easily irritated or
annoyed?
28. Sudden deterioration of
vision?
29. Odd feeling in (lower)
legs or feet when
touched?
30. Shortness of breath
during physical exertion
(walking, chores)?
31. Fuzzy feeling in your
head (difficulty thinking
clearly)?
32. Drinking a lot (all sorts
of beverages)?
33. Difficulty paying
attention?
34. Tingling or prickling
sensations in lower legs
or feet?
Any other symptoms:
35.
36.

No
Yes→→→→
No
Yes→→→→
No
Yes→→→→
No
Yes→→→→

A
little

Moderately Very Extremely

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

No
Yes→→→→

1

2

3

4

5

No
Yes→→→→

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

Yes→→→→

1

2

3

4

5

Yes→→→→

1

2

3

4

5

Yes→→→→

1

2

3

4

5

No
Yes→→→→
No
Yes→→→→
No
Yes→→→→

No
Yes→→→→
No
Yes→→→→
No
Yes→→→→

37.
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SF-12 v2 TM Health Survey
This survey asks for your views about your health. This information will help keep track
of how you feel and how well you are able to do your usual activities.
Answer every question by selecting the answer as indicated. If you are unsure about
how to answer a question, please give the best answer you can.
1. In general, would you say your health is:
Excellent

Very good

Good

Fair

Poor

O

O

O

O

O

2. The following questions are about activities you might do during a typical day.
Does your health now limit you in these activities? If so, how much?
Yes,
limited
a lot

Yes,
limited
a little

No, not
limited
at all

a. Moderate activities, such as moving a table, pushing a
vacuum cleaner, bowling, or playing golf

O

O

O

b. Climbing several flights of stairs

O

O

O

3. During the past 4 weeks, how much of the time have you had any of the following
problems with your work or other regular daily activities as a result of your
physical health?
All of
the
time

Most
of the
time

Some
of the
time

A
little
of the
time

None
of the
time

a. Accomplished less than you would like

O

O

O

O

O

b. Were limited in the kind of work or other
activities

O

O

O

O

O
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4. During the past 4 weeks, how much of the time have you had any of the following
problems with your work or other regular daily activities as a result of any
emotional problems (such as feeling depressed or anxious)?
All of
the
time

Most
of the
time

Some
of the
time

A
little
of the
time

None
of the
time

a. Accomplished less than you would like

O

O

O

O

O

b. Did work or activities less carefully than
usual

O

O

O

O

O

5. During the past 4 weeks, how much did pain interfere with your normal work
(including both work outside the home and housework)?
Not at all

A little bit

Moderately

Quite a bit

Extremely

O
O
O
O
O
6. These questions are about how you feel and how things have been with you
during the past 4 weeks. For each question, please give the one answer that
comes closest to the way you have been feeling.
How much of the time during the past 4 weeks . . .
All of
the
time

Most
of the
time

Some
of the
time

A
little
of the
time

None
of the
time

a. Have you felt calm and peaceful?

O

O

O

O

O

b. Did you have a lot of energy?

O

O

O

O

O

c. Have you felt downhearted and depressed?

O

O

O

O

O

7. During the past 4 weeks, how much of the time has your physical health or
emotional problems interfered with your social activities (like visiting friends,
relatives, etc.)?
All
of the time

Most
of the time

Some
of the time

A little
of the time

None
of the time

O

O

O

O

O

Thank you for completing these questions!
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Well-Being Questionnaire (W-BQ12)
Please circle one number on each scale, from 3 (all the time) to 0 (not
at all), to indicate how often you feel each statement has applied to
you in the past few weeks.
all
the time

not
at all

1. I have crying spells or feel like it …………………………

3

2

1

0

2. I feel downhearted and blue ………………………..….

3

2

1

0

3. I feel afraid for no reason at all …………………..……..

3

2

1

0

4. I get upset easily or feel panicky …………..……………. 3

2

1

0

5. I feel energetic, active, or vigorous …………...………

3

2

1

0

6. I feel dull or sluggish ………………………………………..

3

2

1

0

7. I feel tired, worn out, or exhausted ……………….…… 3

2

1

0

3

2

1

0

3

2

1

0

3

2

1

0

3

2

1

0

3

2

1

0

8. I have been waking up feeling fresh and
rested ……………………………………………………………….
9. I have been happy, satisfied, or pleased
with my personal life ………………………………………….
10. I have lived the kind of life I wanted to …………….
11. I have felt eager to tackle my daily tasks or
make new decisions ……………………………………….
12. I have felt I could easily handle or cope with any
serious problem or major change in my life……….

Please make sure that you have considered each of the 12 statements and
have circled one number in response to each statement.
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Appraisal of Diabetes Scale
People differ in their thoughts and feelings about having diabetes. We would like to know how
you feel about having diabetes. Therefore, please circle the answer to each question which is
closest to the way you feel. Please give your honest feelings—we are interested in how you
feel, not what your doctor or family may think.
1.

How upsetting is having diabetes for you?
1
Not at
all

2.

3.

4.

5
Extremely
upsetting

2
Slightly
likely

3
Moderately
likely

4
Very
likely

5
Extremely
likely

Do you believe that achieving good diabetic control is due to your efforts as compared to
factors which are beyond your control?
2
Mostly
because
of me

3
Partly because
of me and partly
because of other
factors

4
Mostly
because
of other
factors

5
Totally
because
of other
factors

4
Very effective

5
Extremely
effective

How effective are you in coping with your diabetes?
1
Not
at all

7.

4
Very
upsetting

How likely is your diabetes to worsen over the next several years? (Try to give an estimate
based on your personal feeling rather than based on a rational judgment.)

1
Totally
because
of me
6.

3
Moderately
upsetting

How much control over your diabetes do you have?
1
2
3
4
5
None at
Slight
Moderate
Large
Total
all
amount
amount
amount
amount
How much uncertainty do you currently experience in your life as a result of being
diabetic?
1
2
3
4
5
None at
Slight
Moderate
Large
Extremely
all
amount
amount
amount
large amount

1
Not likely
at all
5.

2
Slightly
upsetting

2
Slightly
effective

3
Moderately
effective

To what degree does your diabetes get in the way of your developing life goals?
1
2
3
4
5
Not at
Slight
Moderate
Large
Extremely
all
amount
amount
amount
large amount
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Ferrans and Powers
QUALITY OF LIFE INDEX©
DIABETES VERSION – III

HOW SATISFIED ARE YOU WITH:
1. Your health?

Very Dissatisfied

Moderately Dissatisfied

Slightly Dissatisfied

Slightly Satisfied

Moderately Satisfied

Very Satisfied

PART 1. For each of the following, please choose the answer that best describes how satisfied
you are with that area of your life. Please mark your answer by circling the number. There are no
right or wrong answers.

1

2

3

4

5

6

2. Your health care?

1

2

3

4

5

6

3. The amount of energy you have for everyday activities?

1

2

3

4

5

6

4. Your ability to take care of yourself without help?

1

2

3

4

5

6

5. Your ability to control your blood sugar?

1

2

3

4

5

6

1

2

3

4

5

6

1

2

3

4

5

6

8. Your chances of living as long as you would like?

1

2

3

4

5

6

9. Your family’s health?

1

2

3

4

5

6

10. Your children?

1

2

3

4

5

6

11. Your family’s happiness?

1

2

3

4

5

6

12. Your sex life?

1

2

3

4

5

6

13. Your spouse, lover, or partner?

1

2

3

4

5

6

14. Your friends?

1

2

3

4

5

6

5

6

6. The changes you have had to make in your life because
of diabetes (such as diet, exercise, taking insulin or
diabetes pill, checking blood sugar)?
7. The amount of control you have over your life?

1
2
3
4
15. The emotional support you get from your family?
(Please Go To Next Page)
©
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Very Dissatisfied

Moderately Dissatisfied

Slightly Dissatisfied

Slightly Satisfied

Moderately Satisfied

Very Satisfied
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1

2

3

4

5

6

17. Your ability to take care of family responsibilities?

1

2

3

4

5

6

18. How useful you are to others?

1

2

3

4

5

6

19. The amount of worries in your life?

1

2

3

4

5

6

20. Your neighborhood?

1

2

3

4

5

6

21. Your home, apartment, or place where you live?

1

2

3

4

5

6

22. Your job (if employed)?

1

2

3

4

5

6

23. Not having a job (if unemployed, retired, or disabled)?

1

2

3

4

5

6

24. Your education?

1

2

3

4

5

6

25. How well you take care of your financial needs?

1

2

3

4

5

6

26. The things that you do for fun?

1

2

3

4

5

6

27. Your chances for a happy future?

1

2

3

4

5

6

28. Your peace of mind?

1

2

3

4

5

6

29. Your faith in God?

1

2

3

4

5

6

30. Your achievement of personal goals?

1

2

3

4

5

6

31. Your happiness in general?

1

2

3

4

5

6

32. Your life in general?

1

2

3

4

5

6

33. Your personal appearance?

1

2

3

4

5

6

34. Yourself in general?

1

2

3

4

5

6

HOW SATISFIED ARE YOU WITH:
16. The emotional support that you get from people other
than your family?

(Please Go To Next Page)
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Very Unimportant

Moderately Unimportant

Slightly Unimportant

Slightly Important

Moderately Important

Very Important

PART 2. For each of the following, please choose the answer that best describes how important
that area of your life is to you. Please mark your answer by circling the number. There are no
right or wrong answers.

1. Your health?

1

2

3

4

5

6

2. Your health care?

1

2

3

4

5

6

3. Having enough energy for everyday activities?

1

2

3

4

5

6

4. Taking care of yourself without help?

1

2

3

4

5

6

5. Controlling your blood sugar?

1

2

3

4

5

6

1

2

3

4

5

6

1

2

3

4

5

6

8. Living as long as you would like?

1

2

3

4

5

6

9. Your family’s health?

1

2

3

4

5

6

10. Your children?

1

2

3

4

5

6

11. Your family’s happiness?

1

2

3

4

5

6

12. Your sex life?

1

2

3

4

5

6

13. Your spouse, lover, or partner?

1

2

3

4

5

6

14. Your friends?

1

2

3

4

5

6

15. The emotional support you get from your family?

1

2

3

4

5

6

16. The emotional support you get from people other
than your family?

1

2

3

4

5

6

HOW IMPORTANT TO YOU IS:

6. The changes you have had to make in your life
because of diabetes (such as diet, exercise, taking
insulin or diabetes pill, checking blood sugar)?
7. Having control over your life?

(Please Go To Next Page)
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Page 3

Very Unimportant

Moderately Unimportant

Slightly Unimportant

Slightly Important

Moderately Important

Very Important
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17. Taking care of family responsibilities?

1

2

3

4

5

6

18. Being useful to others?

1

2

3

4

5

6

19. Having no worries?

1

2

3

4

5

6

20. Your neighborhood?

1

2

3

4

5

6

21. Your home, apartment, or place where you live?

1

2

3

4

5

6

22. Your job (if employed)?

1

2

3

4

5

6

23. Having a job (if unemployed, retired, or disabled)?

1

2

3

4

5

6

24. Your education?

1

2

3

4

5

6

25. Being able to take care of your financial needs?

1

2

3

4

5

6

26. Doing things for fun?

1

2

3

4

5

6

27. Having a happy future?

1

2

3

4

5

6

28. Peace of mind?

1

2

3

4

5

6

29. Your faith in God?

1

2

3

4

5

6

30. Achieving your personal goals?

1

2

3

4

5

6

31. Your happiness in general?

1

2

3

4

5

6

32. Being satisfied with life?

1

2

3

4

5

6

33. Your personal appearance?

1

2

3

4

5

6

34. Are you to yourself?

1

2

3

4

5

6

HOW IMPORTANT TO YOU IS:

©

Copyright 1984 & 1988 Carol Estwing Ferrans and Marjorie J. Powers
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APPENDIX G
MISSING DATA

152

153

Missing Data Replaced by Imputation
Measurement Tool
Health Questionnaire
Access to diabetes care item
CIRS
Well-Being Questionnaire 12
DSC-R
SF-12 Health Survey (v2)
Appraisal of Diabetes Scale

Item
Duration of
Diabetes
CIRS #15
#5
#11
#14
#17
#4
#16
#29
#2a
#2

Missing
Count
%
(n)
4
3.7
1
1
1
1
1
1
1
1
1
1

0.9
0.9
0.9
0.9
0.9
0.9
0.9
0.9
0.9
0.9

Group Individual Replaced
Mean Mean
Value
12.6

--

12.5

4.11
2.39
1.51
3.01
1.90
0.53
1.47
0.54
2.28
3.64

3.5
1.5
2.3
2.0
2.0
0.66
2.0
2.0
1.6
2.7

4
2
2
2
2
1
2
1
2
3

154
Missing Data Not Replaced
Measurement Tool
Demographics
Questionnaire
CIRS
Health History
Questionnaire
Glycemic control
Well-Being
Questionnaire 12
Appraisal of Diabetes
Scale

Quality of Life Index

2

Item Description
Income
Height
Weight
#20 (work-related)
#21 (work-related)
#22 (work related)
Detached Retina
Retinopathy
Laser Eye Surgery
A1C
#5 (energy/vigor)
#6 (sluggish)
#3 (uncertainty)
#5 (locus of control)
#7 (life goals impact)
SAT9 (family health)
IMP9 (family health)
SAT11 (family happiness)
IMP11(family happiness)
SAT15 (family support)
IMP15 (family support)
SAT10 (children)
IMP10 (children)
SAT12 (sex life)
IMP12 (sex life)
SAT13 (spouse/partner)
IMP13 (spouse/partner)
SAT22 (work-related)
IMP22 (work-related)
SAT23 (work-related)
IMP23 (work-related)

Missing
Count (n)
%
8
7.5
1
0.9
1
0.9
68
63.6
72
67.3
72
67.3
1
0.9
1
0.9
1
0.9
6
5.6
1
0.9
1
0.9
1
0.9
1
0.9
1
0.9
1
0.9
1
0.9
1
0.9
1
0.9
1
0.9
1
0.9
10
9.3
10
9.3
15
14
18
16.8
21
19.6
20
18.7
72
67.3
69
64.5
45
42.1
37
34.6

Reason not replaced
2
2
2

Expected missing3
Subject (#109) did not
know history
2

Subj. (#135) left blank
2/4 items on subscale
Subject (#178) left blank
3/7 of instrument

Subject (#194) left blank
all family subscale items

Expected missing4

Expected missing3

Data cannot be deductively imputed without excessive risk of distorting relationships between variables.
Missing data related to employment was expected as 67.3 % subjects not currently working outside the
home.
4
Missing data related to partner/children was expected as 42% of subjects are unpartnered (single,
divorced, separated or widowed) and 9.3% of subjects stated no children.
3

APPENDIX H
DATA ANALYSES ASSUMPTIONS

155
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Assumptions for ANOVA
Assumption
Homogeneity of Variance
(Homoscedasticity)
Independent Observations

Dependent variable is an
interval or continuous scale
Normality (of residuals)

Description
Similar variance in each
experimental condition/group
-Uncorrelated error terms
-Uncorrelated independent
variables
Variable is interval or greater
scale
Distributions within groups are
normally distributed

Assumption Met
Levene’s Test nonsignificant
Durbin-Watson = 1 to 3

Yes
Yes

Tests of Normal Distribution
Test

Description

Quality of Life
(QLI)

Assumption
met?

Skewness
Kurtosis

Symmetry (should be zero)
Distortion from bell-curve (should be
zero)
Goodness-of-fit test; should be >.05

-0.623
-0.002

No
Yes

0.200

Yes

Comparison to normal distribution,
should be >.05

0.007

No

KolmogorovSimirnov
Shapiro-Wilk

Assumptions for MANOVA
Assumption
Independence
Random Sampling

Multivariate Normality

Homogeneity of Covariance
Matrices

Description
Uncorrelated independent
variables
Dependent variable is randomly
sampled from population at
interval scale (at least)
Dependent variables are
normally distributed within
groups
Variance-covariance matrices of
groups are equal

Assumption Met
Wilks’ Lambda significant
Yes

Yes

Levene’s test then Box’s
Test (both nonsignificant)

157
Assumptions for Multiple Regression
Assumption
Variable Type

Description
-Interval or greater scale
-Unbounded = no constraints
per instrument’s scale
Variance is non-zero
Predictors’ variance ≠ zero
Multicollinearity
Predictors are not highly
correlated
Predictors not correlated with External variables are those
external variables
not included in the analysis
but are related to the
outcome
Homoscedasticity
Predictor residuals should
have similar variance
Independent error terms
Subjects’ residuals are not
correlated
Normally distributed errors
Residuals are random,
normally distributed, mean =
zero.
Independence
All dependent variable
measurements come from
separate subjects
Linearity
Model relationship is linear
Note: Assumptions and descriptions are from Field, 2009.

Assumption Met
Yes

Yes, per descriptive statistics
VIF should be <10
Tolerance > 0.1
Review of literature per
Chapter 2.

Non-significant Levene’s test
Durbin-Watson = 1 to 3
Yes

Chapter 3, methods show
simultaneous cross-sectional
data collection
Yes
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